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ABSTRACT
Surface-enhanced Raman scattering (SERS) is a technique that can be used for the 
detection of materials down to the single molecule level. The development of the extrinsic 
Raman Label (ERL) that incorporates biorecognition, a Raman reporter molecule, and gold 
nanoparticles (AuNPs), is the base for an extensible, sensitive, and selective SERS-based 
sandwich immunoassay. The use of SERS as a quantitative detection platform, however, 
has not progressed past the laboratory.
Research presented here in describes how the analysis and production of a SERS 
immunoassay substrate has a significant role in the reliability and reproducibility of SERS 
substrates. First, the analysis of the SERS immunoassay platform and can be simulated as 
a random distribution of points on a surface. Simulation results indicated the best method 
to improve the accuracy of the analysis was through increasing the number of 
measurements or increasing the area measured by a single measurement. The precision of 
the measurement, however, was only improved by increasing the analysis area. This 
indicates that a larger laser spot used for analysis improves the accuracy and precision of 
SERS measurements. Second, to produce a SERS substrate with a random distribution of 
ERLs, the adsorption of ERLs should follow diffusional transport to increase the 
uniformity of ERLs on the substrate. By inverting the substrates during the ERL incubation 
step, sedimentation of the ERLs is directed away from the substrate and stable ERLs left
in suspension diffuse to the substrate. Diffusional transport and a more even distribution 
of ERLs increased the reliability and reproducibility of the SERS substrates.
Improved SERS immunoassay techniques implemented in conjunction with a novel 
pretreatment of serum samples for tuberculosis (TB) diagnostics was used to validate the 
SERS method. The TB marker mannose-capped lipoarabinomannan (ManLAM) is a 
lipopolysaccharide cell wall component that is constantly sloughed off the surface of the 
virulent bacterium, Mycobacterium tuberculosis. Normally ManLAM complexes with 
serum protein inhibiting detection but the use of a simple five step pretreatment method 
frees ManLAM improving the limit of detection (LoD). Improved SERS methodologies 
and sample pretreatment provide promising sensitivity and specificity for set of patient 
samples.
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Early diagnosis of disease is a worldwide problem that involves the identification 
of a disease causing agent at the early stage of disease progression. In the preliminary stages 
of a disease the patient can be asymptomatic and may have low levels of disease markers 
readily available for detection. This can require a test that bridges the gap between a 
screening test, performed periodically for asymptomatic individuals, and a diagnostic test, 
designed to diagnose a systematic patient. The term diagnostic is, however, commonly 
used to describe any method for the identification of a disease causing agent. The term 
diagnostic test is most often used to describe both types of tests.
Detecting disease at an early stage is important in improving patient prognosis as 
well as reducing the spread of communicable diseases. This can improve a patients’ quality 
of life, increase life expectancy, and/or allow for effective treatment of potentially fatal 
diseases. Common limitations in the utility of available testing include speed, cost, and 
reliability of the test. However, the implementation of new testing has additional 
considerations for the practicality of a diagnostic method for the region of interest and 
factors specific to the disease. These considerations include local resources, regional health
2considerations, cost adjustments, impact of false positive/false negative results on patient 
heath, and safety of the working environment and training/availability of resources for the 
analyst.
Building on work that has previously been reported, this dissertation is an 
expansion on the development of a nanoparticle (NP)-based surface-enhanced Raman 
scattering (SERS) immunoassay for disease diagnostics. The document is organized into 
seven separate sections including an introduction, five original chapters, and conclusion. 
The introduction outlines and defines the general understanding of what constitutes an ideal 
diagnostic method for reliable detection of disease, as well as an introduction to the basic 
history and background of important topics used throughout the dissertation.
The five original research chapters that follow the introduction are as follows. 
Chapter 2 discusses the influence of sampling on SERS immunoassay readout in terms of 
accuracy and precision. Chapter 3 investigates the influence of ERL sedimentation on the 
reliability of the SERS immunoassay substrate during assay preparation. Chapter 4 
describes the development of a SERS immunoassay for the tuberculosis (TB) marker 
phosphoinositol-capped lipoarabinomannan (PILAM) in buffer, synthetic urine, and 
serum, as well as multiplexed detection of three antigenic markers. Chapter 5 extends the 
methodology developed in Chapter 4 to the detection of mannose-capped (ManLAM) and 
a panel of patient samples from endemic areas. This dissertation concludes with general 
statements on the reliability of SERS-based immunoassays and speculation on the impact 
of the cumulative findings in the dissertation.
1.2 An “Ideal” Diagnostic Method 
A diagnostic test is a medical test designed to detect the presence of disease in a 
host.1-4 This is typically performed through the detection of a “marker” that is present in 
the host due to the existence of disease. Diagnostic test results give the medical professional 
the information required to take the next step for a patient, be it additional testing or a 
treatment plan. The primary components of a diagnostic test are a reliable disease marker, 
recognition element, and detectable label. It is also important to know that a diagnostic test 
is not inherently useful on its own. A test may require additional sample handling, 
preservation, and sample treatment to provide reliable results. The entire process for the 
identification of a disease-causing agent in a patient sample is called the diagnostic method. 
The validity of the diagnostic method is based on the ability to accurately predict the 
presence of disease in large sets of patient samples. The performance of a diagnostic test 
is typically determined by the percentage of patient samples that have a true positive 
(clinical sensitivity) and a true negative (clinical specificity) results compared to the best 
available method. In order to visualize the difference between multiple sample sets a 
receiver operating characteristic (ROC) curve can be used.5 The ROC curve was developed 
as a statistical method to visually represent binary systems. In the case of a diagnostic 
method, the classifiers for true positive and true negative rates can the strength of the 
method.6 Example ROC curves are illustrated in Figure 1.1 and indicate the potential 
differences in the performance of diagnostic methods. An ideal method has a vertical 
segment of the line at 0% false positives and then a horizontal segment of the line at 100% 
true positives. This represents a method with 100% sensitivity and 100% specificity. A 
straight line from the lower left to the upper right portion of the graph indicates no
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Figure 1.1. Biomedical ROC curve displaying the difference from diagnostic methods. 
The ROC curve displays the results from diagnostic analysis of patient samples with a 
known disease status as the true positive rate versus the false positive rates. The position 
of the segmented line represents the overall performance of the diagnostic method and 
shows where there is a tradeoff between true positives and false positives. The overall 
predictive value of the method is displayed from the ideal method in black, to decreasing 
values from purple, blue, red, green, violet, and finally no predictive value for the dashed 
line. Each point represents the progression of the ROC curve based on the results of a 
patient sample.
diagnostic value. Most methods display a stepped line representing the performance of the 
method on patient samples and visually indicating the ability of the test to distinguish 
between positive and negative samples.
While there is always a push for improvement in terms of sensitivity and specificity 
for early diagnostics, the access to methods available in well developed countries is 
remarkable. There are redundancies in many of the testing options which increases the 
probability of accurate diagnosis. When one diagnostic method lacks specific aspects of 
ideal performance there are additional options available.7 This stems from the availability 
of resources that produce core facilities outfitted with expensive equipment, highly trained 
professions, and a communal infrastructure that allows for rapid transport and 
communication. Patient samples can be shipped and processed by highly qualified facilities 
and results available with minimal turnaround times, often without consideration to the 
expense. Considering the number of resources that comprise medical diagnostics in 
well-developed countries, it is good to keep in mind the global problem that persists and 
requirements that prohibit the use of currently available methods. The need for new 
diagnostic methods is highlighted by a list of the top 12 causes of death worldwide in 2008 
(Table 1.1). 8 Of the top 12 causes of death on the list only two are nondisease related and 
rank in the 10th and 12th positions, demonstrating the global hardship of disease.
High profile and high-risk diseases most easily display the need for readily 
available diagnostic methods that can help reduce the spread of the diseases as well as 
improve patient prognosis. Global health scares such as the one associated with the 2014 
Ebola outbreak in Western Africa9, 10 are harsh reminders of the potential catastrophic 
threat of highly communicable and deadly diseases. Fortunately, only a few diseases
5





Percent of all 
deaths
1 Ischemic heart disease 7.25 12.8
2 Cerebrovascular disease 6.15 10.8
3 Lower respiratory infections 3.46 6.1
4 Chronic obstructive pulmonary disease 3.28 5.8
5 Diarrheal diseases 2.46 4.3
6 HIV/AIDS 1.78 3.1
7 Trachea, bronchus, lung cancers 1.39 2.4
8 Tuberculosis 1.34 2.4
9 Diabetes mellitus 1.26 2.2
10 Road traffic accidents 1.21 2.1
11 Hypertensive heart disease 1.15 2.0
12 Prematurity and low birth weight 1.00 1.8
display similar fast-acting development along with the high mortality rate exhibited by 
Ebola. However, preventable and treatable infectious diseases still have a high impact in 
low-resource regions with reduced hygiene standards that enable the continual spread of 
communicable diseases. In these regions the availability, access, and reliability of detection 
methods play a major role in the number of people that actively seek out diagnostic testing. 
The effectiveness of a diagnostic method is therefore primarily related to the monetary and 
time costs associated with testing.
There are, however, necessary components for a diagnostic test to be applicable in 
any region of the world. It is easy to define an ideal diagnostic method as rapid, cost 
effective, and reliable,11 but the utility also depends on the burden associated with testing. 
This requires taking into account all socioeconomic factors that increase the number of 
constraints used for development. Each community has different requirements for the cost, 
resources, and complexity that a diagnostic method requires. In well-developed regions, a 
glucose sensor for diabetes is an example of a widely available and simplistic diagnostic 
tool. However, some low-resource regions must combat problems associated with the lack 
of clean needles, electrical power, and individuals with the proper education to perform 
testing and interpret results. While it at times seems impossible to meet all these 
qualifications, by working as a scientific community small improvements can potentially 
be combined to an eventual solution.
Regional restrictions can also be compounded by unique characteristics of a 
disease. A high impact example for the global need for improved diagnostic methods with 
unique requirements is the detection of tuberculosis (TB) infection. Tuberculosis, while 
commonly considered a disease of the past in well-developed regions, persists as the
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8world’s second greatest killer due to a single infectious agent. TB is second only to human 
immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS).12, 13 
Caused by the bacillus Mycobacterium tuberculosis (M. tuberculosis) TB is a preventable 
and curable disease but has specifically adapted to evade eradication attempts.
The high threat of TB infection to patients in regions of Asia and Africa is due to a 
combination of hygiene standards, coinfection with immune suppressing diseases, and 
limited resources. While simple skin testing is commonly used in the United States, this 
test can be rendered inaccurate due to coinfection with immune suppressing diseases. The 
test is based on the presence of antibodies to TB in the host. False negatives are caused 
immunocompromised hosts not producing antibodies and false positives by a patient’s 
exposure to M. tuberculosis without infection. Due to this limitation, current diagnosis 
methods in high-burden regions primarily depend on sputum smear microscopy (SSM) and 
commercially available serological tests.14 However, the World Health Organization 
(WHO) has recently issued a policy urging resource-limited countries to ban these 
serological tests. The alarmingly high inaccuracy of serological tests that results in negative 
impact on the patients’ health leaves SSM as the primary available test. SSM requires an 
advanced stage of pulmonary disease for detection.
The global problem of TB testing is a reasonable model system that can be used to 
test the reliability and accuracy of new diagnostic methods. The ability to develop a 
diagnostic that can meet all the requirements outlined by the problems associated with TB 
diagnostics would fill a large void in the currently available diagnostic technologies. The 
adaptation of a SERS-based immunoassay towards the development of a rapid, low-cost, 
and reliable detection method for immune compromised patients is a focus of discussion
9for this dissertation. The system also has the benefits of robust low-tech detection of the 
antigenic TB marker ManLAM (shown in Figure 1.2).15-18
1.3 Data Acquisition and Sampling
The development of any new analytical method requires the consideration of the 
potential impact of sampling on the results.19-21 Often times, measuring an entire population 
is impractical, due to the time and expense of assessing a potentially excessively large 
population. In many cases a small portion of the whole population, a sample, is tested and 
results are considered to represent the population. A sample can refer to multiple processes 
during analysis and should always be considered. While some populations are inherently 
homogenous (e.g., a uniformly colored solution), while not all populations are (e.g., a soil 
sample). Problems with sampling arise when the sample does not accurately represent the 
population. This can occur due to undersampling which leads to statistically inaccurate 
results due to the sample dispersity relative to the sample size. This is visually depicted in 
Figure 1.3 where two populations and samples of equal size display distinctly different 
distributions. The populations and sample sizes are equal, but Figure 1.3a sampling 
displays representative results while Figure 1.3b sampling is nonrepresentative of the true 
population.
Typically a sampling problem originates when a researcher is under the assumption 
that an analyte of interest is evenly dispersed at a high enough concentration within the 
sample to accurately represent the entire population. However, when a sample size is too 
small to contain the analyte of interest at a statistically relevant level, there is a high 
probability the result will not match the population. There should also be consideration as
10
Figure 1.2. Structure of LAM, represented as the four primary components: 
phosphatidylinositol mannoside (PIM) anchor, mannan core, arabinan chains, and 
capping agents. The length and number of branches of the mannan core and arabinan 
chains are fewer than those found in nature. Phosphor-wyo-inositol-caps produce 
PILAM and mannose-caps produce ManLAM.
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Figure 1.3. Visual representation of (a) representative and (b) nonrepresentative 
sampling. Sampling can dictate the accuracy and precision of the final result which can 
potentially misrepresent the population.
to whether the sample size accounts for heterogeneity within in the sample. The accuracy 
and precision of sample size is dependent on the heterogeneity of the sample.
Sampling can occur during several different points in an experiment. Typically 
sampling occurs when an aliquot of a bulk material is taken for analysis. When this is done 
there are multiple potential sources of error, including techniques used for sample 
collection, storage, processing, preservation, and preparation. There can also be a problem 
associated when the analysis method that only measures a portion of the prepared sample. 
Sampling of material during the analysis step can be of equal importance. If the use of an 
analysis method is adapted for a new technique, the impact of the setup on the results 
should be examined.
High-resolution data collection performed with small analysis areas can be used to 
display the distribution of an analyte within a sample. This type of high-resolution data 
collection is very useful but is designed to inherently indicate minor deviations in analyte 
concentration. This technique is counterproductive if  the goal of analysis is to determine 
the mean or true value for the population. In this case the sampling size should be large 
enough to statistically display an accurate and precise result for the system. Minor errors 
associated with sampling can be accounted for with blanks, standards, and reference 
samples. However, options are limited if the sample measured is nonrepresentative. 
Methods are available to determine the source of error present in the analysis.
Inherent errors are present in any sample preparation and analysis method. These 
errors can lead to deviations from expected values as well as variations in signal. Small 
variations in signal and their relation to the true value are described by the accuracy and 
precision. The precision of the result associated with the measurement can be described by
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the relative variance associated with the method (s^ )  and the relative variance that is 
present due to the sample (s 2). In order to separate which portion of the error is present 
due to the method versus the sample, the overall variance (s%) is determined by the 
variance in the measured readout.22, 23 The difference of between the and give the 
variance that is directly related to the sample which is described by the following.24
= s ^ +  ss2 (1.1)
This equation shows that the overall variance of a measurement is either limited by the 
sampling error or by the error of the method and can be rewritten to encompass a variety 
of known sources of error. From Equation 1.1 determination of the primary source of error 
can be determined as coming from either the or s 2. Depending on the primary source 
of error, it can be determined if replicate measurements will or will not improve the quality 
of the result. When is larger than s 2, replicate measurements are not beneficial to the 
analysis.
Youden explained the ratio of the standard deviations — indicates the percentage
s m
of Sq that is present due to the different components.25 If ss is three times as large as sm 
then only 10% of the variance comes from the method. The graphical representation of this 
calculation, shown in Figure 1.4, displays the law of diminishing returns for the benefits of 
improving the method when the error in the sample is larger than that in the method. The 
analysis also indicates that low-quality samples can limit the ability of a method to display 
precise measurements. There is also a question about what the optimum sample size should 
be to produce an accurate analysis. A common example of this type of sampling problem
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Figure 1.4. Relationship between the contribution of variance in the method to the 
overall variance versus the ratio of the standard deviation of the sample (ss) to the 
standard deviation of the method (sm). The red dashed line represents that when the 
variance of the sample is three times higher than the variance for the method, the overall 
contribution of the error from the method is only 10%.25
is a solid sample that is composed of two or more components with an analyte of interest 
in low quantities. In this type of sample there is a question of how much sample should be 
analyzed to ensure that the results will display an accurate level of the analyte of interest. 
The sample size then dictates the accuracy and precision of the results. The sample taken 
from the bulk has to be sufficiently large to contain a statistically relevant amount of the 
analyte to accurately measure the concentration of the material.
Several methods to estimate the amount of a sample needed to exceed a 
predetermined level of uncertainty have been previously addressed. Ingamells determined 
a relationship between the decreases in the error associated with a measurement of a sample 
and increasing the sample size.26 The relation:
m R 2 = Ks (1.2)
where m  represents the amount of sample analyzed (g), R is the relative standard deviation 
of the sample (%), and Ks is the sampling constant or the sample mass required for 1% R 
(g). The sampling constant represents the amount of the sample that is required to limit the 
sampling uncertainty to 1% with 68% confidence. This method can be used to estimate the 
mass of a sample needed for a given R.
One of the most well-known examples of this method was used for determining the 
sodium content of liver samples via radiotracing of 24Na.27 The analysis was used to 
evaluate specimen collection, processing, storage, and analysis for the National Bureau of 
Standards (NBS). The study required a small portion of the liver specimens to be analyzed 
from a stored specimen. Variability in the result for the content of 24Na in a liver sample
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was demonstrated to be dependent on the sample size. This is to ensure that variations in 
the result were due to specimen collection, processing, and storage. The results of the 
sampling experiments are shown in Figure 1.5; they clearly show decrease in signal 
variability with increased sample size. The K s for the sample type was calculated as 35 g.
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1.4 Raman Laser Spot Size Diameter 
Raman instrumentation commonly consists of an excitation source, spectrograph, 
and fiber optic probe. The area of the surface, which defines the sample size, that is, 
analyzed by a Raman instrument is based on the excitation area defined by a focused laser 
spot.28 While the true laser spot is not always circular and the laser strength follows a 
Gaussian distribution, a circular area on the surface is a reasonable estimation of the sample 
size. The spot size and signal collection efficiency are both, in large part, determined by 
the objective. The numerical aperture (NA) for an objective indicates the relative laser spot 
size and collection efficiency, which are inversely proportional to each other. From this 
relationship, we see that a smaller laser spot size has a higher collection efficiently or 
signal. When selecting an objective for quantitative analysis, the analysis area should be 
large enough to properly represent the sample.
The laser spot size diameter is dependent on the laser wavelength, incident beam 
diameter, and the NA of the objective displayed in Figure 1.6. The focused spot size can 
be estimated by Equation 1.3
Fn =
n  A Ld 
NA Bd (13)
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Figure 1.5. Sampling diagram for sodium-24 counts of homogenous human liver 
samples. (Adapted from reference “The Sampling and Analysis of Human Livers.”)27
18
Figure 1.6. Visual representation of the diameter of the laser spot size produced by an 
incident beam focused through a lens.
where, FD is the laser spot size diameter, n  is the index of refraction, A is the laser 
wavelength, LD is the lens diameter, and BD is the incident beam diameter. The equation 
indicates that as the NA  is increased the FD decreases, thus reducing the laser spot size. A 
larger NA  is desired for analysis of many SERS-active substrates due to the increased 
collection efficiency, which can aid in lowering detection limits. However, based on 
Equation 1.2, there is also an inherent decrease in sampling size. An objective that is 
sometimes in SERS analysis is a 50x Olympus,29, 30 which produces an F d  of ~0.5 p,m or 
analyses area of 0.79 p,m2. In comparison to a 3.0 mm area the area analyzed would be a 
ratio of 1.1 x 10-7 of the surface, resulting in the measurement of an exceptionally small 
portion of the overall sample.
1.5 Immunoassay Development 
The beginning of modern diagnostic tests began in the 1940s with colorimetric 
detection of enzymes and metabolites in biological fluids.31 These experiments confirmed 
that biological components of bodily fluids contained molecules indicative of disease. The 
concept led to deployment of an immunoassay performed by Landsteiner in 1945 which 
demonstrated that small molecules (haptens) could illicit an immune response when 
conjugated to larger carrier molecules.32 The use of antibodies produced by a host increased 
the sensitivity of diagnostic platforms acting as recognition elements for the targeted 
marker.33
The first successful use of an immunoassay was developed by Yalow and Berson 
in the late 1950s.34 This radioimmunoassay (RIA) used a known quantity of 131I-labeled 
insulin (labeled antigen) which was exposed to a known quantity tracer antibody. After a
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set incubation period, the labeled antigen was bound to the tracer antibody at equilibrium 
quantities in the solution. A patient sample was then added to the solution and the free 
antigen in solution competed to bind to the tracer antibody, changing the equilibrium of 
the solution. The ratio o f free-to-bound labeled antigen was directly proportional to the 
amount o f free antigen in a patient sample. This procedure is known as a competitive 
immunoassay that requires separation o f the bound and free labeled antigen in solution for 
analysis. While many different techniques have been used for the separation of the free and 
bound materials, all are time consuming and cumbersome. Despite these drawbacks, the 
RIA was introduced into the diagnostic market in the late 1960s35 and the developers were 
awarded the Nobel Prize in Physiology or Medicine in 1977 for the breakthrough in 
diagnostics.
The solid-phase immunoassay (SPI) as shown in Figure 1.7 was developed by Catt 
and Tregear in the late 1960s; it increased the sensitivity and reduced costs of diagnostics.36 
The SPI immobilized capture antibodies on a solid interface. The surface was then exposed 
to a solution or patient sample containing the homologous antigen, and was extracted from 
solution and immobilized on the surface, allowing the excess solution to be rinsed away. 
This provided a reasonable alternative to the cumbersome separation techniques used by 
RIA. The success o f basic SPI detection methods has been widespread with techniques that 
include radioactive isotopes, enzymes, fluorophores, electrochemistry, and 
chemiluminescent labels; many of these methods are still currently in use. 37-41
One of the largest advancements in immunoassays was the introduction of enzymes 
in the 1970s as alternative radioisotope labels.42, 43 The use of enzymes produced one of 
the most widely used immunoassay techniques: the enzyme-linked immunosorbant assay
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Figure 1.7. Basic solid-phase sandwich immunoassay format.
(ELISA).37 The success of ELISA is based on the inherent ability of the enzyme to increase 
the rate o f a chemical reaction, thus increasing the signal output with time. The enzyme is 
conjugated with a tracer antibody and used to locate the antigen immobilized in a SPI. The 
reaction vessel is then filled with substrate and the product o f the enzyme-substrate reaction 
can be detected with a large variety of methods including visual assessment, colorimetry, 
fluorimetry, luminometry, or electrometry.37, 44-47
While the development of ELISA has to be the most notable advancement in SPI 
technology, there are still drawbacks to the technique that have prompted the development 
of new detection methods. Some problems associated with enzymes used for immunoassay 
are associated with the environmental sensitivity o f the enzyme. Changes in the 
environmental conditions surrounding the enzyme such as pH, ionic strength, and 
temperature can cause fluctuations in the activity of the enzyme. Conjugation techniques 
used to attach the enzyme to the recognition element can cause localized denaturation or 
conformational changes which also impede the enzyme activity. The physical properties 
and structure of the enzyme also allow the adsorption to surfaces used in SPIs. There is 
also an inherent complication in multiplexing capabilities o f enzyme-based detection. The 
challenge lies in the ability to find multiple enzymes that will produce unique and reliable 
readout without any interactions between the enzymes and the substrates.48
The demand for diagnostic methods to have increased speed, sensitivity, lower 
detection limits, and higher throughput have helped broaden the potential tools available. 
Technological advancements in detection methods and instrumentation has produced 
several novel techniques including surface plasmon resonance,49-56 quantum dots,57-65 giant 
magnetoresistance66, 67 and surface-enhanced Raman scattering,68-88 to name a few. Each
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o f these techniques, displays great potential for the progression o f diagnostic technologies 
with immunoassay having many applications for use in clinical,89, 90 environmental,91 and 
agricultural diagnostics.92, 93
1.6 Raman Spectroscopy and Surface -enhanced Raman Scattering
Raman spectroscopy is a vibrational spectroscopy technique discovered in 1928 by 
Sir Chandrasekhara Venkata Raman.94, 95 Raman signal is produced when an incident 
photon causes molecular vibrations that influence the polarizable electron density and 
inelastic scattering. While, a majority of scattered light, has a conserved frequency, 
Rayleigh scattering, the inelastic scattered light is shifted in frequency due to a gain or loss 
in energy. The gain or loss of energy is described as anti-Stokes and Stokes shifts, 
respectively. The change in energy is equal to the transition o f an energy state producing a 
molecular fingerprint of the molecule. The Stokes shifts have higher signal intensity than 
the anti-Stokes intensity due to the higher probability of energy loss versus an energy gain. 
Modern instrumentation uses a laser to provide a simple and powerful excitation source, 
and a long pass filter removes the signal from Rayleigh scattering and anti-Stokes lines. 
The resulting Raman vibrational spectrum is dispersed by a grating and the resulting 
spectrum is detected with a charge couple device (CCD). The final result is plotted as the 
signal intensity in counts per unit time versus the Raman shift in wavenumber relative to 
the excitation source.
Raman spectroscopy is rich with vibrational information. However, the signal is 
inherently weak produced by only 1 in 106 incident photons and not all molecules are 
Raman active. Historically the weak signals associated with Raman spectroscopy have
limited the use of the technique. The invention of lasers in the 1960s96 and the discovery 
of surface-enhanced Raman scattering (SERS) in the 1970s renewed interest in the field of 
Raman spectroscopy.97-99 Both scientific advancements were paramount to overcoming 
some of the shortcomings of Raman spectroscopy.
SERS displayed significant increases in the Raman signal produced by Raman- 
active molecules adsorbed to a roughened metal surface. Surface enhancement factors have 
been reliably measured to be on the order of 106 to 108,100-112 with sensitivity demonstrating 
single molecule detection.113-116 The early success of SERS detection and subsequent 
promises made about the potential of the technique are based primarily based on the 
increased level of sensitivity provided by SERS over traditional Raman. However, the 
success has also been surrounded by debate over the enhancement mechanism, 
reproducibility of the signal strength, and reliability of the method as a quantifiable 
detection platform.
The SERS effect was originally achieved when Raman-active molecules were 
adsorbed on a roughened coinage metal surface.97-99, 117, 118 The original discovery of SERS 
found that the signal enhancement was produced by the increase in the number of adsorbed 
molecules on the roughened surface.97 The proper identification of the active role of the 
surface in signal enhancement and the true beginning of SERS was the discovery by 
Albrecht and Crieghton as a chemical effect 98 and Jeanmaire and Van Duyne as an 
electromagnetic effect,99 in 1977. The initial false interpretation and subsequent two 
surface theories lead to confusion in the field as to the true mechanism for SERS 
enhancement.
Since that time, defining the mechanisms of the signal enhancement has been a
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difficult and long process with highly complex mathematical and theoretical 
explanations.100, 117, 118 The scientific community developed theories based on early reports 
and determined that the enhancement mechanism was a combination of chemical and 
electromagnetic enhancement factors. The chemical enhancement theory, accepted as the 
lesser of the two sources of the effect, is attributed to a resonant charge-transfer state 
between the adsorbed Raman-active molecule and substrate.119-121 On the other hand, the 
electromagnetic theory, considered the predominant source of the effect, is consistent with 
the observed experimental dependence of the roughness and dielectric properties of the 
SERS substrate.100, 101, 103, 110, 122-124 The electromagnetic enhancements contributes to the 
signal through the production of a localized surface plasmon resonance (LSPR), as 
displayed in Figure 1.8. Coinage metal materials (copper, silver, and gold) are the most 
commonly used substrates for the production of SERS substrate. Incident photons, on a 
similar order of magnitude as the size of the metal features, cause a collective oscillation 
of the conduction electrons producing LSPR which can be tuned to maximum enhancement 
of surfaces with uniform roughness features. The enhancement displayed by SERS has 
been attributed to both mechanisms, but with unequal contributions to the overall signal 
enhancement. The chemical component is generally believed to be responsible for 10 to 
100 enhancement factors and the electromagnetic component is thought to be responsible 
for enhancement factors of 105 to 106.100-112
While the majority of the enhancement in SERS originates from the large LSPR 
from nanometer-sized asperities the conduction of electrons in the bulk smooth films 
producing a surface plasmon resonance (SPR) can also contribute to the enhancement.125- 





Figure 1.8. Illustration of a localized surface plasmon resonance of a metal sphere. The 
incident electric field component o f a light source causes the collective oscillation o f the 
conduction electron cloud.
interactions. The theoretical calculations indicate that the LSPR and SPR are dependent on 
the NP-substrate spacing in addition to the size, shape, composition, and dielectric constant 
of the materials involved.132-134 By isolation Raman labeled AuNPs on a gold substrate 
which increases enhancement reproducibility but reduces the overall signal enhancement 
that is achievable. However, fine tuning of the components of the assay.
SERS is therefore in the category of highly sensitive readout methods that can be 
used in detection platforms. The advantages to using SERS as a detection method is based 
on several inherent and beneficial attributes of Raman spectroscopy.68-83 The most 
important attribute of SERS detection is the simplicity and cost-effective production of 
currently available Raman instrumentation. The simplistic design, fast readout, and 
decrease in cost of more reliable components now sees Raman instrumentation that are 
available for ~$7,000 or more.
SERS also displays signal intensities comparable to those of fluorescence. 
However, compared to fluorescence, Raman bands are much narrower. The narrow bands 
reduce the likelihood of spectral overlap from multiple labels, which is beneficial in a 
multiplexed assay detection.87 This is due to the excitation being dictated by the enhancing 
substrate rather than the scattering molecule, allowing for a single excitation source. 
Plasmonics of the system also allow for red-shifted excitation, reducing natural 
fluorescence produced by biological materials that can cause background interference. 
Raman scattering is unaffected by its surrounding environment (e.g., pH, ionic strength, 
quenchers) resulting in a more stable and reproducible signal and long-term sample storage. 
This helps the Raman active molecules be more photostable due to the extremely short 
liftetime of the excited state.
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1.7 Nanoparticle-based SERS Sandwich Immunoassay 
Historically, SERS substrates were electrochemically roughened silver substrates. 
The production method produced a roughened substrate that was not easily controlled on 
the nanometer scale, and thus these substrates were considered irreproducible from a 
production stand point. Recent developments in the controlled production of nanoparticles 
(NPs) with specified sizes and shapes135 in combination with smooth substrates allows for 
a simplified approach to the fabrication of nanometrically roughened substrates.70, 136 NPs 
in colloidal suspension have added benefits produced by the conjunction of the NPs with 
smooth substrates.132, 136, 137 NPs immobilized on smooth metallic surface are 
straightforward constructions of a nanometrically roughened surface with consistent shape 
of the features. Hybridization of the plasmon created by the NP and the surface also 
increase the observed enhancement.138 The SERS signal enhancement has been 
demonstrated to have a dependence on the distance between the NP and the surface,139 size 
of the NP,140 angle of incidence,141 dielectric properties of the medium,141, 142 and 
composition material of the NP and surface.143, 144 The enhancement is considered to be 
produced primarily in the nanometeric region next to the NP between the NP and the 
surface creating a small “hot spot” or “hot junction” when the Raman active molecule is 
within a few nanometers of the NP surface.145
Before the introduction of the first NP-based SERS sandwich immunoassay, there 
were several attempts to create a SERS immunoassay. The first SERS sandwich 
immunoassay was demonstrated by Rohr and collaborators using a roughened silver 
surface coated with a capture antibody and was used to immobilize thyroid stimulating 
hormone (TSH).73 TSH was then labeled with a tracer antibody covalently coupled to p-
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dimethylaminoazobenzene (DAB), a Raman resonance dye. Another developmental step 
by Dou and collaborators was the demonstration of an enzyme and silver NP-based 
immunoassay.72 The detection of mouse IgG was performed using a basic ELISA platform 
in which the resulting product of the enzyme-substrate reaction was Raman active. The azo 
compound produced by the substrate reaction was removed and spontaneously adsorbed 
on silver colloids for solution-based analysis. The work of Zhang and collaborators 
successfully developed a label-free SERS platform for an anthrax biomarker.76 That work 
described the release of the biomarker calcium dipicolinate (CaDPA) via sonication in 
nitric acid and subsequent adsorption onto a silver film coating a nanoshere. The method 
demonstrated the usefulness of the system via the identification of Raman active 
biomarkers.
The Porter laboratory developed the first NP-based SERS sandwich immunoassay 
that has been used for a variety of disease markers, as shown in Figure 1.9.69, 70, 84-88. Our 
format is based on a sandwich immunoassay platform, and uses SERS as a detection 
method. The platform includes antigen selectively via the incorporation of a selective and 
Raman-active extrinsic Raman label (ERL) and capture antibodies bound to an atomically 
smooth gold capture substrate. The ERL consists of 60-nm gold nanoparticle (AuNP) with 
a Raman label chemisorbed to the surface, followed by a layer of tracer antibody. The 
antigen is sandwiched between a smooth gold substrate and an AuNP maximizing the 
enhancement of the SERS substrate and producing a quantifiable signal based on the 
number of ERLs adsorbed to the substrate. O f the many types of SERS-based platforms 
that have demonstrated the NP-based sandwich immunoassay, it is one of the most 
extensible and applicable in terms of analyte detection.
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Figure 1.9. The three main components of the SERS-based immunoassay: (a) ERL 
preparation; (b) capture substrate preparation; and (c) assay steps. The ERLs are prepared 
with AuNP core modified with a Raman reporter molecule and tracer antibody. The 
capture substrate is prepared by chemisorption of a linker molecule and immobilization 
of the capture antibody. Preparation of the ERLs and capture substrate are carried out 
prior to the assay. The capture substrate is exposed to the antigen solution and 
subsequently to the ERLs are added to complete the NP-based SERS immunoassay.
The ability to quantitatively measure the number o f antigens in a solution is based 
on the sandwich immunoassay design. In the sandwich immunoassay the antigen is 
immobilized by a capture substrate and subsequently labeled by a tracer antibody modified 
for detection. In the performance of an ideal SERS sandwich immunoassay, this indicates 
that each bound ERL is indicative o f a bound antigen. ERL can then be used as a measure 
of the number of antigens in solution. However, for SERS to be a reliable and quantitative 
detection tool, the signal from each of the ERLs bound on the surface should provide the 
similar quantity of signal. It is known that SERS enhancement is increased for large 
aggregates of NPs.146, 147 Due to the complexity of the mechanism behind SERS signal 
enhancement, more simplistic systems, such as the influence based on the interaction o f 
two particles, has been studied.110, 111, 125-132 The plasmon behavior of NP pairs is different 
from individual particles, causing shifts in the position of the LSPR and influencing the 
strength of enhancement.11, 102, 110, 113-132, 134 While the increased signal enhancement of 
paired NP is an advantage in terms of sensitivity, it is undesirable for quantitative analysis 
unless the dimer formation can be strictly controlled. Controlled aggregation o f particles is 
difficult to achieve. The demonstration of individual particles having detectable signal 
indicates that the use of aggregated particles is not entirely necessary.71 An ideal surface 
for SERS-based immunoassay has minimal ERL interactions to ensure a linear signal 
increase with increasing ERL densities. The spacing of the particles only needs to be on 
the order of ~100 nm, or just over the diameter of the particle, with reports stating most 
interactions occur within a one-diameter distance relative to the NP size.122, 123, 148, 149
The SERS immunoassay platform developed in the Porter laboratory has 
successfully demonstrated many of the advantages of SERS detection. The assay first
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demonstrated the ability to achieve low limits of detection (LoDs) of prostate specific 
antigen (PSA) in the femtomolar range. The detection of femtomolar concentrations of 
PSA was achieved with a cost-effective Raman instrument; the most expensive assay 
element was the biological recognition elements.70 This design has also been applied 
multiplexed detection to the simultaneous detection of rabbit, human, and mouse IgG 
proteins.71, 87 Development of methods for decreased assay times to decreases turn-around 
times via increased flux to the SERS-based immunoassay substrate.150 The extensibility 
and adaptability of the SERS-based immunoassay also allows for the detection of different 
antigens70, 84-86, 88 and demonstration of fundamental applications.71, 86, 87, 115, 151
1.8 Nanoparticle Transport 
In a colloidal suspension NPs are normally considered to move in solution based 
on Brownian motion.152 Brownian motion occurs due to the collisions between the particles 
and the fast moving atoms or molecules in the suspending fluid. The movement of the 
particles is also considered to be based on diffusional transport, which is dependent on the 
size of the particle, temperature, and media viscosity. A diffusion coefficient for a spherical 
NP suspended in solution can be calculated with the Stokes-Einstein equation for 
diffusivity, given by:
D _  kBT (1.4)
6 n-qr
where kB is Boltzman constant (1.3807x10'23 J K-1), T is the temperature (K), ^ is the 
viscosity of the suspending fluid (kg m-1 s-1), and r  is the particle radius (m).153 The root
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mean square distance (x2) of a NP moving based on diffusion is explained by:
(x2) (1.5)
t  =  -— - 2D
where the time it takes for a given particle to travel an average total distance in one 
dimension is based on the diffusion coefficient for the particle. From this relationship it 
can be concluded that if  the movement of a particle is based on diffusion, then the 
displacement of the particle will have a linear relationship with respect to the square root 
of time.
It is a commonly held belief that a colloidal suspension is stable and predominantly 
displays diffusional or Brownian motion. However, NPs of adequate size and composed of 
sufficiently dense material are also susceptible to settling due to gravitational force.154 The 
rate of particle settling is influenced by buoyancy, drag, and gravity. Buoyancy and drag 
forces can oppose the gravitational forces and can increase the stability of particles in 
solution. Buoyancy is the force exerted by the fluid displaced by a particle and is a function 
of the particle volume and the density of the liquid. The drag force is produced by the fluid 
motion acting on the particle based on fluid viscosity, particle size, and velocity. Stoke’s 
Law describes the terminal settling velocity of a particle in a solution
_  d (Pp Pm)d 
Vsed= 18^ (1.6)
where g is the acceleration due to gravity (m s 2), pp is the particle density (g m 3), and
pm is the media density(g m-3).155 This formula shows that settling increased with particle 
density and the square o f the particle radius, matching experimental and theoretical results 
based on the behavior of NP sedimentation.154, 156, 157
The Stokes-Einstein equation and Stokes Law define the transport of NPs in 
suspension based on diffusion and sedimentation. The final component that can influence 
the transport of NPs in suspension is the interaction between the particles that causes 
aggregation. NP aggregation is an extremely complex phenomenon with a few well- 
defined descriptions and calculations for estimating the kinetics of NP aggregation.158-160 
However, the accepted methods that typically describe particle transport assume that the 
particles do not interact in suspension. Movement of particles in a stagnate suspension 
under a uniform force, such as gravity, can then be described by the Mason-Weaver 
equation.161
dC d2C dC
7 i ~ D ~dz2 + Vsed~te ( 17 )
In Equation 1.7 C is the concentration of particles in solution (mol L-1), t is time (s), and 
z  is the vertical direction opposing gravity. In this equation vsed can also be displayed as 
the sedimentation coefficient (s) multiplied by gravitational force (g), two terms are which 
is sometimes displayed separately. The partial differential equation describes the 
movement of the particles in suspension as a function of both time and position after an 
initial point where all particles are evenly distributed in the suspension.
Most research involving NP incubations look at the size, shape, and surface 
chemistry of nanoparticles as having an influence on the interactions of NPs with biological
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materials.162-165 Few articles have taken into account the influence of sedimentation on NP 
incubations.154 If it can be assumed that the dominate transportation of NPs in suspension 
is defined by the diffusion influenced by the behavior of the tracer antibody immobilized 
on the surface of an NP, then the diffusion and adsorption should follow a t 1/2 adsorption 
dependence.
1.9 Dissertation Overview 
The bulk of the work in the dissertation is based on the themes introduced above. 
The primary aim is to address the concerns presented by the scientific community centered 
on the reliability of SERS-based detection method. Each of the chapters is presented as an 
individual manuscript that investigates differing aspects of the reliability of the SERS- 
based immunoassay. The foci of the chapters is on the influence of sampling and particle 
transport on the reliability of the SERS readout and the impact of the implementation of 
new techniques on the SERS analysis. Chapter 2 describes the investigation into the 
influence of sampling on SERS readout. Chapter 3 explains the development of procedures 
used for the SERS immunoassay towards the development of diffusional transport of ERLs 
in suspension in order to increase the likelihood of random dispersion on the immunoassay 
substrate. Chapter 4 discusses the development and implementation of the new techniques 
for the detection of TB markers. Chapter 5 outlines the validation of the platform via 
analysis of patient samples. This dissertation is concluded with a summation of the insights 
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CHAPTER 2




Surface-enhanced Raman scattering (SERS) has emerged as a powerful tool for the 
analysis of a wide range of materials.1-3 However, the reliability of this surface-sensitive 
technique to serve as a basis for quantitative measurements remains an ongoing concern.4- 
8 Part of the issue rests with the intrigue and importance of creating nanostructured 
materials that have ever-larger enhancements. Many of these materials, however, can be 
difficult to prepare reproducibly or have a size and/or shape that may have limited structural 
stability.9, 10 As a result, several laboratories,4-8, 11-18 including the Porter laboratory,3, 19-26 
have pursued tactics that have proven useful in overcoming the reproducibility of SERS 
measurements. Our approach sacrifices the extraordinarily high-levels of enhancement 
afforded by some types of nanostructured materials (e.g., nanocavity arrays,5, 8 27 
nanostructured metal surfaces,28-31 and porous metal films32) by using particle geometries 
(e.g., spherically-shaped particles), which are more readily produced with a more 
controllable and stable size and shape dispersity but do not have as large of a plasmonics- 
based signal enhancement.33, 34 This “management of reproducibility”33, 35-37 has begun to
demonstrate the merits of SERS as an quantitative analysis tool in diagnostic testing 3 7 22, 
38, 39 and other arenas.2, 40-42
This paper examines another obstacle encountered when attempting to take 
advantage of the strength of SERS as a quantitative measurement tool: sampling error. By 
sampling error, we are referring to the error introduced in a measurement when the size of 
the sample analyzed is below that needed to represent reliably the composition of the 
sample. We show herein how sampling error occurs with SERS due to the small size of the 
focused laser spot that is typically used to measure the concentration of biolytes captured 
and labeled in the sandwich-styled, SERS-based immunoassay shown in Figure 2.1. 
Indeed, this type of sampling error is exactly the same as the classic sampling problem 
encountered when, for example, the size of the sample collected and analyzed from a large 
waste site fails to match accurately that of a larger, more representative sample, which 
introduces bias into the measurement.
The statistical underpinning of this situation is found in the central limit theorem. 
This theorem states that the data collected from a sufficiently large sampling of a 
population will be normally distributed about the mean value of the population.43, 44 This 
theorem also indicates that the variance of the measured distribution will decrease as the 
size of the sampled population becomes larger and/or the number of samplings of a 
population, r^eplicate, at a fixed sample size is increased. The benefits of increasing n is,
however, governed by the law of diminishing returns.45 The law of diminishing returns 
dictates that the decrease in the variance of the measurement, and thus improvements in 
the “trueness” of the mean, improves with Vn .
We hypothesized that a significant and unrecognized portion of the error associated
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Figure 2.1. The three primary steps of the SERS-based immunoassay: (a) preparation of 
extrinsic Raman labels (ERLs); (b) preparation of the capture substrate; and (c) 
procedure for the production of the antigen sandwich. The first two primary steps are 
performed prior to the assay. The immunoassay is performed by incubating a 20 ^L 
droplet on the capture substrate at room temperature. The sample is then rinsed, exposed 
to a 20 ^L droplet of ERLs, rinsed, dried under ambient conditions, and analyzed. (d) 
Analysis of the SERS-based preparation is performed via excitation of the SERS 
substrate with a focused laser spot. The SEM images shows ERLs on the capture surface 
and the SERS spectrum collected from a focused laser spot with a 5 p,m diameter.
with SERS readout, especially when attempting to push limits of detection (LoD) to lower 
levels, is due to sampling error. In diagnostic tests like enzyme-linked immunosorbent 
assays (ELISA),46 the signal arises from a measurement of the homogenous solution 
produced at the end of the assay. This type of readout inherently averages the response 
across the entire capture address located at the bottom of each well in a microplate. 
However, the optics associated with a Raman spectrometer are designed to have high light 
collection efficiencies by using optical components with large numerical apertures, which 
result in small laser spot sizes, that is, small surface sampling areas. In most Raman 
spectrometers, the actual area of the focused laser spot is exceedingly small (tens of 
microns in diameter), which examines only a small fraction of the total surface of the 
sample (e.g., a 10 p,m laser spot interrogates ~10-6 of the geometric surface area of a 3 mm 
diameter address). It follows that a small analysis area can result in an inherent sampling 
error that can lead to a large measurement variance and a biased “apparent” mean value, 
both of which become more problematic as the analyte concentration in the assayed sample 
decreases.
There are several statistical methods that can be used to assess the impact of the 
variance of an analytical measurement. The overall variance47-49 of the analytical result, 
Sq , equals the sum of the relative variance due to sampling, s 2, and the relative variance 
due the actual measurement, s 2. This relationship can be written as:
s i  = s 2 +  ss2 (2.1)
Assuming that all of the other components of the assay are under statically control,50 s 2
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can be found by measuring repeatedly a sample that produces a consistent signal. That is, 
the variance in the measurement represents the overall instrumental error, for example, 
power fluctuations and detector noise. As a result, s 2 can be determined from the difference 
between and s | .  Too often, however, attempts to improve the precision of a 
measurement focus on reducing s 2, while neglecting the importance of . Youden’s Rule 
of Thumb states that if  s 2 is nine times greater than s 2, only marginal improvements in 
will be realized when attempting to improve s 2. In such a case, more notable improvements 
in will be achieved by lowering sj, which entails either an increase in the number of 
replicate samplings (^ replicate) of fixed size or an increase in the overall size of each sample
being analyzed in one sampling.
One approach to this type of analysis is to determine the amount of sample needed 
to produce results at a predefined level of reliability (i.e., accuracy and precision). 
Classically, this can be done using the sampling constant, Ks :
Ks = mR2 (2.2)
where m  is the mass of the sample and R is the percent relative standard deviation (%RSD) 
due to sampling error. While the use of Ks is frequently associated with the analysis of 
particulate-based samples51, 52 (e.g., the analysis of a small fraction of a powdered sample), 
it can be applied to other types of analyses that may be plagued by undersampling. This 
approach is most useful in the sampling region where the accuracy and precision of the 
results is sensitive to the sample size. Ks can then be calculated to determine the mass 
required to realize, for example, a 1% RSD for a particular sample type.
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Herein, we examine the impact of sampling error when using SERS as a 
quantitative analytical tool in a sandwich-styled immunoassay. In doing so, we first 
construct a simple random accumulation model to represent the SERS immunoassay 
substrate removing any systematic or experimental error. Analysis o f the modeled substrate 
is then used to determine the error associated strictly with the analysis of the substrate.
2.2 Experimental
2.2.1 Reagents and Materials
Borate buffer packs (pH 8.5), modified Dulbecco’s phosphate buffed saline packs 
(pH 7.4), dithiobis(succinimidyl propionate) (DSP), and StartingBlock were obtained from 
Thermo Scientific. Acetonitrile (ACN), Tween 20, sodium chloride, and bovine serum 
albumin (BSA) were purchased from Sigma-Aldrich. Goat antihuman immunoglobulin G 
and human IgG were acquired from Pierce; Epoxy 377 from EPO-TEK; octadecanethiol 
(ODT) from Fluka, poly(dimethyl siloxane) (PDMS) from SlyGard; and 200-proof ethanol 
from Pharmco-AAPER. The synthesis of the Raman reporter molecule 5-5’- 
dithiobis(succinimidyl-2-nitrobenzoate) (DSNB) has been described previously.22 All 
reagents were used without further purification.
2.2.2 Preparation of Extrinsic Raman Labels (ERLs)
A detailed description of the SERS assay procedure has been described 
previously.19 The ERLs were prepared in batches using a 0.96 mL suspension of 60-nm 
gold nanoparticles (AuNPs) at 2.6 x 1010 AuNPs/mL, and adjusting the buffer strength by 
the addition of 40 ^L of 50 mM borate buffer (BB, pH 8.5). The buffered AuNPs (2.0 mM
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BB) were then modified by the addition of 10 |iL of 1.0 mM DSNB, followed by 10.0 p,g 
of antihuman IgG (13.3 |iL of 1.5 mg/mL stock solution), and 100 |iL of 10% BSA (20 
mM BB), which produced a 1% BSA solution. After letting the resulting suspenstion stand 
for 7 h, excess reactants were removed by centrifugation of the suspension at 2,000g for 
10 min to pellet the ERLs and then by withdrawing carefully the supernatant. The ERLs 
were resuspended with 1.0 mL 1% BSA (2.0 mM BB). This cleanup process was repeated 
two more times. As a result of these steps, the ERLs were concentrated to 4.0 x 1010, as 
determined using the spectrometric method of Haiss and collaborators.53
2.2.3 Preparation of the Capture Substrate and 
SERS Immunoassay Procedure
The capture substrate was prepared on template stripped gold (TSG) by first 
creating a hydrophobic boundary, which defined address diameter (2.0 or 3.0 mm) address, 
using microcontact printing with ODT. The address was then reacted with DSP (14-16 h), 
followed by 2.0 |ig/mL of the capture antibody, antihuman IgG, in 10 mM phosphate- 
buffered saline with 1% Tween 20 (PBST, pH 7.4) for 7 h. These capture substrates were 
rinsed three times with PBST and treated with StartingBlock. Finally, the substrates were 
incubated with antigen solution (20 ^L), rinsed three times with PBST, inverted, exposed 
to the ERL suspension for 16 h, rinsed with BB [0.1% Tween 20, 10 mM NaCl (BBT, pH 
8.5)], and allowed to dry under ambient conditions for a least 1 h.
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2.2.4 Instrumentation
Analysis and mapping of the sample substrates by SERS used a Thermo Scientific 
DXR Raman microscope that was equipped with a HeNe laser (632.8 nm), a 
thermoelectrically cooled to (-65 °C) CCD detector, and a 50 p,m entrance slit. The spectral 
resolution changed from 5.2 to 8.8 cm-1 over the spectral acquisition range of 50 to 3500 
cm-1, respectively. All spectra were collected by averaging the signal from two 1-s 
integrations at each sample location. The microscope was fitted with a 10x Olympus MPlan 
N objective, which predicts a 5-p.m diameter laser spot, or a 50x objective, which predicts 
a laser spot diameter of 0.5 p,m.
The Raman map was collected in 20-p.m steps over the entire assay address (2.0 
mm) by using a translation stage with a 1-p.m resolution. Maps for 2.0-mm addresses 
consist of ~14,500 data points (i.e., a square matrix of ~120 rows and columns) of data, 
whereas the 3.0-mm maps contain ~26,000 data points (i.e., a square matrix of ~160 rows 
and columns) of data. The intensity at each location was determined from the SERS 
spectrum based on the peak height at 1336 cm-1 [us(NO2)] of DSNB after baseline 
correction, which was then normalized to the average signal o f 4,000 data points at the 
center of the address. The x- and ^-coordinates for each pixel were converted to polar 
coordinates in order to analyze and present the data as a function o f the radial displacement 
of the signal from the center of the address. Next, the frequency of the signal strengths 
were then organized by binning the normalized intensities into 0.01 increments, with the 
resulting histogram fit to a Gaussian distribution by means of a nonlinear least squares 
analysis. Finally, the residuals of the Gaussian fit were plotted to examine the quality of 
the fit with respect to the actual data distribution about the mean value.
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Scanning electron microscopy (SEM) images were obtained using a field emission 
scanning electron microscope (NanoNova SEM, FEI) equipped with a through-the-lens 
detector. Post imaging analysis used ImageJ software (National Institutes of Health, 
Bethesda, MD).
2.2.5 Computational Modeling
In order to understand the impact of sampling size on the measurement (i.e., the 
area of the capture surface interrogated by the focused laser light), Monte Carlo simulations 
(C++ programing language) were designed to mimic the analysis of the sample by SERS. 
The first step in the simulation produced a two-dimensional (2D) surface (3.0 mm diameter 
only) composed of a random distribution of point-sized adsorbates (PSAs). The next step 
simulated the analysis of the surface by a focused laser spot by randomly placing a disk of 
predetermined area on the simulated capture surface and counting the number of PSAs 
encompassed within the disk. Different predetermined numbers of replicate measurements 
were then made by repeating the procedure, with the average and standard deviation of 
PSAs per unit area used to assess the accuracy and precision of the results.
To produce a 2D surface with a random PSA distribution, a 3 x 1015 by 3 x 1015 x- 
y  network was populated by using a pseudo-random number generator with 15 digit 
accuracy. A location was rejected if  it was positioned outside the defined 3.0-mm diameter 
address. This process was repeated until reaching a specified number of randomly selected 
locations across the address.
Given the spacing between PSAs, the x- and y-coordinates in both directions have 
a step size of 1 x 10-15 mm. This produces PSAs of an equal square size of 9.0 x10-18 nm2
that were then populated with 1 x 107 PSAs (unless otherwise defined) within the defined 
3.0-mm disk. We did not account for the possibility of PSA co-occupancy, but the 
probability of populating the same location was extremely low.
To simulate the analysis of an address by a laser spot, a pseudo-random number 
generator was used to select another set of x- and ^ -coordinates to serve as the center of a 
predefined circular analysis area. If the entire analysis area was contained within the 
bounds of the defined 3.0-mm diameter address, the number of PSAs was counted and 
recorded. An analysis area was rejected if any portion of the analysis area extended beyond 
the defined 3.0-mm address, and a new location was chosen.
The results from all of the simulations are reported as the area analysis ratio (AAR). 
The AAR is defined as the area contained within a single circular analysis area divided by 
the total area of the simulated substrate. A majority of results presented are for AAR values 
from 0.99 to 1x 10-7. By way of example, a substrate with a 3.0-mm diameter has an area 
of 7.07 x 106 ^m2. AARs of 0.99 and 1x 10-7, and therefore equate to simulated laser spots 
with areas of 7.0 x 106 and 7.1 x 10-1 ^m2, respectively; these AARs correspond to circular 
analysis diameters of 2.9 mm and 0.95 |im.
2.3 Results and Discussion
2.3.1 SEM Imaging and Development of a Monte Carlo 
Simulation for an NP-based Immunoassay Substrate
To set the stage for the sampling problem associated with the analysis of an NP- 
based SERS immunoassay substrate, we devised a random accumulation model (RAM) to 
document how the accuracy and precision of the measurement are affected by the surface
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area of the sample analyzed. We opted to construct a computational model of the 
immunoassay in order to eliminate any impact from possible experimental biases in 
preparing the assay components or from carrying out the assay. To do so, we first defined 
a standard (i.e., an expectation value) to use for the RAM from SEM images of a SERS 
substrate after the completion of an assay. A representative image is shown in Figure 2.2. 
This image is for a capture substrate that was first exposed to an antigen (H-IgG) 
concentration of 6.67 x 10-11 M (10.0 ng mL-1 H- IgG) and subsequently to a suspension 
of ERLs with a gold core of ~60 nm.
The image consists largely of isolated ERLs, a few cluster-like (for example, 
dimers, trimers, and short filaments) arrangements, and clearly visible voids. A few 
nonspherically-shaped ERLs are also evident. This distribution is characteristic of 
randomly accumulated particles on a surface,54 and is representative of 5 images obtained 
from different locations across the sample surface. Determination of the number of ERLs 
in the 5 images yielded an average density of 13.5 ± 1.5 ERLs pm-2. For the Monte Carlo 
simulations, we used a lower PSA density (1.415 PSAs pm-2 or 1.000 x 107 PSAs for a 3­
mm diameter address) in order to manage computational time, which proportionally 
corresponds to a H-IgG concentration of 4.35 x 10-11 M (~0.74 ng/mL H- IgG). The true 
value for the computational simulation was defined to have 4 significant figures in order 
to more fully assess the impact of the results. We have assumed that each captured antigen 
is tagged by one ERL.
Figure 2.3a presents an example of the random accumulation of PSAs on a 3-mm 
diameter substrate. For visual clarity, the representations show only 5,000 of the randomly 
distributed PSAs. Each PSA is represented by an oversized cross that is ~1031 times larger
55
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Figure 2.2. SEM image of a SERS immunoassay substrate for H-IgG at a concentration 
of 6.67 x 10"11 M (10.0 ng mL-1), which has an ERL density of ~13.5 ± 1.5 ERLs p,m-2. 
The brighter circular features in the SEM image are consistent with a 60 nm AuNP core 
used to produce ERLs. (a) Image area of ~290 p,m2; (b) enlargement of the highlighted 
area in the center of (a).
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Figure 2.3. Visual representation of pseudo-random distribution of PSAs on a 3.0-mm 
diameter substrate. (a) 5,000 oversized PSAs (1 x 1031 times larger than actual size) on 
the simulated address. (b) Same simulated substrate with five randomly located analysis 
areas, each with a 300-pm diameter or an AAR of 1.0 x 10-2.
than an actual PSA; the actual size o f a PSA is not be visible at the length scale o f the two 
representations. The analysis example in Figure 2.3b shows the location of 5 randomly than 
placed, disk-shaped analysis areas (neplicate = 5), each with a diameter of 300 |im or an
AAR of 1.0 x10-2. The analysis counts the number of PSAs within each disk, and the 
average and standard deviation of the results for different sizes and numbers of sampling 
areas are then compared to the true value (mean) for the simulated substrates to determine 
the accuracy and precision o f the measurements.
2.3.2 Importance of Replicate and Sample Size
Using a Simulated Assay
Assuming all other components o f the assay are under statistical control, the 
reliability of a measurement can be improved by increasing the sample size. The sample 
size is related to the number of measurements on the substrate (Replicate) for a given AAR
and/or by increasing the actual size o f each sampling (AAR). Data for assessing the impact 
of each approach are shown in Figure 2.4 by plotting the PSA density, average absolute 
deviation from the mean (DAvg), and standard deviation (s) from the mean as a function of
neplicate for three values of AAR: 1.0 x 10-7 (0.95 p,m diameter), 1.0 x 10-6 (3.0 p,m 
diameter), and 1.0 x 10-5 (9.5 ^m diameter). These results are from 10 separate simulations 
with neplicate equal to 1, 2, 3, 4, 5, 10, 25, 50, 75, and 100 in order to examine the trends in
DAvg and s. Figure 2.4a shows the raw simulation results with many of the points 
overlapping due the discrete values for PSA analysis with small AARs. Values for DAvg 
and s  indicate trends in the simulated data for the accuracy and precision, respectively.
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Figure 2.4. Results from 10 simulations of the random accumulation of PSAs indicate 
the impact of Replicate on the (a) raw simulation results for PSA density (b) accuracy 
expressed as the DAvg, and (c) the precision expressed as the s for PSA counting, with 
no provided value for Replicate of one. Results are shown for several AARs that were 
selected based on the magnitude of change in the accuracy and precision.
As evident, increases in both Replicate and AAR improve the accuracy of the 
measurement (that is, DAvg approaches zero). The improvement with Replicate is the most
notable for the smallest AAR, 1.0 x 10-7. That is, the rate of convergence in accuracy is 
dependent on the total area sampled; thus, the largest of the sampled areas (AAR = 1.0 x 
10-5) has the highest rate of convergence, and the smallest of the sampled areas (AAR =
1.0 x 10-7) has the lowest rate of convergence. The error in the accuracy for an AAR of 1.0 
x 10-7 for an Replicate of 1 is ~80% larger than that for Replicate > 25. Similar improvements 
in accuracy are also evident for the larger AARs (1.0 x 10-6 and 1.0 x 10-5), though not as 
dramatic. These results indicate, as expected, that increases in both Replicate and AAR can 
be used to improve the accuracy of the measurement.
Figure 2.4c plots how the precision (i.e., 5) of the simulated measurements is
influenced by Replicate as a function of the same three AAR values. The results show that 5 
at a given AAR fluctuates at low values of Replicate, but then converge to different limiting 
levels as Replicate increases. The smallest AAR value, 1.0 x10-7, approaches a limit in 5 at 
an Replicate of ~50. This value of 5 indicates that the error in the measurement is larger than
the mean value of the measurement (Figure 2.4c), that is, representing a large fundamental 
error due to undersampling. The two larger AARs, 1.0 x 10-6 and 1.0 x 10-5, approach 
smaller limiting values in 5 after only 10 measurements, which document a clear
improvement in the error associated with sampling. As will be shown later, the fundamental 
error associated with sample size is a large source of the actual experimental error reported 
in our SERS-based immunoassay results. Note also that the value for 5 follow the expected
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decrease with respect to the Vn as expected.
These results can be used to estimate the minimum value for Replicate at a given 
AAR that is needed to produce a true value by using the sampling variance at each AAR. 
The minimum value of Replicate, calculated for a chosen confidence interval, for a target 
RSD is expressed as:
t 2s 2
nreplicate = g$Q2 (2.3)
where t can be found from the Student’s t-table at a given confidence level. With a 
confidence interval of 95%, a relative standard deviation of 1% (an RSD of 0.014 with 
respect to the true value of 1.415 PSAs pm"2), and a value for s  (determined by the
simulation for values of Replicate > 50), the minimum value of Replicate required to produce 
a result at the specified tolerance can be calculated.
Using these parameter values, the simulated results indicate that an Replicate of 1 is
sufficient to measure the true PSA density of 1.415 PSAs |im-2 for AARs larger than 1.0 
x 10-2 (> 300 |im diameter). For the smaller AARs of 1.0 x 10-3 (95 |im diameter), 1.0 x 
10-4 (30 ^m diameter), 1.0 x 10-5 (9.5 ^m diameter), 1.0 x 10-6 (3.0 ^m diameter), and 1.0 
x 10-7 (0.95 |im diameter), the required values of Replicate are 1, 8, 857, 8,768, and 81,359,
respectively. If the %RSD is increased by a factor of 5 to 5%, which approximates the error 
expected from the noise of the instrument used in our experiments (see section 2.3.6), the 
values of Replicate for 1.0 x 10-4, 1.0 x 10-5, 1.0 x 10-6, and 1.0 x 10-7 decrease to 3, 34, 
355, and 3,254, respectively. All larger AARs require only a single measurement.
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The impact of increasing AAR was also examined and these results are presented 
in Figure 2.5. The inserts have an x- and _y-axis on a log scale in order to show the small 
changes in the results. The evolution in DAvg and s  indicate that neplicate has a larger impact
on the results for lower AARs. Improvements in the results for different numbers of neplicate
are evident for lower AARs, but are only marginally distinguishable, at best, at higher 
values of AAR. The AAR that shows the greatest increase in accuracy and precision is for 
an AAR of 1.0 x 10-7 to ~1.0 x 10-2. When the value of AAR is ~1.0 x 10-2 (i.e., a 300- 
|im diameter laser spot), the simulated measurement for a PSA density of 1.415 PSAs p,m"2 
is > 99% accurate and has an RSD of 1% or better for neplicate > 2. AARs matching the
laser spot size (e.g., 0.5 to 5 p,m laser spot diameter) would indicate that larger laser spot 
sizes would produce more accurate and precise results. The benefit o f using a larger laser 
spot does none the less come with a tradeoff. That is, the use o f a lower numerical aperture 
to increase the spot size also decreases the collection efficiency, and thus, LoD o f the 
objective.
2.3.3 Normal Distribution of Simulation Results for a Given AAR.
Another way to examine the differences in the impact of sample size is to analyze 
the results in terms of the normal distribution of 100 simulations, each at an neplicate = 1.
These plots are shown in Figure 2.6. The center of the distribution represents the mean of 
the results, whereas the standard deviation is directly linked to the width of the distribution. 
The normal distribution for an accurate and precise result therefore depends on a given 
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Figure 2.5. Monte Carlo simulation results indicating the impact of sample size in terms 
of the AAR on the (a) PSA density, (b) accuracy expressed as the DAvg, and the (c) 
precision expressed as the s  from the mean. Insets show the same data with the x- andy- 
axis on a log scale to highlight small changes in the data. Results are shown for several 
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Figure 2.6. Normal distribution curves for data collected from 100 simulation results.
(a) Normal distribution curves for AARs between 99 and 1.0 x 10-6. (b) Normal 
distribution curves for AARs between 0.10 and 1.0 x 10-3. (c) AARs between 1.0 x 10-3 
and 1.0 x 10-6 on different vertical and horizontal scales to show differences in the height 
and width of the distributions. The values for |i and o for each fit are shown within the 
figure.
at a larger value of AAR.
As expected, the results show that the highest probability of measuring an accurate 
and precise value occurs at an AAR of 0.99. The precision in the measurement, however, 
degrades with decreases in AAR. This is represented, for example, by the increase of the 
width of the distribution at the AAR of 0.10, the center of the normal distribution of the 
profile shifts away from the true mean value, indicating inaccuracy in the results. It is also 
important to note that the accuracy of the measurements begins to diminish as AAR 
decreases. Below an AAR of 0.99 represents how small decreases in AAR have an impact 
on the potential distribution of the results. We note that the analysis of an AAR of 1.0 x 
10-7 is not shown because the extremely small sample size produces discretized results that 
are dominated by zeros and cannot be reliably fit.
2.3.4 Determination of the Sampling Constant (Kv) for the 
Simulated SERS Substrate
The simulations show that the accuracy of the results converge more rapidly 
towards the true value with increases in AAR, following the expectations of the sampling 
problem associated with the accuracy and precision often found when determining trace 
constituents in geological samples.51 Along these lines, Equation 2.2, which is used to 
establish the mass of a sample required in geological analysis to reach a given accuracy 
and precision, was adapted to determine Ks for the simulated SERS substrate by setting m  
equal to AAR.
To predict the Ks value, 10 separate simulations were carried out and analyzed to 
determine the spread of the results for evenly spaced increments of AARs between 1.0 x
65
10-3 to 0.5. The resulting PSA densities versus AAR are presented in Figure 2.7a. The 
distributions again exhibit an increase in the accuracy and precision of the measurement 
with larger values of AAR. This plot was used to calculate values of the RSD for the 
measurement at each AAR, which was then applied to construct the graph in Figure 2.7b 
of %RSD versus the diameter of the sampling area. For a 1% RSD, the laser spot size has 
a diameter of 550 ^m, which corresponds to a value for Ks of 3.4 x 10-2 AAR. After finding 
Ks , Equation 2.2 can be rearranged to calculate the AAR required for a given RSD. By 
loosening the tolerance in the precision, for example, from 1% RSD to 5% RSD, the 
required value of AAR decreases from 3.4 x 10-4 to 1.4 x 10-3 or from a sampling diameter 
of 550 to 56 ^m, respectively. The results for the 5% RSD are of particular interest, being 
a readily achievable laser spot diameter. A laser diameter of 100 p,m, which is available in 
commercially available instrumentation, would require a laser power of 2 W to achieve an 
equivalent power density as a laser spot diameter of 5.0 |im at 5 mW.
2.3.5 Monte Carlo Simulations on the Influence of AAR on LoD
The LoD of a method is defined as the lowest concentration that can be 
distinguished from the blank based on a specified level of confidence.55 In terms of NP- 
based SERS detection, a single ERL can produce a signal that is distinguishable from the 
background (this analysis assumes that there is not a contribution to the measurement from 
nonspecific adsorption).3, 24 Using this performance level as a guiding metric, we can define 
the LoD for the simulations as the ability to find at least one PSA with 95% confidence for 
a given AAR. We assume that there is no nonspecific adsorption, no mass transfer 
limitations, infinite sample volume, and that the binding affinity has a linear relationship
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Figure 2.7. Determination of the sampling constant (Ks) based on simulation results. (a) 
Sampling diagram of simulated results for PSA counting of a random distribution of 
PSAs on a 3.0-mm substrate with 1.415 PSAs |im-2 for 10 simulations results with an 
n-eplicate of one. (b) Plot of analysis diameter (mm) versus percent relative standard 
deviation equal to ^K s/ m  based on Equation 2.2. The calculation predicts the percent 
relative standard deviation past the substrate diameter because the calculation assumes 
an infinite substrate size.
with the ERL density displayed for the 10 ng mL"1 sample down to a blank with zero 
binding. For this analysis, the number of PSAs on a 3.0-mm diameter substrate was varied 
and analyzed with a value of Replicate of 100 for densities ranging from 1 to 1 x 107 PSAs 
p,m"2 at intervals of half an order of magnitude. The average number (x) and standard 
deviation (5) for the PSAs accumulated by the simulation were then used to calculate the
lowest PSA density in which at least one PSA will be detected at 95% confidence from an 
individual simulation. The t value for a one-sided (0.5%) probability distribution with 
(n -1 )  degrees of freedom is 1.645, which indicates that if  the value of x  - 1.645s > 1, then
the AAR is of sufficient size as defined by the LoD. A pictorial representation of the 
predicted LoD is shown in Figure 2.8, and the LoD versus AAR is presented in the insert.
The LoD versus AAR plot indicates that increases in AAR yield lower LoDs. The 
inset shows the _y-axis on a log scale to highlight changes in the LoD for larger AARs. The 
largest impact on the LOD is again found for the lowest AARs. At an AAR of ~0.1 (1.1 
mm diameter) or larger, the benefit of further increases in the AAR in terms of LoD is only 
marginal. An AAR of 0.1 gives and LoD equivalent to a PSA density of 5.66 x 10"5 PSAs 
p,m-2. Based on a simple linear projection of the ERL densities given in Figure 2.2, these 
findings point to a low LoD at femtomolar concentrations. The inset of Figure 2.8 shows 
above and AAR of 0.1, there are small but continual decreases in the LoD but no more than 
a single order of magnitude. There is, however, a significant drop in the LoD that occurs 
at an AAR of 0.99. This decrease is present due to minimal percentage of the surface that 
is missed by the laser spot pressing the LoD closer to the limit of 1 PSA per address and 
corresponds to attomolar concentrations LoD.
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Figure 2.8. Monte Carlo simulation results for LoD. AAR vs. LoD in PSAs p,m-2 based 
on 95% confidence that the measurement was above 1 PSA on the substrate. Inset shows 
the same data with the _y-axis on the log scale. Simulations for a random distribution of 
particles on a 3.0-mm circular substrate for various particle densities with 100 Replicate 
were used for the 95% confidence calculations.
2.3.6 Analysis of SERS Immunoassay Substrates
This section examines the degree of signal variation in the form a high density 
Raman map for a SERS-based immunoassay substrate. The sample was prepared using the 
procedure described in the Experimental section. Figure 2.9 presents a 2 x 2 mm Raman 
map (Figure 2.9a) of a 2-mm diameter capture substrate and the subsequent analysis of the 
signal distribution (Figures 2.9b-d). The map was constructed by mounting the sample on 
an x-y translation stage that was moved in 20 pm steps and analyzing each location with a 
10x microscope objective (laser spot diameter of 5.0 pm at 5 mW). These intensities were 
normalized to the average SERS intensity for the central 4,000 data points [data within an 
approximate 700 pm diameter (red circle)], which was selected to omit the inclusion of the 
obvious defects in the sample just beyond the area bound within the circle. The plot has a 
normalized signal intensity of 1.00 ± 8.30 x 10-2, which was produced from a raw signal 
with an average and standard deviation of 1223 ± 104 cts s"1. The green color represents 
the normalized single of 1.0, with orange and red colors depicting higher signals of 1.5 and 
2.0, respectively. The blue and violet colors signify the lower signals of 0.5 and no 
observable signal, respectively. Note that the signal intensity outside of the defined address 
area are comparable to that of the background.
To examine the signal distribution across the substrate, the data map was converted 
from Cartesian to polar coordinates and then plotted in Figure 2.9b as the normalized SERS 
intensity versus radial distance from the center of the address. The average SERS intensity 
(x), which was normalized to unity, and the corresponding 95% confidence interval 
surrounding the mean (±1.96 x s) are represented by the solid and dashed black lines, 
respectively. A least squares fit to the data was also performed by converting the signal to
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Figure 2.9. SERS immunoassay substrate analyzed with (a) high density Raman color 
contrast mapping of the normalized signal intensity. Green represents the mean signal 
from the central 4,000 data points (within the red circle). Warmer and cooler colors 
indicate higher and lower signal intensities, respectively. (b) Normalized SERS signal is 
shown in polar coordinates to highlight differences in the signal distribution from the 
center to the outer edge of the address. (c) The central 4,000 data points represented in a 
histogram with the data are binned into 0.01 normalized increments with a linear least 
squares fit to a normal distribution. (d) Residuals for the least squares fit to a normal 
distribution. The solid black lines represent a normalized signal of one, the dashed black 
lines indicate the 95% CI, and red lines indicate the 4,000 data point cutoff.
a histogram (Figure 2.9c) in 0.01 normalized intensity steps. The residuals for a least 
squares fit to the histogram (Figure 2.9d) do not have a notable pattern, indicating a 
reasonable representation of the data.
To quantify the contribution of the signal variance from sampling error, s 2, the 
signal variance from the instrument, s 2, was determined by collecting 100 spectra from the 
on a freshly polished glassy carbon substrate and analyzing the peak height from the 1332 
cm-1 band. A normalized signal of 1.00 ± 3.02 x 10-2, which equals a s 2 of 9.34 x 10-4, 
was calculated from the raw signal intensity of 175 ± 6 cts s-1. The overall variance, , 
was calculated from Equation 2.1 as 5.97 x 10-3 or 1.00 ± 8.30 x 10-2. The value for s |  
was determined to be 6.39 times the value of s 2. The higher signal variance for the analysis 
of the same substrate indicates addressing the sampling issue will lead to more 
improvements in the signal than from improving the variance due to the instrument.
The SERS substrate in Figure 2.9 was also analyzed with a 50x microscope 
objectives (AAR = 6.3 x10-8, 0.5-^m diameter laser spot at 0.5 mW) to assess the impact 
of sampling area on the measurement results. These data are shown in Figure 2.10. The 
high density SERS maps collected from the two experiments are normalized because of the 
large differences in signal intensity due to the collection efficiencies for the 10x and 50x 
microscope objectives. The average and standard deviation for 100 randomly selected laser 
spots within the central portion of the addresses produced signals of 1235 ± 108 (1.00 ± 
0.09 when normalized) and 4782 ± 862 cts s"1 (1.00 ± 0.18 when normalized) for the 10x 
(5.0 mW) and 50x (0.5 mW) objectives, respectively. The laser power was lowered to 0.5 
mW in the 50x objective measurements due to saturation of the CCD at higher laser 
powers. Differences in the signal are indicated by the DAvg, s, and normal distribution of
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Figure 2.10. Raman analysis of ERL-based SERS-based immunoassay substrate for the 
detection of H-IgG at 10.0 ng mL-1. The impact of r^eplicate on the (a) accuracy expressed 
as DAvg, and (b) precision expressed as s  for the two different spot size. (c) Normalized 
distributions of the signal from 100 Replicate measurements on the same substrate for 
analysis diameters of 5 and 0.5 pm.
the data.
Empirical analysis demonstrates the benefits of using an obj ective with a larger spot 
size for increased accuracy and precision in the measurements. While sensitivity of the 
sample size is less significant, the differences are likely present due to the increased density 
of ERLs on the substrate (Figure 2.2) relative to the PSA density of 1.415 PSAs p,m"2 
investigated in a majority of the simulations. However, the data does indicate that 
undersampling the surface with the 50x objective introduces a fundamental error 
associated with the analysis method that impacts the accuracy and precision of the 
measurements. The results for the minimal required Replicate for accurate analysis is 4 and
51 for the 10x and 50x objective, respectively. The data can also be used to calculate a Ks 
of 5.5 x 10-2 AAR (470 p,m diameter) for a 1% RSD on the 2-mm SERS substrate. Further 
analysis with a 5% RSD indicates a required AAR of 5.5 x 10-4 (47 p,m diameter).
2.4 Conclusions
There is no question as to the benefits of using SERS over classical Raman 
spectroscopy in terms of detection. However, a deficiency in the reproducibility of the 
signal enhancement continues to limit its application. This work has shown, both through 
simulations and experiments, the importance of sample size, as related to the focused laser 
spot, on reproducibility. Too small of spot size, that is, a classic undersampling problem, 
results in large deviations in the accuracy and reproducibility of the measurement. By 
judicious use of the concepts herein, we believe that a key, but unrecognized component 
to the SERS reproducibility can be readily overcome by carefully considering the impact 
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CHAPTER 3
UNDERSTANDING THE IMPACT OF NANOPARTICLE 




Nanoparticles (NPs) have unique optical,1-5 photothermal,6-8 and magnetic9-11 
properties of importance in a range of fundamental and technical areas.12-16 The research 
detailed herein is focused on understanding the impact o f the transport process which 
controls the delivery of NPs in aqueous suspensions that are used as labels in heterogeneous 
immunoassays (e.g., surface-enhanced Raman scattering (SERS),17-19 giant 
magnetoresistance (GMR),20, 21 atomic force microscopy (AFM),19 and aggregation-based 
detection methods22, 23).
Brownian motion indicates that the transport of NPs in a stable suspension should 
be controlled by diffusion.24 However, repeated attempts to confirm that this point-of-view 
applies to the AuNPs (60-nm gold core) that we use as tags for captured antigens proved 
unsuccessful. We have found that suspensions composed of gold nanoparticle (AuNP)- 
based labels, used in our SERS immunoassay platform, indicate that AuNP accumulation 
surpasses predictions for transport controlled by diffusion.
The inability to verify that diffusion controlled the transport of AuNPs indicate that 
a range of other possible mechanisms, previously viewed as not significant, were operative. 
Experiments described in this chapter therefore examined the sensitivity of AuNP 
suspensions relative to stability in terms of aggregation and sedimentation. For this 
purpose, a range of surface modified AuNPs were constructed and characterized, with zeta 
potential, dynamic light scattering (DLS), and UV-Vis spectrophotometry used for 
suspension characterization. The possible impact of sedimentation which proved to be a 
dominate contributor to AuNP transport, was measured by optically monitoring settling 
rates that were than analyzed by the Mason-Weaver equation to calculate terminal 
sedimentation velocities.25 Experiments were also carried out to further establish the 
impact of sedimentation by examining the differences in the signal generated in our SERS- 
based assay by positioning the capture substrate in different orientations to separate the 
contributions of diffusion and sedimentation on NP transport. These results, along with 
those that demonstrate the improvements in the quality of measurements not affected by 
sedimentation, are described.
3.2 Theory
3.2.1 NP Transport Kinetics
Transport kinetics for an NP suspension can be broken into three primary 
categories: gravitational settling, agglomeration, and fluid dynamics. We have assumed 
that the transport of NPs in a stagnant solution proceeds minimal particle-particle 
interactions. The transport of NPs in stagnant solution can then be defined by the 
combination of diffusional and sedimentation transport.
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The Stokes-Einstein equation for diffusivity is given as:
kBT
D = ^ ~  (3.1)bm^r
where the diffusion coefficient D (m2 s-1), kB is the Boltzman constant (1.3807x10-23 J 
K-1), T is temperature (K), is the dynamic viscosity of the suspending fluid (kg m-1 s-1), 
and r  is the particle radius (m). Equation 3.1 describes the diffusion of a spherical particle 
in stagnant solution.
The root mean square distance (x2) traveled by an ensemble of particles in a one- 
dimension is given as:
(x2) = 2Dt (3.2)
This equation also describes the amount of time required for an ensemble of particles to 
travel a given root mean square distance. The relationship holds true for all directions, so 
(x2) = 2Dt, (y2) = 2Dt, and (z2) = 2Dt. Equation 3.2 indicates that displacement from 
the origin increases with the square root of time.
NPs are also potentially susceptible to settling due to gravitational forces. The rate 
of particle settling is influenced by buoyancy, drag, and gravity. Stoke’s Law describes the 
terminal settling velocity of a particle in a solution:
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2d (Pp — Pm)r2
^ --------  (33)
where g  is the acceleration due to gravity (m s-2), pp is the particle density (kg m-3), and 
pm is the media density (kg m-3). Equation 3.3 shows that the rate of particle settling 
increases with both particle density and the square of the particle radius.
Equations 3.1 and 3.3 can be combined if NPs: (1) do not interact in the suspension 
solution, and (2) are affected by a uniform force, such as gravity. Under these assumptions, 
NP transport can be described by the Mason-Weaver equation:25
dC d2C dC
j i  =  D ! F + v ^  (34)
where C is the concentration of particles in the suspension (mol), t  is time (s), and + z  is 
defined as the direction opposing the gravitational force. Equation 3.4 can also be written 
with the sedimentation velocity (vsed) expressed as the product of the sedimentation 
coefficient (s) and gravitational force (g). This partial differential equation describes the 
movement of the particles in suspension as a function of both time and position relative to 
the — z  direction, which reflects the net transport of the NPs due to the settling caused by 
gravitational forces.
As constructed, this system is governed by the continuity equation in that the 
concentration of NPs throughout the suspension is assumed to change only as a function 
of the height of the suspension due to competition between gravity-induced sedimentation 
and the tendency of diffusion to restore uniformity. The continuity equation can be written
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as:
dC _  dj  
dt dz (3.5)
where J  is the flux of the nanoparticles in the suspension relative to the z  direction. 
Equation 3.5 can then be written to account for the change in concentration in a volume 
element, dV, with respect to the flux of points through the area, dS, bounding the volume 
element and is given in Equation 3.6:
where n  is the normal unit vector from the surface in the z  direction. To use a finite 
difference method to solve Equation 3.6 the flux is discretized into a one-directional 
domain in the z-direction. The concentration of particles with in each finite volume element 




The flux is therefore directly dependent on the length of the finite volume element (Az), 
reducing the volume integral term of Equation 3.5 to:
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d
dt j  CdV (3.8)
The integral conservation law can be used to rearrange the Equation 3.8 into a time 
evolution equation that is defined by the flux in the z-direction as given in Equation 3.9.
where i indicates the element position.
The suspension height (H) was then discretized using a computational cell-centered 
method in which the particle concentration within each volume element is uniform. The 
flux at each of the surfaces o f a volume element is then given, as in the Mason-Weaver 
derivation, by Equation 3.10.
The diffusion term is approximated using a second-order, central difference formula:
(3.9)
ACJi = - Cvsed - D — (3.10)
(3.11)Az Az
The model was solved with the no-flux boundary conditions, Jz=0iH =  0, and the 
discretized conservation equation for each volume element at each time step is given by:
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jn _  jn Ji+1/2 Ji-1/2
Az (3.12)
where n indicates the time step being evaluated.
The finalized form of the Mason-Weaver equation was numerically solved using a 
commercial software package (MATLAB R2012b, MathWorks Inc., Nattick, MA), using 
experimentally determined parameters where appropriate. Values for the terminal 
sedimentation velocity and the absolute suspension height were varied in an iterative 
process to determine the best fit parameters for experimental values based on a least squares 
approximation. Results for the model will be presented in Section 3.4.4.
3.3.1 Reagents and Materials
Gold nanoparticles [60-nm diameter, 2.1 x 1010 particles/mL] were synthesized by 
BBI International (BBI) and obtained from Ted Pella. Dithiobis(succinimidyl propionate) 
(DSP), StartingBlock, modified Dulbecco’s phosphate-buffered saline (PBS) packs (10 
mM, pH 7.4), and borate buffer (BB) packs (50 mM, pH 8.5), are Thermo Scientific 
(Wilmington, DE) products. Tween 20 (T20), sodium chloride, and hydrogen peroxide 
(30%) from Fisher Scientific. Bovine serum albumin (BSA), acetonitrile (ACN), and 
sulfuric acid were obtained from Sigma-Aldrich (St. Louis, MO). Poly(dimethyl siloxane) 
(PDMS, SlyGuard), 200-proof ethanol (ACS grade, Pharmco-AAPER), octadecanethiol 
(ODT, Fluka), Contrad 70 (Decon), and optical adhesive 61 (Norland) were obtained from 
their respective venders or VWR (West Chester, PA). Human IgG (Pierce) and antihuman
3.3 Experimental
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IgG (Pierce) were purchased from Fisher Scientific. 5-5’-dithiobis(succinimidyl-2- 
nitrobenzoate) (DSNB) was synthesized by an earlier procedure.17 All reagents were used 
as received.
3.3.2 NP-based SERS Immunoassay Platform
The NP-based SERS immunoassay platform is based on a solid-phase sandwich 
immunoassay and is depicted in Scheme 3.1. In this type of assay, a surface is first modified 
with a layer of capture antibodies (Abs). The surface is then exposed to a solution 
containing an antigen (Ag), which is selectively extracted from the solution by the capture 
Abs. Next, a rinse step removes excess solution and other materials from the surface. 
Finally, the substrate is exposed to a solution containing a label that selectively tags the 
captured Ags and another rinse step removes excess reactant.
To adapt the assay for SERS readout a thin (~200 nm) layer of smooth gold is used 
as the substrate and the labels, referred to earlier as ERLs, are composed of AuNPs coated 
with a Raman reporter molecule (RRM) and a layer of tracer Abs. For this study, the ERLs 
were prepared with a 60-nm AuNP core modified with the RRM DSNB and tracer Abs 
(antihuman IgG). The ERLs produce a SERS signal that is proportional to the amount of 
antigen in a solution.
3.3.3 Preparation of the Capture Substrate
Detailed procedures for fabricating the capture substrate have been described 
previously.26 Briefly, template stripped gold (TSG) was used as the base for the capture 
substrate. The process for preparing TSG produces an atomically smooth, glass-supported
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Scheme 3.1. NP-based SERS sandwich immunoassay platform.
gold surface that facilitates imaging captured NPs. To prepare TSG, 200 nm of gold (99.9% 
purity) was deposited onto a 4” p-type silicon <100> wafer via vapor deposition using an 
Edwards 306A resistive evaporator. The glass squares, cut as 1 x 1 cm sections from 
carefully cleaned microscope slides, were then affixed to the surface of the exposed gold 
with optical adhesive 61. After curing for 4.0 h under UV light, the glass squares were 
detached from the surface by applying light pressure to the edge of the squares. This step 
exposes the underlying atomically smooth gold substrate.
The gold substrate was then immediately modified by using microcontact printing 
to form a circular hydrophobic boundary with a PDMS stamp that had a 2-mm diameter 
hole in its center, the stamp was inked with a layer of 2.0 mM ethanolic ODT that was 
subsequently dried by N2. The unmodified 2-mm address is modified with a 1-mM solution 
of DSP in ethanol (14 to 16 h), and the substrates were removed from the DSP solution, 
rinsed with 200 proof EtOH, and thoroughly dried with N 2. Capture Abs were then 
immobilized via electrostatic interactions with a 20 ^L droplet of 2.5 p,g/mL solution in 10 
mM PBS with 0.1% T20 (PBST) by a 7-h incubation step carried out in a humidity 
controlled (97% relative humidity) environment at room temperature. The substrates were 
rinsed with 2 mL of PBST immediately before moving to the Ag capture step.
3.3.4 Preparation of Extrinsic Raman Labels (ERLs)
ERLs were prepared from 60-nm (nominal) diameter citrate-capped AuNPs. The 
AuNPs are the core for the ERLs and were modified with a RRM and a tracer antibody to 
produce a Raman-active and immunologically specific label. ERLs are designed to produce 
a strong Raman signal for assay readout and have selective recognition of a desired antigen.
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Along these lines, DSNB was designed to provide two functional components: (1) a 
disulfide moiety that produces a chemisorbed thiolate monolayer on the surface of the 
AuNP and (2) a nitro group that has an intrinsically strong Raman scattering cross section 
centered at 1336 cm-1 based on the symmetric nitro stretch.
The production steps for ERLs are summarized in Scheme 3.2. Initially, the AuNPs 
suspension was adjusted to contain 2.0 mM BB by adding 40 ^L of 50 mM BB to 0.96 mL 
of AuNP suspension. The AuNPs were then modified by adding 10.0 ^L of DSNB to 1.0 
mL of the buffered AuNP suspension. The resulting thiolate monolayer was allowed to 
assemble at room temperature onto the surface for 7 h on a horizontal rotator plate. Then
10.0 ^L of a 2.5 p,g/mL solution of purified antihuman IgG (a-HIgG) Abs were added to 
the suspension and allowed to react at room temperature for 16 h on a horizontal rotator. 
The surface of the modified AuNPs was then blocked by incubating BSA in a 1.0% (w/v) 
BSA solution (2.0 mM BB) at room temperature for 7 h on a horizontal rotator.
Excess and unreacted materials were removed from the suspension via three 
centrifugation, decanting, and resuspension steps. The centrifugation step was performed 
at 2026g for 10 min to settle the modified AuNPs on the bottom of the centrifuge tube. The 
supernatant was decanted, leaving the modified AuNPs behind in a minimal volume (~40 
^L). The modified AuNPs were resuspended with 1.0 mL of 1.0% (w/v) BSA in 2.0 mM 
BB. These steps were repeated with new aliquots of the AuNP solution, with a final set of 
preparation steps designed to yield an AuNP concentration ~16x (~3.2 x 1011 particles 
mL-1) its initial level with a NaCl concentration of 0.15 M to mimic physiological 
conditions. This suspension was used in all of the assays, whereas an ERL concentration 
of ~2 x 1010 particles mL-1 were employed in the particle characterization stages.
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Scheme 3.2. ERL preparation.
Concentrations of BSA in the suspension solutions is defined by the number of 
BSA monolayers available relative to the NP surface area. This is done due to the discovery 
of the ERL stability being related to the ratio of BSA monolayers relative to the total AuNP 
surface area (dependent on the AuNP concentration) rather than the solution based 
concentration.
The BSA quantities in the Results section are expressed as the number of BSA 
monolayers in suspension solution relative to the AuNP surface area. First, the AuNP 
surface area is calculated assuming all particles are 60-nm diameter spherical particles. 
Second, the number of BSA molecules per an AuNP was determined by taking the Stokes 
radius of BSA as 3.48 nm27 and assuming that the molecules arrange on the surface as 
hexagonally closest packed circles, which give a 90.96% coverage of the surface area.28 
These assumptions indicate that a single AuNP has ~270 BSA molecules on the surface 
and is equal to 1 BSA monolayer. The AuNP stock suspension measured as 2.1 x 1010 
particles mL-1 via UV-Vis analysis29 and the number of BSA monolayers in the final ERL 
suspension can be calculated as 1.28 x 105.
3.3.5 SERS-based Immunoassay and ERL Labeling Protocol
The immunoassay was performed by incubating the capture substrate with a 20.0- 
^L drop of H-IgG diluted in 10 mM PBS with 0.1% Tween 20 (PBST) to yield 1.0 and 5.0 
ng/mL concentrations. The H-IgG was incubated on the surface of the substrate for 7 h in 
the upright position in a humidity controlled environment at room temperature. The 
samples were then rinsed three times with 2.0 mM BB with 0.1% (v/v) Tween 20:150 mM 
NaCl. A 20.0 ^L drop of freshly prepared ERLs was then placed on the surface and the
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substrate was incubated in the upright or inverted position for intervals from 30 s to 16 h 
in a humidity chamber at room temperature. The assay substrate was rinsed three times 
with 2.0 mL 2.0 mM BB with 0.1% (v/v) Tween 20:10.0 mM NaCl. The samples were 
allowed to dry under ambient conditions. Note that due to handling variations the 
incubation times of H-IgG steps are accurate to ± 1 min of the indicated time and the ERL 
steps are accurate to ± 5 s of the indicated incubation times.
3.3.6 Zeta Potential and Dynamic Light 
Scattering (DLS) Measurements
Zeta potential is the measure of the electrokinetic potential, commonly referred to 
as the surface potential, that provide insights into the charge on the particle surfaces and 
how the charge influences electrostatic interactions between suspended NPs. Surface 
potentials greater than ±30 mV are usually sufficient to be considered electrostatically 
stabilized for these types of suspensions, as long as the presence of ionic components (for 
example, NaCl) in the suspension are taken into account.30
DLS determines the average hydrodynamic diameter of modified suspended NP.31 
Average hydrodynamic diameter results are plotted based on the intensity based 
measurement of the z-average and standard deviations from five measurements of the same 
suspension and the distributions of particle diameters are discussed where necessary (in 
Section 3.4.3). These measurements were used to examine the possible aggregation of the 
NPs and how it may effect suspension stability.32
The surface potential and the hydrodynamic diameter for the AuNP suspensions 
were determined using a Malvern Zetasizer Nano-ZS. Comparative measurements were
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made with the as-received AuNPs. Modified AuNPs (prepared before adjusting the 
suspension solution with 0.15 M NaCl) and ERLs (fully prepared ERLs in 0.15 M NaCl) 
were characterized at a concentration of ~2 x 1010 particles mL-1.
Measurements were collected for a duration of 24 h with a 1 h incremental breaks 
between measurements for a total of 23 measurements. The suspension properties were 
measured five times at each point. Data presented is shown in Section 3.4.3 as the average 
and resulting standard deviation for each measurement.
3.3.7 UV-Vis Measurements
UV-Vis spectra of AuNP suspensions were collected on a Cary UV-Vis-NIR 3000, 
which was used to collect data in the visible spectrum between 350-700 nm in 15 
increments. As-received AuNPs were analyzed without any modifications at the stock 
concentration 2.1 x 1010 particles mL-1. Modified AuNP and ERL suspensions were run at 
concentrations similar to the stock concentration of ~2 x 1010 particles mL-1 with the 
specified number of BSA monolayers. A specially adapted reduced volume quartz cuvette 
with a 2-mm wide solution chamber and a 5mm path length was employed (Figure 3.1). 
The cuvette was filled with 145 pL of freshly prepared and evenly dispersed suspension, 
tightly sealed with several layers of parafilm to minimize evaporation. The height of the 
liquid in the cuvette was ~14.5 mm. A 2.0-mm high sample window was positioned 1.5 
mm below the top of the liquid suspension. The window was defined by masking with a 
flat black paint. Note that the positioning of the sample window at the top of the liquid 
reduces the analysis time of each experiment, which typically range for 80 h. The UV-Vis 









Figure 3.1. Quartz cuvette setup for UV-Vis measurements designed to monitor the 
diffusion and sedimentation based transport of AuNPs within a given sample window.
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observation window.
3.3.8 Instrumentation and Data Analysis
Raman spectra were obtained using either a modified NanoRaman spectrometer 
(Concurrent Analytical, Loveland, CO)33 or a DXR Raman microscope (Thermo 
Scientific). The modified NanoRaman spectrometer has three primary components: laser 
excitation source (He:Ne laser, 22mW), spectrograph (f/2.0 Czerny Tunrer imaging 
spectrometer (6-8 cm-1) resolution and a Kodak 0401E charge coupled device (CCD) 
thermoelectrically cooled to 0°C), and fiber optic probe. Raman spectra were collected by 
irradiating the sample surface with a 20-^m diameter laser spot at 3.0 mW and a 1-s 
integration time. The laser power was found to vary no more than ±0.1 mW after warmup. 
Sample data was collected at 10 separate locations on each substrate. All spectra were 
baseline corrected. The height intensity of the symmetric nitro stretch, Vs(NO2), at 1336 
cm-1 was used for quantification.
High density Raman maps of the sample substrates were colleced using a Thermo 
Scientific DXR Raman microscope. This instrument consists of four primary components: 
laser excitation source (HeNe laser, 8 mW), spectrograph (CCD detector thermoelectrically 
cooled to -65 0C), fiber optic probe, and optical and Raman compatible objectives. The 
optical/Raman microscope was fitted with a 5x Olympus MPlan N objective that gave a 5- 
p,m diameter laser spot size. The instrument has a motorized sample stage (5” x 3” travel 
dimensions in the X and Y directions, respectively, with a ±1-p,m step size resolution), 
allowing for automated high density data collection. Spectra were obtained at 50-p.m steps 
across the sample at 3.00 ± 0.01 mW laser power and a 50-p.m slit width spectrograph
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aperture.
3.4 Results and Discussion
3.4.1 As-received AuNP Properties
Modified AuNPs (DSNB, tracer Ab, and BSA modified AuNPs) and ERL (DSNB, 
tracer Ab, and BSA modified AuNPs with 0.15 M NaCl in the suspension solution) 
suspensions were characterized using zeta potential, DLS, UV-Vis spectrophotometry, and 
sedimentation-based simulations as described in Sections 3.4.2 to 3.4.4. This section 
summarizes the result found for characterization of as-received AuNP suspensions for 
comparative purposes. Zeta-potential for the AuNPs averaged over the 24-h observation 
period was -57  ± 1 mV. The plot of the hydrodynamic diameter distribution had a mean 
and standard deviation of 59 ± 27 nm that changed in 24 h to 56 ± 22. UV-Vis 
spectrophotometry was also used to determine the average AuNP size as well as the 
suspension concentration.29 The extinction maximum occurred at 535 nm, equating to an 
average AuNP diameter of 58 nm, and a concentration of 2.1 x 1010 particles mL-1. Fits to 
the Mason-Weaver simulations (see Section 3.4.4) yielded a size of 56 nm and a terminal 
sedimentation velocity of 3.5 x 10-8 m s-1.
3.4.2 Modified AuNP and ERL Suspensions: Zeta 
Potential Analysis
Zeta-potential measurements for the modified AuNP and ERL suspensions were 
collected over a 24-h period. The results show that the zeta-potential (Figure 3.2a) for the 
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Figure 3.2. Zeta potential measurements of (a) modified AuNP, and (b) ERL 
suspensions. Zeta potential measurements for as-received AuNPs are shown for 
reference. Values for zeta potential at the start (tc) of the analysis and at the end (t24) are 
shown in the figure legend.
The modified AuNPs without BSA have an average zeta-potential of -43 ± 1 mV over the 
same time period. The zeta-potential moves to more positive values with the addition of 
BSA. The change with the lowest level of BSA (1.6 x 103 BSA monolayers equivalent) is 
initially 34 ± 2 mV mV evolving to a slightly more positive value (30 ± 1 mV mV) in 24 
h. The addition of higher levels of BSA 4.0 x 103 to 1.3 x 105 monolayer equivalents pushes 
the zeta-potential by at most another 7 mV changing by +2-3 mV in 24 h. These data 
indicate an electrostatic destabilization of the modified AuNPs with increases in the level 
of BSA.
After adding NaCl to a final concentration of 0.15 M, the zeta-potentials for the 
ERL suspensions decreased to -12  mV (Figure 3.2 b). These zeta-potentials again signify 
a possible decrease in the charge-based stability of the ERLs. However, the addition of a 
charge carrier (NaCl) to the solution can alter the accuracy of these measurements, limiting 
their predictive value.30, 34
3.4.3 Modified AuNP and ERL Suspensions: DLS Analysis
DLS measurements indicate an increase in the hydrodynamic diameter of the 
as-received AuNP after modification with DSNB and tracer Abs, as well as after the 
addition of BSA. The DLS data in Figure 3.3 indicates a 13 nm increase in hydrodynamic 
diameter to 70 ± 1 nm after the addition of DSNB and the tracer antibody in comparison to 
the as-received AuNPs (57 ± 1 nm). The increase in diameter is consistent with that 
expected for the addition of a small molecule (DSNB) and Ab (~10 nm diameter).35 The 
hydrodynamic diameter after the addition of BSA results in a further increase in 
hydrodynamic diameter, which, for all BSA levels, slowly approaches ~77 nm in 24 h. This
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Figure 3.3. DLS measurements of the intensity-based average hydrodynamic diameter 
for (a) modified AuNP suspensions, and (b) ERL suspensions. Average hydrodynamic 
diameters for as-received AuNPs are shown for reference. Values for zeta potential at 
the start (tc) of the analysis and at the end (t24) are shown in the figure legend.
is consistent with the 3.5 nm diameter BSA.27
ERL suspensions have a much larger variation in the measured size stability with 
respect to the amount of added BSA. Without BSA, the suspension is highly unstable; with 
respect the average hydrodynamic diameter increases from by approximately a factor ~5to 
~50 during the 24 h measurement. The dramatic increase triggers warnings from the 
instrument, for example, poor data quality and sedimentating particles, and the resulting 
micron-wide diameter distributions clearly signal aggregate formation. We note that the 
drop in diameter after ~16 h arises from the loss NP aggregates due to sedimentation. 
Sedimentation is also indicated by a clear suspension at the end of the measurement.
3.4.4 NP Transport by Diffusion and Sedimentation
This Section quantifies the sedimentation of ERLs using UV-Vis 
spectrophotometry and an iterative least squares approximation of the Mason-Weaver 
model solved using MATLAB. First, the accuracy of the Mason-Weaver simulation for NP 
transport due to diffusion and sedimentation was tested by monitoring transport for the 
as-received AuNP, which have an average diameter of 59 nm from DLS and 58 nm per the 
position of the optical extinction maximum. The AuNPs were transferred into the quartz 
cuvette, after acid cleaning, shown in Figure 3.1.
The spectrophotometer was programed to collect spectra from 440-580 nm (3-nm 
resolution) every 15 min for 80 h (the data is shown for 1 h increments). The results of 
these measurements are shown in Figure 3.4, after normalization of the spectrum at time 
zero. Note that the extinction decreases for the first 60 h at which time the extinction has 
reached an immeasurable level. The calculated normalized AuNP concentrations versus
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Figure 3.4. UV-Vis spectra of stagnant suspension as-received 60-nm AuNPs with the 
specialized sample cuvette described in Figure 3.1. Data is shown for 1 h intervals for 
an 80-h duration. The spectra were baseline corrected and normalized based on final and 
initial suspension measurements, respectively.
the 80-h duration of the measurement are shown in Figure 3.5 by the blue open circles. The 
normalized concentrations were determined using the progression of the spectral data at 
535nm, the extinction maximum.
Next, an iterative least squares approximation to the Mason-Weaver simulation was 
performed by inputting the values of the Boltzmann constant (1.38 x 10-23 kg m2 s-2 K-1), 
dynamic fluid viscosity (8.9 x 10-4 kg m-1 s-1), AuNP density (1.92 x 104 kg m-3),36 density 
of water (9.9 x 102 kg m-3), gravitational acceleration (9.81 m s-2), temperature (298.15 
K), suspension height (1.45 x 10-2 m), and the UV-Vis window location (from 1.30 x 10-2 
to 1.45 x 10-2 m) relative to the suspension (1.10 x 10-2 m to 1.10 x 10-2 m). Based on the 
anticipated diameter of the as-received AuNPs, the model iterated the results for 45 to 65 
nm AuNPs in 1 nm steps. The simulation results produces profiles for the net transport of 
AuNP of different diameter as a function of time. The net flux shows a decrease in AuNP 
concentration for the duration of the first ~60 h of analysis, in general agreement with the 
experimental results. Application of a least squares approach gave the best fit for the 
AuNPs in the suspension of 56 nm, which agrees well with the diameters found by two 
different experimental measurements and support the reliability of the Mason-Weaver 
simulation. It is also worthwhile to note that the shape of the AuNP sedimentation curve 
produced by the simulation matches that measured experimentally and indicates that the 
sedimentation rate monitored by the designated observation window has three distinct 
regions. There is an initial region that remains constant for ~5 h. This is followed by a 
second region (5 to 30 h) in which there is a decrease in the AuNP concentration, and then 
a final region (30 to 60 h) in which the AuNP concentration undergoes slower decay. This 
profile can be explained by examining the evolution of the AuNP concentrations
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Figure 3.5. UV-Vis experimental data collected for sedimentation of as-received 60 nm 
AuNPs. Data is the normalized AuNP concentration calculated from data in Figure 3.4. 
Blue circles represent the experimental data collected while the grey lines indicate 
simulation results for the Mason-Weaver model. The red line indicates model results for 
AuNPs with a 56-nm diameter from the least squares approximation to the Mason- 
Weaver model.
throughout the entire height of the suspension as described by the Mason-Weaver model. 
These model results are shown by the 3D plots in Figure 3.6. The slow initial onset of 
sedimentation at the top of the suspension represents the time required for a measurable 
change in AuNP levels to reach the top of the observation window (13 mm). Up to this 
point, the number of AuNP moving out of the window roughly equals to the number of 
AuNPs settling into the window. Once the sedimentation reaches the observation window, 
a decrease in the AuNP concentration is observed as they settle out of the window at a 
fairly steady rate. The final section of the curve shows a gradual slowing of the rate of 
decrease in remaining ~5% of the AuNPs in the suspension. This reflects the concentration 
gradient caused by the sedimentation of the AuNPs, which increases the diffusion of 
AuNPs directed upward against gravitational force. The sedimentation model does not 
actually reach a value of zero for the AuNP even after a 250-h simulation. An incremental 
decrease in concentration is still underway, but is so small that it is undetectable by the 
spectrometer.
After the validation of the Mason-Weaver model, experiments were ran for 
empirical analysis of modified AuNP and ERL suspensions without BSA and at monolayer 
equivalents of 1.60 x 104, and 1.28 x 105. The normalized AuNP sedimentation curves 
produced are shown in Figure 3.7. All of the results indicate that the NP transport curves 
used to determine the terminal sedimentation velocities are dependent on BSA levels.
To obtain a least squares best fit to the Mason-Weaver model in order to quantify 
the terminal sedimentation velocity, the suspension height terminal sedimentation velocity 
was varied from 14.5 to 14.3 mm and 1.0 x 10-8 to 6.0 x 10-8 m s-1, respectively. The 0.3 
mm variation is the suspension height results from potential changes in the meniscus level,
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Figure 3.6. Mason-Weaver 60-nm AuNP transport sedimentation model results. The 
suspension height plotted versus normalized AuNP concentration and time. The 
suspension starts at time zero, which is a homogenous distribution of AuNPs from the 
top of the cell to the bottom (not shown). Over time, the distribution of AuNPs in the 
suspension shifts due to diffusion and sedimentation. The normalized AuNP 
concentration profile indicates that sedimentation causes the AuNPs to accumulate in the 
bottom of the suspension at high concentrations.
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Figure 3.7. Normalized AuNP concentration for 0, 1.60 x 104, and 1.28 x 105 BSA 
monolayers suspension based on UV-Vis spectra and least squares approximation to the 
Mason-Weaver solutions for AuNP transport. (a) Modified NPs suspensions show 
terminal sedimentation velocities of 5.4 x 10-8, 3.0 x 10-8, and 2.9 x 10-8 m s-1, 
respectively. (b) ERL suspensions show terminal sedimentation velocities of not 
determine, 3.8 x 10-8, and 2.7 x 10-8 m s-1, respectively. The terminal sedimentation 
velocities for the ERL suspension with 0 BSA monolayers could not be determined due 
to a fluctuating AuNP size determination during sedimentation. The BSA levels are 
expressed as the number of BSA monolayers in suspension. As-received AuNP 
suspension is shown for reference.
which is impeded from visual inspection due to the cuvette masking used to define the 
sample window.
The terminal sedimentation velocity of the as-received AuNPs was calculated to be
3.6 x 10-8 m s-1, based on the solution to the Mason-Weaver equation and a particle 
diameter of 56 nm. The results also show that modified AuNPs have terminal 
sedimentation velocities that decrease with increasing levels of BSA. The terminal 
sedimentation velocities for BSA levels of 0, 1.6 x 104, and 1.28 x 105 BSA monolayer 
equivalents for modified AuNPs are 5.4 x 10-8, 3.0 x 10-8, and 2.9 x 10-8 m s-1, 
respectively, with the latter two terminal sedimentation velocities effectively the same.
The ERL suspensions for 1.6 x 104 and 1.28 x 105 BSA monolayers show similar 
trends in the velocities of 3.8 x 10-8, and 2.7 x 10-8 m s-1, respectively. We were unable to 
fit the data for the ERLs in the absence of BSA due to their size instability as found by the 
DLS measurements. The ERL suspension with 1.28 x 105 BSA monolayers displays 
slightly lower terminal sedimentation velocity than the as-received AuNPs, indicating 
reasonable sedimentation stability. This suspension was used in the NP-based SERS 
immunoassay results discussed in Sections 3.4.5 and 3.4.6.
The differences in the terminal sedimentation velocities can be used to project a 
value for the normalized NP concentration increase in the lower 1 |im portion of the 
solution that would occur near the surface of the capture substrate by the end of a 16-h ERL 
incubation. Our NP-based immunoassays incubate a 20-^L droplet with the capture 
substrate. Therefore, the suspension volume was modeled as a 20-^L cylinder with a 2-mm 
diameter. The Mason-Weaver model predicts that the measured terminal velocities for 
modified AuNPs with 0, 1.6 x 104, and 1.28 x 105 monolayers equivalents of BSA and
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ERL suspensions with 1.6 x 104, and 1.28 x 105 BSA equivalents would have normalized 
NP concentration increases of 23, 8.3, 7.9, 12, and 7.0, respectively. These numbers are an 
indicator for the potential number of ERLs settled on a SERS substrate and point to a 
possible explanation of the level, at least in part, of nonspecific ERL adsorption in these 
measurements, which is now examined.
3.4.5 ERL Transport to SERS-based Immunoassay Substrate
To determine how the inherent sedimentation of ERLs affects the NP-based 
immunoassay readout, ERL incubations in upright and inverted positions were compared. 
With sedimentation following the direction of gravity, upright ERL incubations direct 
sedimentation to the substrate while an inverted ERL incubation direct the sedimentation 
away from the substrate. SERS capture substrates with Ag concentrations of 5.0, 1.0, or 0 
ng/mL H-IgG were exposed to ERLs in the upright and inverted positions between 30 s to 
16 h. ERL suspension used for these experiments was chosen based on the highest stability 
found earlier with respect to aggregation and sedimentation (a BSA level of 1.38 x 105 
monolayer equivalents, at 3.2 x 1011 particles mL-1). Figure 3.8 summarizes the results 
using average and standard deviations of the signal strength of the 1336 cm-1 [us(NO2)] 
peak of the RRM layer prepared from DSNB.
The data for the three different H-IgG concentrations were examined to determine 
if a linear t1/2 dependence (Figure 3.8c and 3.8d), which indicates diffusional transport, 
were evident. The t1/2 data for the upright incubation (Figure 3.8c) shows clear deviations 
from linearity, which is supported by the residuals plot in Figure 3.8e. Note that the 
response measured for the negative control samples (PBST only) also fails to follow a t1/2
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Figure 3.8. SERS-based immunoassay for human IgG in PBST. Dose-response plot for 
five separate calibration runs for human IgG (1 and 5 ng/mL) and a negative control 
sample with ERLs incubated in the upright (a) and the inverted (b) incubation positions. 
Dose-response plot for human IgG calibration versus t1/2 for an upright (c) and inverted 
(d) ERL incubation. Residuals for linear fit to a t12 dependence for upright (e) and 
inverted (f) ERL incubations.
dependence.
The same experiments were performed with SERS substrates for the ERL 
incubation in the inverted position. The results (Figure 3.8d) show a lower SERS signal 
intensity, and thus a lower accumulation of ERLs. The data (shown in Figure 3.8d and 
3.8d) indicates a linear t1/2 dependence and thus supports diffusional transport. The most 
significant decrease in the overall accumulation is observed for the negative control 
substrates (PBST only), which have an almost immeasurable response at all incubation 
times. This decrease in nonspecific adsorption clearly demonstrates the detrimental impact 
of sedimentation in the upright position. The inverted substrates also have smaller 
coefficients of variance, which indicates a greater reliability as well as the existence of a 
diffusional dependence on accumulation.
3.4.6 Distribution of SERS Response on the Substrate
SERS maps of two representative sample substrates (5 ng mL-1 H-IgG) that were 
incubated for 16 h with ERLs in the upright or inverted position are shown in Figure 3.9. 
These maps were produced by collecting spectra in 50 ^m steps with a 5-^m diameter laser 
spot size. The results are visually represented as the signal intensity of the strongest Raman 
feature at 1336 cm-1 that were normalized to the average signal on the substrate. The high 
density maps highlight the differences in the signal distribution on the SERS substrates 
produced by the upright versus inverted configurations.
The color plot of the “inverted” SERS data (Figure 3.9a) shows large signal 
variations across the substrate. These deviations became more evident by converting from 
Cartesian to polar coordinates so that the normalized signal can be plotted versus the radial
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Figure 3.9. High density Raman surface analysis for 5 ng/mL of human IgG 
immunoassay substrates in upright and inverted ERL incubation position. The high 
density map consists of 50 ± 1 p,m steps on the surface taken at 3 mW of power with a 
5x Olympus objective with a 5 |im spot size. (a) Representative sample substrate with a 
SERS signal intensity normalized to the average SERS signal from the inner 1.6 mm 
diameter radius of the substrate from an upright and (b) inverted ERL incubation. (c) 
Normalized signal intensities versus the radial component of polar coordinates showing 
differences in the signal variation for an upright and (d) inverted ERL incubation. (e) 
Average and standard deviation of the average normalized SERS intensity for concentric 
and separate rings for upright and (f) inverted ERL incubation.
distance from the center of the circular address. This data is plotted in Figure 3.9c and 3.9d 
as the average and standard deviation for 100-^m wide concentric rings moving out from 
the center of each address. Analysis indicates a large variability in the SERS signal for the 
upright incubation relative to inverted position.
The inverted ERL incubation shows a relatively even distribution of the SERS 
signal across the substrate surface. The color plot shows a majority of the surface with a 
yellow color with some orange on one side and a little green on the other, indicating a small 
signal gradient, but a relatively consistent signal. The conversion of the data to polar 
coordinates indicates a tighter variation in the signal.
3.4.7 Equilibrium Between Sedimentation and Diffusion
The data in Section 3.4.7 demonstrates the ability of a method to direct the inherent 
sedimentation of the ERLs away from the substrate in order to reduce nonspecific 
adsorption and more evenly distribute ERLs on the surface via diffusional-based transport. 
Ideally, the AuNP core of the ERL could be altered to increase stability with respect to 
sedimentation, eliminating the need for inversion during the ERL incubation. To determine 
the most effective method to reduce sedimentation, particle transport reinvestigated from 
a mathematical standpoint.
The transport of particles is described in Section 3.4. The net transport of the 
particles is based on the net flux of particles in the z  direction as described by Equation 
3.10 Jz = —Cvsed — DAC/Az. When the net flux Jz is equal to zero, sedimentation flux 
(Cvsed) of the NPs equals the negative of the diffusional flux (DAC/Az). When this is true, 
the opposing forces of sedimentation and diffusion are at equilibrium.
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A mathematical expression of the particles at equilibrium can be found by 
substituting Stoke’s law from Equation 3.3 [2g(pp — Pm)r2/9v]  for vsed and Stokes- 
Einstein equation in Equation 3.1 (kBT/6nnr)  for D into Equation 3.10 Jz after setting to 
zero.
2.q(pv — Pm)r2 AC— ? ^ _ C = D —  (3.14)
9n Az
Equation 3.14 can then be integrated when Ct and C2 are set to the equilibrium 
concentrations at positions z x and z2, respectively, to give:
(C2\ 4 n g (pp — Pm) r 3 (3 i5 )
l n [ - J = ------- -------------- (Z2 —Z' } (315)
The adjustable variables in the Equation 3.15 are T, r, and the ratio between pm and pp. 
At equilibrium, where the left side of the equation is equal to zero, T equals infinity, r 
equals zero, and/or pp and pm are equal.
Considerations of the three possible solutions, for example, T, r, and the ratio 
between pp and pm are as follows: (1) The temperature of the suspension cannot be 
logically raised to a high enough point that the suspension solution would continue to be 
at a liquid state. The Mason-Weaver simulation indicates that even at 373.15 K, the 
terminal sedimentation velocity of the particles is decreased only by 1%; (2) the mass of 
the particle can be reduced. There is only a 2-times decrease in the terminal sedimentation 
velocity of particles with only a 5-nm decrease in the particle radius from 30 nm; and (3)
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the density o f the particle can be reduced to more closely match the suspension solution 
density. This has the largest impact when the density o f the particle is matched for example, 
to that o f the polystyrene particle; the terminal sedimentation velocities decrease by two 
orders o f magnitude.
Thus, reducing the particle size and decreasing the density o f the particle are 
possible solutions to the reduction in sedimentation. However, the location of the plasmon 
resonance is important to the strength o f the SERS signal. Our SERS-based immunoassay 
has been developed based on the optical properties o f 60 nm AuNPs. A possible solution 
is to use polystyrene core gold nanoshells or other SERS active materials such as silver or 
aluminum, which also have lower densities.37-39
3.5 Conclusions
This work has demonstrated the importance o f gravity-induced sedimentation on 
the movement o f AuNPs (60 nm diameter) on their delivery to the capture substrates used 
in an immunoassay. Results also indicate that the quality o f the analysis o f the capture 
substrates is improved by elimination of sedimentation, and thus the transport o f AuNPs to 
diffusion. Work is underway to develop approaches that will simplify the ability to apply 
the implications o f these findings to our and other NP-based platforms.
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CHAPTER 4
THE DEVELOPMENT OF A TUBERCULOSIS 
DIAGNOSTIC TOOL USING SURFACE- 
ENHANCED RAMAN SCATTERING
4.1 Introduction
Despite modern advances in diagnostics and treatment, tuberculosis (TB) persists 
as the world’s second deadliest infectious disease from a single infectious agent.1, 2 TB 
ranks second in mortality only to human immunodeficiency virus (HIV)/acquired immune 
deficiency syndrome (AIDS). TB disease caused by the growth of Mycobacterium 
tuberculosis (M. tuberculosis) bacillus. In well-developed countries, TB is normally 
considered to be a disease of the past, and, as a bacterial infection, is a curable and 
preventable disease. However, in resource-limited regions of the world, primarily in Asia 
and Africa, a high incidence of TB infection persists due to outdated diagnostic methods, 
coinfection with immune suppressing diseases, and limited treatment options. Diagnosis in 
these high-risk regions depends primarily on sputum smear microscopy and serological 
tests.3 The World Health Organization (WHO), however, has issued a warning that these 
serological tests be avoided due to their inherent inaccuracy, due to the prevalence of 
immunocompromised patients. The poor performance of these tests pose health risks due
to delays in treatment from a false-negative result or unnecessary/improper treatment from 
a false-positive result. The ability to reliably test for TB in regions that have limited 
resources is therefore a crucial step in the efforts to reduce the worldwide mortality rate 
from TB.4 This chapter focuses on the development o f a new, sensitive, cost-effective, and 
reliable diagnostic test for TB infection, which has the potential, when paired with early 
treatment, to reduce the loss of life due to this preventable and curable disease.
The difficulty associated with the accurate diagnosis of M. tuberculosis infection 
in resource-limited regions results from complications associated with the disease and/or 
available resources. There are three primarily factors: (1) TB is associated with a latent 
phase of infection in which the immune system of an individual suppresses the bacterial 
growth. Under normal circumstances, latent TB infection has a 5-10% risk o f turning into 
active infection. However, the risk significantly increases for individuals with a 
compromised immune system, such as that due to HIV/AIDS;5 (2) coinfection with 
HIV/AIDS can also impair the accuracy of detection methods by reducing levels of 
immunomarkers (e.g., antibodies), changing the normal progression of the disease, and/or 
altering the expected distribution of the bacterial load within the body; and (3) resource- 
limited regions with a high TB burden have a serious need for new diagnostic methods that 
can be used in area where it is needed the most. However, it is also imperative that these 
testing positive have ready access to antiTB treatment regimes.
Currently, a wide variety o f detection methods for TB infection are available that 
test for one or more of the following: the bacteria, an antigen produced by the bacteria, 
DNA/RNA sequence specific to the bacteria, or antibodies produced in response to 
bacterial exposure.6 The most accurate and reliable method for diagnosing TB infection is
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bacterial culture.7 Most types o f biological patient samples (e.g., sputum) can be cultured, 
can be used to track the response to treatment. However, specialized facilities and 
incubation times of several weeks are essential to culture and grow M. tuberculosis, both 
of which present significant problems for resource-strapped regions that cannot tolerate the 
significant financial burden or time delay for diagnosis with this type o f testing.
Due to the time and cost limitations associated with bacterial culture, less accurate, 
but lower cost and more rapid tests for TB detection are often used, including a skin test 
and sputum smear microscopy.8 In regions with low TB incidence and lower HIV 
occurrence, the skin test is the most common first step in diagnosis.9 The skin test uses an 
intradermal injection on the forearm of a patient o f purified protein derivative (PPD) from 
M. tuberculosis.10 If antibodies for TB are present, a distinct red induration will appear at 
the injection sight. This test, however, can only determine if  an individual has been exposed 
to M. tuberculosis, but not necessarily the existence o f active infection. The test can also 
be inaccurate if the patient has a compromised immune system and is unable to a produce 
sufficient number o f TB antibodies for a positive reaction to the PPD. These screening 
shortcomings are particularly in areas undesirable with a high TB incidence and large 
numbers o f the population with undiagnosed HIV.7
In resource-limited regions o f the world with a high likelihood of exposure to TB 
and HIV/AIDS infection, sputum smear microscopy is the primary method for detection. 
Microscopy is a technique developed over 100 years ago as a rudimentary way of detecting 
and identifying microorganisms.11-13 A sputum sample, which should contain a large 
amount of the M. tuberculosis bacilli if the patient has pulmonary TB infection, can be 
used to determine the presence o f the bacteria. The bacteria, when present at a high load
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(~5,000 to 10,000 bacilli mL-1),14 are identified by using an acid fast stain to bacteria in 
the genus Mycobacterium, which can, in turn, be visually identified with microscopy. This 
method is low cost, fast, and widely available. However, sputum smear microscopy 
requires the presence of a detectable level of bacterial load in the lungs. Smear-negative 
(i.e., false negative) results are high among many classes of TB-infected patients including 
children, HIV positive patients, and extrapulmonary patients, due to deviations from the 
normal progression of the disease.15
The need for more reliable and accessible detection methods has played a major 
role in the development of today’s methods for TB diagnosis, including detection by 
enzyme-linked immunosorbent assays (ELISA),16, 17 radiometry,18 and the polymerase 
chain reaction (PCR).19 While these methods can be sensitive with antigen detection at 1 
ng mL-1, all require advanced facilities and highly trained personnel, which makes them 
methods impractical for resource-limited regions.
This paper describes a TB immunoassay based on surface-enhanced Raman 
scattering (SERS) as the readout mechanism. Using SERS, a Raman signal can be typically 
amplified by a factor of 104-106;20 with values as high as 1014reported in a few cases.21 
SERS enhances the Raman signal by means of the inherent plasmonic properties of 
substrates consisting of asperities of nanometrically-sized coinage metals on a surface.22 A 
SERS-active substrate generates localized surface plasmon resonance (LSPR) when an 
excitation source matches the natural frequency of the conduction electrons of the 
material,23 which magnifies the electric field near the surface of the asperity, and therefore 
effective Raman cross section of a Raman-active molecule adsorbed on the SERS-active 
substrate. The signal enhancement is a distinct advantage of SERS detection, but other
120
attributes include using a red-shifted excitation source, which reduces the native 
fluorescence, and low susceptibility to photobleaching, which reduces signal degradation.
The advantages of SERS detection have led to the development of a SERS-based 
immunoassay that has proven to be a sensitive and robust system for bioanalytical 
analysis.24-28 A variety of different biological agents have been detected with this platform, 
including proteins, viruses, and microorganisms. The SERS-based immunoassay consists 
of an atomically smooth gold substrate, biorecognition elements, and gold nanoparticles 
(AuNPs) labeled with a Raman reporter molecule (RRM). These components are then 
carefully constructed to create a sandwich immunoassay which is paired with SERS as the 
readout method.
The SERS-based immunoassay is carried out by first immobilizing a capture 
antibody on a gold substrate, which is then exposed to a solution of the TB-containing 
sample. This step binds a TB marker to the capture antibody on the surface. The 
immobilized antigen is then selectively labeled with an extrinsic Raman label (ERL), which 
consists of gold NPs modified with a RRM and a tracer antibody. Finally, the tagged 
antigen is indirectly detected by the SERS signal of the ERL.
The bulk of this paper discusses the development of a SERS immunoassay for the 
detection of lipoarabinomannan (LAM). LAM is a 14-17 kDa lipopolysaccharide and 
major component of the cell wall of Mycobacteria that is continually shed by the organism. 
As a result, LAM is a unique and an excellent candidate to serve as an antigenic marker for 
TB infection. PILAM, which is LAM terminated by phosphor-myo-inositol and produced 
by the relatively fast growth of M. smegmatis. The nonvirulent nature of this strain of 
Mycobacterium makes it an ideal surrogate for method development.29, 30
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Two other antigenic markers, a-crystalline protein (ACR) and Rv0363c, are also 
used herein for the development o f a multiplexed assay. ACR is a dominate, 16 kDa heat 
shock protein produced by M. tuberculosis that is possible a marker for latent infection,31 
and Rv0363c is a 36.5 kDa gene that encodes for the glycolysis enzyme fructose- 
bisphosphate aldolase.32 The combination of the three markers can be used in a multiplexed 
platform for the detection o f TB. The benefits o f using multiple markers have four primary 
advantages. First, multiplexed detection uses a smaller amount of the patient sample for 
testing.33 Second, test efficiency increases due to faster turn-around times associated with 
parallel analysis. Third, the increased number o f markers reduces false positive and false 
negative results. And fourth, tracking multiple markers is more informative for guiding 
treatment. However, a marker is only a viable candidate if it is present in patient samples 
at levels measurable by the detection method.
The research presented in this paper will describe the development o f the SERS- 
based sandwich immunoassay for the detection o f TB infection. The findings indicate low  
limits o f detection via SERS detection with antigenic TB markers spiked into biologically 
relevant media. In order to determine the most effective method for TB diagnosis the results 
from three types of biological media, multiplexed detection of three antigenic TB markers 
in serum, and pretreated serum for the detection of PILAM were compared. The 
performance o f the SERS assay for the detection o f PILAM in pretreated serum was 
determined to provide the most useful diagnostic information based on the limit of 




4.2.1 Reagents and Materials
Dithiobis(succinimidyl propionate) (DSP, > 95%), modified Dulbecco’s phosphate 
buffered saline packs (pH 7.4), borate buffer (BB) packs (pH 8.5), magnesium chloride 
hexahydrate (ACS grade), potassium chloride (ACS grade), potassium carbonate, 
SuperBlock and StartingBlock were obtained from Fisher Scientific. Acetonitrile (ACN, 
Spectroscopy grade), Tween 20, sodium chloride, 70% perchloric acid, and bovine serum 
albumin (BSA) were purchased from Sigma-Aldrich. Urisub, a synthetic urine matrix, was 
received from CST Technologies; poly(dimethyl siloxane) (PDMS) from SlyGuard; Epoxy 
377 from EPO-TEK; calcium chloride from EM Science; monobasic sodium phosphate 
(ACS grade) from BDH; dibasic sodium phosphate (ACS grade) from JT Baker; 200-proof 
ethanol (ACS grade) from Pharmco-AAPER; octadecanethiol (ODT) from Fluka; AuNPs 
(60-nm ~1 x 1010 particles mL-1) from NanoPartz; and LAM-specific TB antibodies and 
purified PILAM antigen from B.E.I. resources. ACR and a-ACR (BIIIc4B11B6C5C7), 
were obtained from Frederick Quinn (Georgia State University, GA) and recombinant 
protein Rv0363c and rabbit a-Rv0363c from Delphi Chatterjee (Colorado State University, 
CO). An allergen powder containing galactomannan purchased from Greer Laboratories 
(Lenoir, NC), heat-killed Escherichia coli O157:H7 was provided by Nancy Cornick 
(Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, 
Ames), and heat-killed Mycobacterium avium subsp. paratuberculosis (MAP) was 
obtained from BD Diagnostic Systems (Hunt Valley, MD). All o f these reagents were used 
without further purification.
The synthesis o f the Raman reporter molecule 5-5’-dithiobis(succinimidyl-2-
nitrobenzoate) (DSNB)28 and that of citrate-capped 30-nm NPs34 followed previously 
described procedures.
4.2.2 Preparation of Extrinsic Raman Labels (ERLs)
For additional information on the background and history of the procedures used 
for ERL and capture substrate preparation, please refer to previous publications.26-28 These 
procedures, shown in Scheme 4.1, were subsequently modified to increase the sensitivity 
of the measurement. Briefly, ERLs were prepared by first concentrating the 30-nm 
diameter AuNP suspension as follows. The NPs (4 mL, 1.3 x 1011 particles mL-1 as 
received) were centrifuged at 2,000g for 20 min and the clear supernatant was carefully 
decanted from the sedimented NPs. The NPs were then resuspended in 1 mL of 2 mM BB 
to yield a final concentration of 5.2 x 1011 particles mL-1. The concentration of the NP 
suspension was verified using the UV-Vis method developed by Haiss and collaborators.35 
Next, the NPs were incubated with 10 ^L of 1.0 mM DSNB in acetonitrile at room 
temperature and agitated on a horizontal rotator at 2 Hz for 1.5 h.
DSNB was designed to serve three primary functions: (1) disulfide group forms a 
chemisorbed monolayer on the NP surface via thiolate formation, (2) the succinimidyl 
groups for amide linkage of biorecognition elements, and (3) the NO2 groups produce an 
intrinsically strong and unique signal as a RRM. After DSNB incubating 5 p,g of antiLAM 
monoclonal antibodies (mAb) were added to the suspension and the primary amines on the 
antibody were allowed to react with the succinimidyl group on DSNB for 1.5 h at room 
temperature on the rotator, allowing the tracer antibodies to react with the modified NP 
surface. A 100-^L aliquot of 10% BSA solution, dissolved in 2 mM BB, was subsequently
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Scheme 4.1. SERS-based Sandwich Immunoassay
added to the NPs to block nonspecific adsorption sites and to stabilize the colloidal 
suspension. The resulting supernatant was mixed for 1.5 h on the rotator at room 
temperature, which completed the preparation of the ERLs. Residual reactants were then 
removed in a three step process. For this, the ERLs were pelleted in a centrifuge tube 
2,000g  for 20 min, the clear supernatant was carefully removed, and the particles were 
resuspended with 1.0 mL of 1% BSA in 2 mM BB. The centrifugation and resuspension 
steps were repeated two additional times, with the final resuspension conducted in 0.5 mL 
of the 1% BSA in 2 mM BB. Finally, the ionic strength of the ERL suspension was adjusted 
by adding an aqueous NaCl solution to the ERLs to achieve an NaCl concentration of 150 
mM. Upon the completion of these processing steps, the ERL concentration was ~4.0 x 
1011 particles mL-1.
4.2.3 Preparation of Capture Substrate
The capture substrates were prepared using 1 x 1 cm template stripped gold 
(TSG).36 The TSG was modified via microprinting with a PDMS stamp dipped in a 2 mM 
ethanoic solution of ODT and thoroughly dried before being pressed into conformal contact 
on the clean TSG surface. The stamp creates an unmodified, 2-mm address in the center of 
the substrate that is surrounded by a hydrophobic boundary; the address was then modified 
with an ethanolic DSP solution for 1 h, rinsed with ethanol, and thoroughly dried with 
N2(g).
A 2.5-^g mL-1 solution of antiLAM mAb 906.7 was prepared by diluting a freshly 
thawed aliquot of the mAb in 10 mM phosphate-buffered saline containing 0.1% Tween 
20 pH 7.4 (PBST). A 20-^L drop of the a-LAM solution was then applied to the DSP-
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modified surface and allowed to react for 1 h at room temperature in a humidity-controlled 
environment (97% relative humidity). ACR and Rv0363c are incubated with either a 20 
pL droplet of 100 pg mL-1 a-ACR or a-Rv0363c, each on separate TSG substrates. These 
substrates were rinsed three times by immersion in 2 mL of PBST in a 24-well microplate, 
removing the rinse buffer with an aspirator between rinses. Next, the substrate was exposed 
for 1h to 20 pL of StartingBlock, a commercially available blocking agent, for 1 h, followed 
by rinsing three times with 2 mL of PBST using the just described procedure.
4.2.4 Antigen Capture and Labeling
The capture substrates were then exposed to 20 pL of PILAM spiked into a buffered 
solution or one of three sample matrices: PBST, Urisub, simulated CSF, or human serum. 
Each of these spiked samples were prepared at an antigen level of at 1.0 mg mL-1 and then 
serially diluted each matrix to different concentrations. Antigen capture incubated the 
capture substrate in an inverted position for 1.0 h in a humidity chamber. The substrates 
were rinsed three times with 2 mL of 2 mM borate buffer containing 150 mM NaCl and 
0.1% Tween 20 (BBT). A 20-pL aliquot of the freshly prepared ERLs was then pipetted 
onto each substrate, and incubated in an inverted position for 16 h at room temperature in 
a humidity chamber. The samples were then rinsed three times with 2 mL of BBT, followed 
by three times with deionized H2O. The samples were dried under ambient conditions and 
analyzed by SERS.
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4.2.5 Biological Samples and Serum Pretreatment
Urine, CSF, and serum were used as biologically relevant sample matrices to assess 
the utility of the SERS diagnostic platform for the detection of PILAM. Relative to serum, 
urine, and CSF are similar simple biological samples that consist primarily of electrolytes 
and a few proteins. Artificial urine and CSF were used to ensure a consistency of these two 
matrices. Synthetic urine was acquired from a commercial source, whereas artificial CSF 
was prepared in the laboratory. The artificial CSF solution contained 148 mM sodium 
chloride, 3 mM potassium chloride, 1.4 mM calcium chloride, 0.8 mM magnesium 
chloride, 0.8 mM sodium phosphate dibasic, and 0.2 mM sodium phosphate (monobasic).37 
The antigen-spiked sample for each matrix was then tested without further pretreatment.
Mixed antigen solutions for multiplexed detection were prepared by spiking antigen 
solution into serum and subsequent exposure to a capture substrate. Studies performed in 
serum did not provide LoDs at levels low enough (1 ng mL-1)8 to meet our preliminary 
detection goals.
Investigation of the markers lead to the discovery that PILAM complexes with 
proteins and the structural stability of the molecule. Denaturing agents then allow for the 
removal of interfering proteins in the serum while leaving the PILAM structurally intact. 
PILAM spiked into serum was treated with two different methods to compare the benefits 
of protein removal methods
The first serum treatment was performed by heating a 500-^L serum sample for 30 
min at 95 °C, followed by centrifugation at 12,000g- for 30 min. The resulting clear 
supernatant was then used for analysis. Raman spectra were collected with a 3-s integration 
time using Raman instrumentation described herein. The second method involved
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perchloric acid pretreatment and neutralization following this simple five-step procedure. 
To start (Step 1), 2.0 of HClO4 (70%) was added to 100.0 |j,L of each calibration/patient 
serum sample in a small centrifuge tube. The sample was immediately vortexed for 10 s 
which brought the pH to ~2 and formed a milky suspension. The sample was then 
centrifuged at 13,000g for 5 min (Step 2), and 75 ^L of the resulting supernatant were 
transferred to a second small centrifuge tube (Step 3). The sample was then neutralized to 
pH 7.5 with 6.0 ^L of an aqueous solution of K2CO3 (2.0 mM) (Step 4). The samples were 
then cooled to 4°C for 30 min and subsequently allowed to warm to room temperature (~20 
min) before being pipetted (20 ^L) onto the capture substrate (Step 5). Perchloric acid 
treated serum samples were analyzed on a SERS immunoassay using 60-nm AuNPs for 
the base of the ERL.
4.2.6 Raman Instrumentation
The Raman instrument used for data collection is a modified NanoRaman from 
Concurrent Analytical (Loveland, CO). The instrumentation has three primary 
components: laser excitation source, spectrograph, and fiber optic probe. The light source 
is a 22-mW, 632.8-nm HeNe laser. The spectrograph consists of an f/2.0 Czerny Turner 
imaging spectrometer with 6-8 cm-1 resolution and a Kodak 0401E charged coupled device 
(CCD) thermoelectrically cooled to 0 °C. The instrument was modified by upgrading the 
fiber optics with SMA connectors and stainless steel protection sheaths and 
micropositioning alignment collimators from Thor labs.
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4.3 Results and Discussion
4.3.1 Antibody Screening
The development o f the assay initially involved screening o f a number o f candidate 
antibodies specific for their ability to capture the M. tuberculosis antigen LAM after 
immobilization on TSG substrates. This test panel was selected by Professor Delphi 
Chatterjee and coworkers at Colorado State University (CSU) based on Western Blot 
analysis. The antibodies selected for screening included those from series 900 and 
subclones of line 906: 906.1, 906.7, and 906.41.38, 39 All 906 line antibodies bind to an 
epitope region specific to the mycobacterium biomarker LAM was primed with whole 
Mycobacterium lepae and given several boosters o f crude LAM. The antibodies were used 
to produce both the capture substrate (produced with capture antibodies) and the ERLs 
(produced with tracer antibodies). Assessment o f the performance o f purified monoclonal 
antibodies was conducted by analyzing SERS data from a 5-pg mL-1 sample o f PILAM 
purified from M. smegmatis spiked in PBST and a blank sample consisting o f only PBST. 
The assay was carried out according to the procedure shown in Schematic 4.1. In short, the 
capture substrate was prepared with a 2.5 pg mL-1 solution o f capture antibody, which was 
first blocked with StartingBlock and then exposed to the sample. The bound antigen from 
the sample was then labeled with ERLs which consisted o f 30-nm gold NPs modified with 
DSNB and the tracer antibody. Each possible combination of capture and tracer antibodies 
was analyzed (Figure 4.1) to determine which combination would be most effective in the 
SERS assay platform, based on sensitivity and LoD.
The DSNB spectral features are shown in Figure 4.1a for the assay performed with 
the 906.7 antibody as both the capture and tracer antibodies at a PILAM concentration of
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Figure 4.1. A representative spectrum for the SERS sandwich immunoassay and results 
from an antibody screening studies for detection of PILAM. (a) Shows a SERS spectrum 
indicating spectral features assigned to the molecule DSNB. The spectrum corresponds 
to data collected for the 906.7 antibody as the capture and tracer antibodies at 5 |ig mL-1 
of LAM. (b) SERS intensities for immunoassays screening a combination of 906 
antibody series 906.1, 906.7, and 906.41 reacted with 5 ^g mL-1 of PILAM in PBST and 
blank PBST samples. The data used for screening studies were collected by measuring 
the peak height from the Vs(NO2) stretch at 1336 cm-1 in counts per second (cts s-1).
5 pg mL-1. Band assignments for the spectra have been described in detail previously but 
will be briefly reviewed here.25, 28 The strongest spectral feature is produced by the 
symmetric nitro stretch (vs(NO2)) at 1336 cm-1. The other bands correspond to the 
scissoring mode for the nitro group at 851 cm-1 and two aromatic ring modes at 1062 and 
1554 cm-1 shown in Figure 4.1a.25 Note that the Raman spectrum for the immunoassay is 
composed only of spectral features that can be attributed to DSNB, there are no 
contributing peaks from the biological elements used in the immunoassay platform.
The peak height produced by the strongest DSNB feature [vs(NO2) centered at 1336 
cm-1] in the sample spectrum is used to quantitate the concentration of antigen in the 
sample. The intensity of the symmetric nitro stretch for each of the data points was 
determined by collecting data from five locations on each of the five assay substrates; the 
results are given as the average for each set of data. Analysis of the data focused on 
identifying which combination of antibodies produced the highest SERS signal for the 5- 
pg mL-1 sample and the lowest relative signal for the blank sample.
The results shown in Figure 4.1b clearly demonstrate that the heterogeneous assay 
using 906.7 antibody as both the capture and tracer antibody gives the highest SERS 
intensity at 1336 cm-1. To determine more clearly which combination of antibodies would 
be the most effective, the projected limits of detection (projected LoDs) were calculated 
for all combinations and summarized in Table 4.1. The projected LoD is defined as its 
blank signal plus three times the standard deviation. The analysis shows that the lowest 
projected LoD was obtained when using the 906.41 antibody as both the capture and tracer 
antibodies. The highest signal strength was observed for 906.7 as the capture and tracer 
antibodies 906.7 used as the capture and tracer antibodies also represents the second lowest
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[LAM], 5 |ig mL-1 Blank
projected 
LoD, ng mL-1
C-906.41 T-906.41* 5855 ± 1118 193 ± 40 106
C-906.41 T-906.1 1892 ± 190 135 ± 79 677
C-906.41 T-906.7 6117 ± 857 290 ± 96 246
C-906.1 T-906.41 4183 ± 486 270 ± 126 481
C-906.1 T-906.1 1407 ± 847 550 ± 98 1718
C-906.1 T-906.7 3606 ± 639 385 ± 72 337
C-906.7 T-906.41 6471 ± 831 393± 120 296
C-906.7 T-906.1 2858 ± 422 166 ± 53 294
C-906.7 T-906.7** 11664 ± 1392 726 ± 205 281
C -  Capture antibody immobilized on the Au capture substrate 
T -  Tracer antibody immobilized on the extrinsic Raman label 
* Shows the lowest projected LoD 
**Shows the highest signal and second lowest LoD
projected LoD. Based on the large signal for the 5 pg mL-1 and on the anticipation of 
reduced nonspecific adsorption upon further development of the system, 906.7 antibodies 
were selected for use as both the capture and tracer antibodies for the remainder of the 
studies.
4.3.2 PILAM Spiked into PBST
Development of the SERS immunoassay for the detection of PILAM began by 
using PBST as a simple sample matrix that was spiked with PILAM concentrations ranging 
from 1.0 x 102 pg mL-1 to 2.5 ng mL-1. The capture substrate was prepared using 906.7 
antiLAM antibodies. The spiked samples were exposed to the capture substrate for 1 h in 
an inverted position. The substrates were then rinsed and exposed to the ERLs modified 
with the 906.7 antiLAM antibodies for 16 h in an inverted position. The resulting SERS 
spectra were collected from two sets of sample substrates by measuring five locations on 
each assay substrate and a 3-s read time. These data were analyzed using the peak height 
of the strongest Raman band produced by the symmetric nitro stretch at 1336 cm-1 after 
baseline correction (Figure 4.2). SERS data show an increase in the signal at 1336 cm-1 
with increasing concentrations of PILAM. The concentration-dependent increase in the 
dose-response curve follows a linear dependence for PILAM over the tested range of 
PILAM concentrations. The LoD is indicated on the graph by the red dashed line, which is 
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Figure 4.2. Spectra and calibration curve for PBST spiked with LAM using the 906.7 
antibody as both the capture and tracer antibody. (a) Raman spectra for SERS-based 
immunoassay for PBST spiked with LAM. (b) Corresponding calibration curve with 
analysis of peak height at 1336 cm-1 for SERS-based immunoassay for PBST spiked 
with LAM with a 3 s integration time. The solid line represents the linear least-squares 
regression of the data with a corresponding fit of y = 1458x + 85 (R2 = 0.98). The red 
dashed line represents the LoD determined as the blank signal plus three times the 
standard deviation, which was calculated to be 76 pg mL-1 or 4.8 pM.
4.3.3 PILAM Spiked in Biologically Relevant Samples
D evelopm ent of a reliable and reproducible assay fo r TB requires th a t th e  detection  
platform can accurately establish whether bacteria are present in a host. The sample 
analyzed is therefore collected from the host, which is a more complex sample matrix. Past 
work has shown that LAM can be present in the urine, CSF, and serum as a result of the 
bacteria sloughing off the lipopolysaccharide of M. tuberculosis.40'42 However, it is still 
uncertain as to the levels expected to be present in these samples. There are also 
complications in dealing with components that can interfere with the performance of the 
assay in the biological samples. Electrolytes, proteins, antibodies, antigens, hormones, and 
possible exogenous substances (e.g., drugs and microorganisms) can be present in the 
patient samples and can influence the performance of the assay. To determine the 
practicality of TB detection in urine, CSF, and serum samples, PILAM was spiked into 
Urisub, a synthetic urine, an artificial CSF solution, and TB-negative human serum.
Serial dilutions of the different solution matrices from 0 to 5 ng mL-1 were prepared 
for use in the SERS immunoassays. These results are shown in Figure 4.3. The results 
indicate that the Urisub and artificial CSF have comparable performance in the SERS assay 
than that in PBST with LoD that are below 1 ng mL-1. It is important to note that Urisub 
and artificial CSF are protein-free surrogates were used in substitution of true biological 
samples. The use of true biological samples may cause signal depletion that is expressed 
in the serum samples. However, the results for the assay in serum indicated no detectable 
signal for PILAM at the given concentrations. SERS signal is observed for PILAM in 
serum at higher concentrations and is discussed later in this chapter. Data analysis was 
performed as previously described. The LoD was determined by calculating the blank 
signal plus three times the standard deviation and determining the intercept with the
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Figure 4.3. Dose response curves for SERS-based immunoassay with CSF, Urisub, and 
serum spiked with LAM. The linear least-squared regression for the different sample 
matrices are as follows: y = 702x + 175 (R2 = 0.91) for CSF, y = 660x + 95 (R2 = 0.99) 
for Urisub, and no linear range for serum, with limits of detection at 100 pg mL-1 for 
CSF and Urisub. Average and standard deviation of the displayed measurements come 
from two substrates measured at five different locations.
corresponding linear calibration. The analysis shows that the urine and CSF data exhibit a 
strong correlation to results produced for PILAM spiked in PBST. The urine and CSF 
samples have a slightly reduced sensitivity but have minimal sample variability. The LoDs 
for the untreated artificial urine and CSF were both determined to be 100 pg mL-1 or 5.9 
pM in comparison to the LoD for PBST, which is calculated on the same order of 
magnitude as 76 pg mL-1 or 4.5 pM. The analysis of the serum samples shows a complete 
loss of detectable signal at the given concentrations but does start to be detectable at higher 
concentrations (data not shown). The reduction in the signal is attributed to potential 
complex formation with the serum components, passivation of the capture substrate due to 
the high concentrations of proteins in solution, and/or increased solution viscosity reducing 
diffusion.
4.3.4 Multiplexed Detection of Three 
Antigenic TB Markers in Serum
Improvements in diagnostics in biological samples can also be achieved by 
increasing the number of biomarkers that are measured in parallel. SERS-based analysis 
for ACR and Rv0363c were performed in a similar fashion as the experiments previously 
outlined for PILAM detection. To test the viability of a multiplexed SERS-based detection 
platform, the assay was run with spatially separated capture substrates exposed to a mixed 
antigen solution and an ERL suspension specific for a single antigen. Due to the speed of 
Raman readout, spatially separated substrates can be analyzed within a few seconds.
Results for the multiplexed detection for the TB markers PILAM, ACR, and 
Rv0363c are shown in Figure 4.4. The results indicate that there is minimal cross reactivity
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Figure 4.4. SERS calibration curves for mixed antigen solutions spiked into serum. (a) 
LAM ERLs selectively binding only the LAM capture substrate. (b) ACR ERLs 
selectively binding to the ACR capture substrate. (c) Rv0363c ERLs showing minimal 
selective binding to the Rv0363c capture substrate. Each data point is the average and 
standard deviation of two substrates analyzed at five separate locations each.
between the different antigenic markers. This is indicated by the limited amount of SERS 
signal for noncorresponding capture substrates and ERLs immunoassays. In Figure 4.4a 
the black circles correspond to the match between the LAM capture substrate and LAM 
ERLs. The data for the detection of PILAM show an increase in SERS signal with increased 
antigen concentration while the capture substrates for ACR and Rv0363c indicate no 
detectable signal. A similar trend in the data is observed for ACR ERLs with the 
quantifiable detection of ACR and minimal cross reactivity with the other antigens. 
Rv0363c ERLs shows limited sensitivity to Rv0363c spiked in serum but are detectable 
above the background at 100 ng mL-1. Results for the multiplex detection are indicated as 
limit of quantification (LoQ) due to the decreased linear range in the data. The LoQ is 
defined as the concentration with the smallest detectable signal that is above the black and 
all of the noncorresponding substrates at all concentrations. From this definition, the LoQ 
for LAM is 50 ng mL-1 (3.6 nM), ACR is 10 ng mL-1 (0.6 nM), and Rv0363c is 100 ng 
mL-1 (2.7 nM). While these are reasonably low LoQs, a goal of 1 ng mL-1 LoD is the goal 
for prompting further development of the assay.
4.3.5 Pretreatment of Serum Samples Spiked with PILAM
Of the three antigenic markers, LAM is unique as a lipopolysaccharide instead of a 
protein. The structure is therefore free of secondary and tertiary protein components that 
are held together with hydrogen and electrostatic bonds. These types of bonds are more 
susceptible to cleavage due to exposure to chemicals and/or a harsh environment,43 which 
can cause denaturation and agglutination of proteins. The covalent bonds that hold together 
the structure and shape of LAM allow the molecule to be more resistant to chemical and
140
heat treatment. Exposure to denaturing agents causes agglutination of serum proteins and 
inactivation of the bacteria without damaging the structure or epitope regions on PILAM. 
Centrifugation of the treated sample allows for extraction of a small volume of a clear 
solution than can be used in the SERS immunoassay.
The heat and perchloric acid treatment of the serum samples is a process that takes 
less than one hour, and has been described in detail in the experimental section. The 
remaining clear supernatant from the serum samples containing PILAM was placed on 
separate capture substrates and subsequently exposed to an ERL suspension. After a final 
rinse and drying step of the immunoassay, the fully prepared samples were analyzed. Data 
analysis was performed in the same manner as previously described by quantitatively 
measuring the relative signal strengths of the Raman spectra at 1336 cm-1 (Figure 4.5). The 
LoD was determined by calculating the blank signal plus three times the standard deviation 
of the signal. The LoD for the heat-treated serum was determined to be 150 pg mL-1 or 8.8 
pM; the LoD of and perchloric acid treatment was calculated as 10 pg mL-1 or 1.0 pM. 
These results are comparable to results of the buffered PILAM. The heat-treated samples 
have a lower analytical sensitivity and the perchloric acid treated samples have a higher 
analytical sensitivity. However, both methods indicate dramatic and significant 
improvements in the LoD from the untreated serum, which displays no detectable signal in 
the same concentration range. The progression in the SERS immunoassay results for 
PILAM from raw serum to treated serum indicates the importance of serum pretreatment 
in the detection of the antigenic marker PILAM.
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Figure 4.5. SERS dose-response curves for (a) heat and (b) perchloric acid treated serum 
containing PILAM. The linear least squares regression for the heat and perchloric acid 
treated serum samples displayed a linear response of y = 203x + 69 (R2 = 0.98) with 
LoDs of 150 pg mL-1 (8.8 pM). The linear least squares regression for the heat and 
perchloric acid treated serum samples displayed a linear response of y = 1665x + 30 (R2 
> 0.99 with LoDs of 10 pg mL-1 (1.0 pM).
[PI-LAM] / ng mLH
4.4 Conclusions
A new SERS-based detection method for TB has been developed. For this work the 
antigenic TB marker LAM was used as an indicator for TB infection. LAM is an ideal 
antigenic marker for TB infection due to the large amount of LAM that is produced by the 
bacteria that is sloughed off of the surface of M. tuberculosis. LAM produced by the 
Mycobacterium, M. smegmatis, was used in the studies due to the simplification of sample 
handling. The sandwich immunoassay developed for the detection of LAM displays a 
clinically significant LoD (below 1 ng/mL)17 for PILAM in a variety of biologically 
relevant sample matrices using the SERS sandwich immunoassay. The analysis of LAM 
spiked into PBST, urine, and CSF all showed comparable results with a consistent and 
reliable LoD below 100 pg mL-1 or 5.9 |iM. While it is possible to perform multiplexed 
detection of LAM, ACR, and Rv0363c with an LoQ of 50, 10, 100 ng mL-1 or 3.6, 0.6, 2.7 
nM, respectively, lower levels of detection were pursued. The unique structure of LAM 
allows for pretreatment of the sample that removes a majority of the proteins from solution. 
Heat treatment produces an LoD for PILAM in serum of ~150 pg mL-1 or 8.8 pM, while 
perchloric acid treatment and subsequent and neutralization yields an LoD of 10 pg mL-1 
or 1.0 pM.
The development of a reliable, cost effective, and field-deployable detection 
method for TB will help increase the chances of early diagnosis and reduced delay time in 
the start of therapeutic treatment. The detection of PILAM in spiked biological samples 
was performed in 17 h and can be analyzed with robust instrumentation for point-of-care 
detection. The implementation of new, reliable, and practical diagnostic methods could 




(1) Global Tuberculosis Report 2012; World Health Organization: Geneva, 2012.
(2) Nester, E.; Aderson, D.; Roberts, C. E.; Nester, M. Microbiology: A Human 
Perspective. 5th ed.; McGraw-Hill: Boston, 2007; pp 593-595.
(3) Albanese, A.; Chan, W. C. W. ACS Nano 2011, 5, 5478-5489.
(4) Keeler, E.; Perkins, M. D.; Small, P.; Hanson, C.; Reed, S.; Cunningham, J.; 
Aledort, J. E.; Hillborne, L.; Rafael, M. E.; Girosi, F. Nature 2006, 444, 49-57.
(5) Brock, I.; Weldingh, K.; Lillebaek, T.; Follmann, F.; Andersen, P. Am. J. Respir. 
Crit. Care Med. 2004,170, 65-69.
(6) Dorman, S. E. Clin. Infect. Dis. 2010, 50, S173-S177.
(7) Pai, M.; O'Brien, R. Sem. Resp. Crit. CareM. 2008, 29, 560-568.
(8) Arias-Bouda, L. M. P.; Nguyen, L. N.; Ho, L. M.; Kuijper, S.; Jansen, H. M.; Kolk, 
A. H. J. Clin. Microbiol. 2000, 38, 2278-2283.
(9) Tuberculosis (TB); Centers for Disease Control and Prevention, U. S. Government 
Printing Office: Atlanta, 2012.
(10) Park, S.; Lee, B.; Cho, S.; Kim, W.; Lee, B.; Kim, S.; Kim, J. Tuber. Lung Dis. 
1993, 74, 317-322.
(11) Apers, L.; Mutsvangwa, J.; Magwenzi, J.; Chigara, N.; Butterworth, A.; Mason, P.; 
Van der Stuyft, P. Int. J. Tuberc. Lung Dis. 2003, 7, 376-381.
(12) Githui, W.; Kitui, F.; Juma, E. S.; Obwana, D. O.; Mwai, J.; Kwamanga, D. East 
Afr. Med. J. 1993, 70, 263-266.
(13) Levy, H.; Feldman, C.; Sacho, H.; van der Meulen, H.; Kallenbach, J.; Koornhof, 
H. Chest 1989, 95, 1193-1197.
(14) Behr, M.; Warren, S.; Salamon, H.; Hopewell, P.; De Leon, A. P.; Daley, C.; Small, 
P. Lancet 1999, 353, 444-449.
(15) Improving the Diagnosis and Treatment o f Smear-negative Pulmonary and 
Extrapulmonary Tuberculosis Among Adults and Adolescents: Recommendations 
for HIV-prevalent and Resource-constrained Settings; World Health Organization: 
Geneva, 2007.
(16) Boehme, C.; Molokova, E.; Minja, F.; Geis, S.; Loscher, T.; Maboko, L.; Koulchin, 
V.; Hoelscher, M. Trans. R. Soc. Trop. Med. Hyg. 2005, 99, 893-900.
145
(17) Davson, H. Physiology o f the Ocular and Cerebrospinal Fluid; Elsevier: 
Amsterdam, 1956.
(18) Middlebrook, G.; Reggiardo, Z.; Tigertt, W. D. Am. Rev. Respir. Dis. 1977, 115, 
1066-1069.
(19) Torres-Chavolla, E.; Alocilja, E. C. Biosens. Bioelectron. 2011, 26, 4614-4618.
(20) Kneipp, K.; Kneipp, H.; Itzkan, I.; Dasari, R. R.; Feld, M. S. Chem. Rev. 1999, 99, 
2957-2976.
(21) Ni, J.; Lipert, R. J.; Dawson, G. B.; Porter, M. D. Anal. Chem. 1999, 71, 4903-4908.
(22) Palonpon, A.; Ichimura, T.; Verma, P.; Inouye, Y.; Kawata, S. Appl. Phys. Express
2008, 1, 092401.
(23) Willets, K. A.; Van Duyne, R. P. Annu. Rev. Phys. Chem. 2007, 58, 267-297.
(24) Wang, G.; J., L. R.; Jain, M.; Kaur, S.; Chakraboty, S.; Torres, M. P.; Batra, S. K.; 
Brand, R. E.; Porter, M. D. Anal. Chem. 2011, 83, 2554-2561.
(25) Dufek, E. J.; Ehlert, B.; Granger, M. C.; Sandrock, T. M.; Legge, S. L.; Herrmann, 
M. G.; Meikle, A. W.; Porter, M. D. Analyst 2010, 135, 2811-2817.
(26) Yakes, B. J.; J., L. R.; Bannantine, J. P.; Porter, M. D. Clin. Vaccine Immunol. 2008, 
15, 227-234.
(27) Driskell, J. D.; Kwarta, K. M.; Lipert, R. J.; Porter, M. D.; Neill, J. D.; Ridpath, J.
F. Anal. Chem. 2005, 77, 6147-6154.
(28) Grubisha, D. S.; Lipert, R. J.; Park, H. Y.; Driskell, J.; Porter, M. D. Anal. Chem. 
2003, 75, 5936-5943.
(29) Mishra, A. K.; Driessen, N. N.; Appelmelk, B. J.; Besra, G. S. FEMS Microbiol. 
Rev. 2011, 35, 1126-1157.
(30) Snapper, S.; Melton, R.; Mustafa, S.; Kieser, T.; WR Jr, J. Mol. Microbiol. 1990, 
4, 1911-1919.
(31) Yuan, Y.; Crane, D. D.; Simpson, R. M.; Zhu, Y.; Hickey, M. J.; Sherman, D. R.; 
Barry, C. E. Proc. Natl. Acad. Sci. 1998, 95, 9578-9583.
(32) Xolalpa, W.; Vallecillo, A. J.; Lara, M.; Mendoza-Hernandez, G.; Comini, M.; 
Spallek, R.; Singh, M.; Espitia, C. Proteomics 2007, 7, 3332-3341.
(33) Granger, J. H.; Granger, M. C.; Firpo, M. A.; Mulvihill, S. J.; Porter, M. D. Analyst 
2013, 138, 410-416.
(34) Turkevich, J.; Stevenson, P. C.; Hillier, J. Discuss. Faraday Soc. 1951, 11, 55-75.
146
(35) Moskovits, M. Rev. Mod. Phys. 1985, 57, 783.
(36) Stamou, D.; Gourdon, D.; Liley, M.; Burnham, N. A.; Kulik, A.; Vogel, H.; Duschl, 
C. Langmuir 1997, 13, 2425-2428.
(37) Commercial Serodiagnostic Tests for Diagnosis o f Tuberculosis: Policy Statement; 
World Health Organization: Geneva, 2011.
(38) Gaylord, H.; Brennan, P.; Young, D.; Buchanan, T. Infect. Immun. 1987, 55, 2860­
2863.
(39) Hunter, S. W.; Gaylord, H.; Brennan, P. J. Biol. Chem. 1986, 261, 12345-12351.
(40) Hamasur, B.; Bruchfeld, J.; Haile, M.; Pawlowski, A.; Bjorvatn, B.; Kallenius, G.; 
Svenson, S. B. J. Microbiol. Methods 2001, 45, 41-52.
(41) Haiss, W.; Thanh, N. T.; Aveyard, J.; Fernig, D. G. Anal. Chem. 2007, 79, 4215­
4221.
(42) Patel, V. B.; Singh, R.; Connolly, C.; Kasprowicz, V.; Zumla, A.; Ndungu, T.; 
Dheda, K. PLOS ONE 2010, 5, e15664.
(43) Scopes, R. K. Protein Purification: Principles and Practice; Springer: Berlin,
2013.
CHAPTER 5
LOW-LEVEL DETECTION OF THE ANTIGENIC TUBERCULOSIS 
MARKER LIPOARABINOMANNAN IN HUMAN SERUM BY 
GOLD NANOPARTICLE LABEL AND SURFACE- 
ENHANCED RAMAN SCATTERING
5.1 Abstract
Diagnostic tests for tuberculosis (TB) are critical for patient care and global 
infection control. This paper describes the development and preliminary clinical accuracy 
assessment of a heterogeneous immunoassay that integrates an innovative serum 
pretreatment process with the detection capabilities of surface-enhanced Raman scattering 
(SERS) for the low-level detection of mannose-capped lipoarabinomannan (ManLAM). 
ManLAM is a 17.3 ± 5 kDa lipoglycan and a major component of the cell wall of 
Mycobacterium tuberculosis (M. tuberculosis), the causative agent of TB. ManLAM is also 
a major virulence factor in the infectious pathology of this disease and has been found in 
the urine, serum, sputum, and cerebral spinal fluid of infected patients. As a result, 
ManLAM has been one of the most investigated antigenic markers for TB diagnostics. The 
effectiveness of ManLAM as a marker, however, has remained unproven for reasons not 
well understood. To this end, we have found that the apparent sequestering of ManLAM
by its association with components in serum, and potentially other body fluids, has a 
strongly detrimental impact on the ability to detect the presence o f this maker when 
performing an immunoassay. Herein we show that a simple serum pretreatment procedure 
can be used to disrupt the complexation o f ManLAM with other serum components, 
enabling its detection at levels ~250x lower than that in untreated serum when using a 
SERS-based immunoassay. We have also carried out a preliminary assessment o f the 
clinical accuracy o f  this approach using serum from 24 TB-positive patients (culture- 
confirmed) and 10 healthy controls. ManLAM was measurable in 21 of the 24 TB-positive 
specimens, but was not detectable in any of the 10 control specimens. More to the point, 
the levels of ManLAM measured in all 21 TB-positive specimens were well below the limit 
of detection for serum prior to pretreatment. Albeit for a small sample set, these findings 
translate to an exceptional level of clinical accuracy, that is, a clinical sensitivity of 87.5% 
and a clinical specificity of 100%. Taken together, these results not only provide much 
needed evidence for the clinical utility o f  ManLAM as a TB biomarker, but also 
demonstrate the potential o f  our overall approach to serve as a new diagnostic test for this 
disease. These findings, along with their possible implications vis-a-vis the difficulties 
found in earlier attempts to use ManLAM in TB diagnostics, are briefly discussed.
5.2 Introduction
Advances in tuberculosis (TB) diagnostics stand as one o f  the top priorities in 
global health.1-3 TB is the world’s second deadliest infectious disease. The challenges 
associated with combatting this disease are magnified by the suppression o f immunological 
responses in individuals co-infected with human immunodeficiency virus (HIV) and the
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emergence of drug-resistant strains of the causative agent of TB, Mycobacterium 
tuberculosis (M. tuberculosis).4 The World Health Organization (WHO) estimates that 
there were 9.6M active cases of TB in 2014 and 1.5 million associated deaths; the majority 
(~80%) of these cases occurred in resource-limited countries.4
If diagnosed early, TB can be cured.5 Early detection is also vital in containing the 
spread of the disease. However, sputum smear microscopy (SSM), the test most widely 
available in resource-limited areas of the world, cannot reliably detect early-stage 
infection.6 Serological diagnostics, which rely on the detection of secondary markers of the 
disease (e.g., antibodies), have also proven ineffective in patients with an immune system 
compromised by HIV coinfection.7-9 Nucleic acid amplification tests (NAATs) can be of 
immense value in early diagnosis,9, 10 but have yet to be engineered and tested in formats 
that meet the rigor of the requirements for deployment in TB-endemic settings (e.g., low 
cost, short turn-around time, and ease of use).10, 11
In recognition of these challenges, there has been a refocus in TB diagnostics 
towards the direct detection of primary antigenic markers for M. tuberculosis in serum and 
other body fluids.12, 13 This strategy parallels a proven approach for the early stage 
diagnosis of malaria and other diseases.14 The potential merits of applying this approach 
TB include: (1) high clinical accuracy (i.e., high clinical sensitivity and clinical 
specificity);1 (2) direct quantifiable evidence of the disease; (3) diagnosis of smear-
1 Clinical sensitivity (SN) and clinical specificity (SP) measure diagnostic test accuracy. 
SN is defined as the percentage of infected individuals correctly identified by the test as 
infected; it is expressed as: [TP/(TP+FN)]100, whereas TP is the number of true positive 
tests and FN and is number of false negative tests. SP is the percentage of uninfected 
subjects correctly identified by a test as being uninfected; it is given as: [TN/(FP+TN)]100, 
whereas TN is the number of true negatives and FP is the number of false positives (FP). 
An ideal test has a SN and SP of 100%.
negative pulmonary infection; and (4) lack of dependence on a functioning immune 
system.12, 13 Assays using serum and other body fluids may also be useful in diagnosing 
extrapulmonary TB;7, 15 this form of TB accounts for ~10% of the globally infected 
population and is often found in children and HIV coinfected adults, rendering detection 
beyond that tractable in sputum specimens.15, 16
Several mycobacterial antigens have been found in serum and other body fluids 
(e.g., urine, sputum, and cerebral spinal fluid) of TB-infected patients.12 The most widely 
investigated antigen for potential use as a marker in TB diagnostics is the mannose-capped 
lipoarabinomannan (ManLAM), a highly branched lipoglycan (17.3 ± 5 kDa)17 unique to 
only mycobacteria.8, 9 13, 18-32 The strong interest in ManLAM reflects several factors. First, 
ManLAM is a major virulence factor in the infectious pathology of TB.33 ManLAM 
suppresses immunological responses to bacterial infection, which include phagosome 
maturation, apoptosis, and interferon-gamma signaling in macrophages.34 Second, 
ManLAM is a loosely associated but large fractional component (~40%) of the 
mycobacterial cell wall.19, 35 It is, therefore, easily shed, potentially in large amounts, by 
metabolically active or degrading organisms into the circulation system of an infected 
patient. Nonetheless, the effectiveness of ManLAM as a TB marker remains unproven in 
spite of extensive investigations.26
Lipoarabinomannan has three unique structural components.36 Two of these 
components, the mannosyl phosphate inositol anchor and the mannan backbone, are 
common to all mycobacteria. The third component, the capping region, is species 
dependent [e.g., the phosphoinositol-capped LAM of the nonpathogenic M. smegmatis 
(PILAM) and the mannose-capped ManLAM of pathogenic M. Leprae, M. Bovis, and M.
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tuberculosis]. The underlying basis for the use of ManLAM therefore rests on the simple 
logic that i f  found in an individual in a TB-endemic region o f the world, the likelihood o f  
the infection originating from TB is extremely high.4
There is another important obstacle to the detection of this antigenic marker -  its 
presence in the circulatory system both in its free and complexed forms.19, 22, 37-39 The latter, 
referred to hereafter as complexed ManLAM, arises from its complexation with proteins 
and other components in body fluids. It is therefore reasonable to expect that the detection 
of ManLAM may be compromised due to the impact of steric effects on the binding and/or 
labeling of ManLAM in heterogeneous immunoassays.26, 37
The basis of the work described in this chapter reflects our hypothesis that the 
diagnostic strength o f ManLAM for TB can be significantly improved by applying a 
simple, but vital, sample pretreatment step to disrupt ManLAM complexation before 
running the immunoassay. To test this hypothesis, we developed a sandwich immunoassay 
for the detection of ManLAM that combines gold nanoparticle (AuNP) labeling, ManLAM 
monoclonal antibodies (ManLAM mAbs), and readout by surface-enhanced Raman 
scattering (SERS). This approach draws on the continued focus of our40-42 and other 
laboratories43-45 on exploiting the strengths of SERS for low-level quantification of disease 
makers.46-49 Herein, we show that the application of a simple pretreatment (acidification) 
process can significantly improves the limit of detection (LoD) of ManLAM in serum by 
~250x over that for untreated serum. We also carried out a preliminary assessment of the 
clinical accuracy of this approach in tests of 24 TB-positive patients (culture-confirmed) 
and 10 healthy controls. As detailed, these findings demonstrate the potential of our 
approach to serve as an important addition to the TB diagnostics toolbox. Prospects and
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challenges in extending this approach for use in clinical and other point-of-care settings, 
along with possible applications to other TB markers and different types of patient 
specimens and diseases, are also briefly discussed.
5.3 Experimental
5.3.1 Assay Format
Figure 5.1, overviews the details of our SERS-based immunoassay,48 which 
sandwiches ManLAM between an extrinsic Raman label (ERL) and a capture substrate. 
ERLs are prepared by modifying 60-nm AuNPs with a thiolate monolayer that forms by 
the spontaneous adsorption of the disulfide-bearing Raman reporter molecule (RRM) 5-5’- 
dithiobis(succinimidyl-2-nitrobenzoate) (DSNB). This step is followed by the deposition 
of a layer of ManLAM mAbs, which forms by the adsorption of the mAb onto the 
hydrolyzed surface of the RRM.50 This construction places the Raman scattering centers 
of the RRM monolayer in close proximity to the AuNP surface in order to maximize the 
SERS signal.51, 52 The smooth, glass-supported gold (~200 nm thick) capture substrate is 
also coated with ManLAM mAbs adsorbed on the thiolate monolayer formed from the 
spontaneous adsorption of dithiobis(succinimidyl propionate) (DSP).50 As a result, the 
presence of captured ManLAM in a sample is indirectly signaled by the characteristic 
Raman spectrum of the RRM, and the amount of ManLAM is indirectly quantified by the 
strength of its most intense spectral feature [i.e., its symmetric nitro stretch, Vs(NO2), 
centered at 1336 cm-1].
It is worthwhile to note some of the considerations that we have adopted in moving 
SERS forward as a reliable analytical measurement tool in diagnostics. This relates, in
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Figure 5.1. The three main components of the SERS-based immunoassay approach for 
LAM detection: (a) ERL preparation; (b) capture substrate preparation; and (c) major 
assay steps. The first two procedures are completed prior to the assay. The assay is 
carried out by incubating a treated (see Experimental Section) serum sample (20.0 ^L) 
at room temperature with the capture substrate. The samples are then rinsed, exposed to 
ERLs (20.0 |iL), rinsed again, dried under ambient conditions, and analyzed by SERS.
large part, to designing an assay in which the enhanced response for SERS is reproducibly 
managed.53 In our case, reproducibility is controlled by: (1) the size and shape distribution 
of the gold nanoparticles that constitute the ERL core, (2) the ability to form a 
monomolecular layer of RRMs and mAbs on the ERLs; and (3) the use of a smooth gold 
capture substrate. The latter component is particularly important due to the plasmonic 
coupling between the gold core of the ERL and the gold support54 of the capture substrate. 
We also use UV-Vis spectrophotometry, per the method by Haiss, and collaborators,55 to 
maintain a fixed concentration of ERLs in the suspension used to tag the captured antigen. 
We add that Class A volumetric flasks were used in all appropriate solution preparations 
and that all reagent and antigenic solutions were deposited on the capture substrate using 
calibrated pipettes (Pipette Repair Service, Midlothian, VA).
5.3.2 Extrinsic Raman Labels (ERLs)
The preparation48 and plasmonic signal optimization54 of ERLs and the synthesis 
of DSNB42 have appeared elsewhere. The preparative steps are summarized in Figure 5.1a. 
First, an aqueous suspension of 60-nm (nominal diameter) AuNPs (NanoPartz, Loveland, 
CO) in 2.0 mM borate buffer (BB, pH 8.5, Thermo Scientific) was mixed for 1.5 h with 
DSNB (10.0 mM in acetonitrile, spectroscopy grade, Sigma-Aldrich) at 4°C. This step 
yielded a DSNB-derived thiolate monolayer on the AuNP surface that forms via disulfide 
cleavage. Next, a small aliquot (10.0 ^L at 100 p,g/mL) of the ManLAM mAb CS906.7 
(BEI Resources, Manassas, VA)56 was added to the suspension, which was incubated for 1 
h at 4°C; the selection of this mAb is detailed below. This step was followed by pipetting 
100-^L of 10% (w/v) bovine serum albumin (BSA, 2.0 mM BB, Sigma-Aldrich) into this
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suspension and then incubating the resulting suspension at room temperature for 1 h. BSA 
serves as a blocking agent and a stabilizer of the colloidal suspension. This suspension was 
subsequently centrifuged at ~2,000g  for 10 min, and the clear supernatant was carefully 
removed. The ERL pellet was resuspended in 1.0 mL of 1% BSA in 2.0 mM BB, and the 
centrifugation and resuspension steps were repeated two more times, with the final 
resuspension using 0.25 mL of 2% BSA in 2.0 mM BB with 150 mM NaCl (Thermo 
Scientific) to achieve an ERL concentration of 8.0 x 1010 particles/mL. In work in 
preparation for submission elsewhere,57 measurements of the amounts of DSNB and mAbs 
coated on the ERLs varied by ±5.0 and ±10.2%, respectively.
5.3.3 Capture Substrate
Capture substrates (Figure 5.1b) were prepared with 1x1 cm glass squares that 
supported a 200-nm layer of template stripped gold (TSG).58 A 2-mm diameter address 
was created in the center of the substrate by octadecanethiol (ODT, Fluka) microprinting 
with polydimethylsiloxane (PDMS, Dow Corning SlyGuard).59 The ODT layer produced 
a hydrophobic boundary around an uncoated 2-mm address, which was modified for 1 h 
with an ethanolic solution of DSP (1.0 mM, Thermo Scientific). Next, the DSP-derived 
monolayer was reacted with a 20.0 |iL drop of capture antibody (2.5 |ig/mL, CS906.7 
ManLAM mAbs) for 1 h to form a layer of ManLAM mAbs on the hydrolyzed surface. 
The substrate was then rinsed three times with phosphate-buffered saline containing 0.1% 
Tween 20 (PBST, pH 7.4, Fisher Scientific); blocked with 20.0 |iL of StartingBlock 
(Thermo Scientific) for 1 h; rinsed three more times with PBST; and exposed (Figure 5.1c) 
to 20.0 |iL of a ManLAM-containing sample. After 1 h, the sample was rinsed three times
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with 2 mL of 2.0 mM BB (150 mM NaCl and 0.1% Tween 20), exposed to 20.0 pL of the 
ERL suspension, and incubated for 16 h. Finally, the sample was rinsed with 2 mL of 2.0 
mM BB, containing 10.0 mM NaCl and 0.10% Tween 20, and dried under ambient 
conditions for ~1 h prior to SERS interrogation.
5.3.4 ManLAM mAb Selection
Three ManLAM mAbs (IgG3 subclass) were screened for effectiveness in our 
SERS assay (Figure 5.1). We note that the same antibodies were screened in the work 
detailed in the companion paper,60 using PILAM as the antigen. These mAbs, which are 
designated as CS906.1, CS906.7, and CS907.41, were first prepared and characterized for 
reactivity at Colorado State University in 1987.56 Each of their possible nine combinations 
was tested for the capture and/or the ERL tagging of PILAM by measuring the SERS 
response of PBST spiked with 5.0 pg/mL of PILAM. The levels of nonspecific ERL 
adsorption were also determined for PBST devoid of PILAM. These results of the nine 
tests with spiked PILAM indicated that the signal measured using the CS906.7 mAb for 
both the capture and labeling of PILAM was about two times stronger than any of the other 
eight mAb combinations. ManLAM detection required higher levels than found for 
PILAM, which indicates a higher affinity for PILAM by CS906.7. In contrast, the 
responses for the nine mAb combinations for the PBST blanks were barely distinguishable 
from each other by statistical analysis. Based on these results, the CS906.7 mAb was used 
as the capture and labeling mAb in all subsequent experiments. We note that the epitope 
structures of either PILAM or ManLAM that are recognized by CS906.7 have not been 
characterized. However, the structure o f PILAM and ManLAM is consistent with the
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presence of a multiplicity of structurally similar antigenic determinants that could react 
with CS906.7.56
5.3.5 Instrumentation and Sample Readout
The Raman spectrometer used was a modified NanoRaman system (Concurrent 
Analytical, Loveland, CO).61 This instrument has three primary components: laser 
excitation source, fiber optic probe, and spectrograph. The light source is a 22-mW, 632.8­
nm HeNe laser with a spectrograph consisting of an f/2.0 Czerny Tuner imaging 
spectrometer with 6-8 cm-1 resolution and a Kodak 0401E charged coupled device (CCD) 
thermoelectrically cooled to 0°C.
SERS readout was performed after the samples had fully dried under ambient 
conditions (~1 h). Raman spectra were collected at a 1-s integration time by irradiating a 
20-^m spot on the sample surface at a laser power of 3.0 mW. The laser power was checked 
periodically in each run and varied by no more than 0.1 mW. Upon assay completion, 10 
different locations on each sample with from triplicate samples were analyzed. All spectra 
were baseline corrected and the height of the Vs(NO2) of the RRM adlayer on the ERLs 
was used for quantification.
5.3.6 Control and TB-Patient Serum
The serum used for the development of the assay and the generation of calibration 
curves (i.e., serum spiked with ManLAM) was prepared using human serum [Human AB 
Serum (Mediatech, Inc., Manassas, VA)]. The vendor prepares this product, referred to 
hereafter as negative human serum, by pooling and sterilizing donor plasma collected at
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centers across the United States. This serum was stored at -30°C and slowly thawed in the 
laboratory to ambient temperature immediately prior to use. All calibration data are 
presented as the average and standard deviation of the collected spectra (i.e., a spectrum 
from 10 different locations per sample from triplicate samples).
The TB-positive sera were collected from patients in South Africa who were 
enrolled in the Tuberculosis Trials Consortium Study Group 22 (TBTC-22) with culture- 
confirmed cavitary TB.62 This study group participated in a randomized clinical trial that 
was designed to test the effectiveness of the antiTB drugs rifapentine and isoniazid in 
treating pulmonary TB in adult, HIV-negative patients. These deidentified samples were 
procured by Colorado State University from the Centers for Disease Control and 
Prevention (CDC) after TBTC-22 approval. This specimen set consisted of 24 different 
serum samples (deidentified), each at a volume of ~100 ^L. We do not have information 
with regard to treatment status (e.g., drug regimen or time course of treatment) for any of 
these specimens. However, tests for immunoblot reactivity confirmed the presence of 
ManLAM antibodies in all TB-positive specimens, but not in any of the healthy controls 
(data not shown). These results suggest that there was a high likelihood that ManLAM 
antigen would also be present in the TBTC-22 study serum specimens.
Healthy, nonendemic control sera, referred to hereafter as healthy controls, were 
obtained from U.S.-born residents of Colorado. These non-Bacillus Calmette-Guerin 
(BCG)-vaccinated residents gave informed consent to participate in a study of reactivity to 
M. leprae and M. tuberculosis antigens.63 These residents had no known exposure to TB 
or leprosy and did not work in a mycobacterial laboratory.
All patient specimen orders and healthy control collections were performed under
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approved IRB protocols at Colorado State University. All assay steps were carried out in a 
biosafety cabinet contained in a BSL-2 (enhanced) laboratory.
5.3.7 Serum Pretreatment
As detailed in the companion paper,60 the detection of PILAM directly from serum 
yielded signal strengths that were negatively affected by complex formation37-39 and much 
weaker than those for PILAM spiked into PBST at similar levels. We therefore adapted a 
classic pretreatment procedure64 designed to disrupt complexation via protein denaturation. 
This procedure, which was applied herein for ManLAM for the same reasons, consists o f  
five steps as outlined previously in Figure 5.2. It begins (Step 1) by adding 2.0 |j,L of HClO4 
(70%, Sigma-Aldrich) to 100.0 p,L of each calibration/patient sample in a small centrifuge 
tube, which brings the pH to ~2 and forms a milky suspension. After vortexing for 10 s and 
centrifuging at 13,000g for 5 min (Step 2), 75.0 p,L of the resulting supernatant were 
transferred to a second centrifuge tube (Step 3) and neutralized to pH 7.5 with 6.0 p,L of 
an aqueous solution of K2CO3 (2.0 mM, Fisher Scientific) (Step 4). The samples were then 
cooled to 4 0C for 30 min to accelerate KClO4 precipitation, warmed to room temperature 
(~20 min) before being pipetted (20.0 p,L) onto the capture substrate (Step 5).
We note that ManLAM is acid-labile.65-67 We have found, however, that such 
degradation appears to not have an effect on the reproducibility o f  the dose-response plots 
presented later in Chapter 5. Experiments to quantify the potential impact of the serum 
pretreatment process on the recovery o f ManLAM are planned.
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Figure 5.2. Step-by-step schematic of pretreatment procedure employing perchloric acid 
to free mannose-capped lipoarabinomannan (ManLAM) from complexation with 
proteins and other components in human serum. A 100-^L aliquot of human serum is 
treated with perchloric acid and vortexed to ensure proper mixing. Next, the protein 
precipitation in spun down and the protein pellet discarded. Finally, the supernatant 
containing ManLAM is treated with potassium carbonate to neutralize the perchloric 
acid. This step produces a precipitate results in a much cleaner sample matrix in the 
supernatant.
5.3.8 Data Analysis
Due to the small volumes received for the TB-positive and TB-negative serum 
specimens (~100 |j,L), the patient serum samples were run as duplicates. As a consequence, 
the levels of ManLAM in all patient samples are reported as averages and uncertainties as 
the range of the values from reading 10 sites per sample from 2 separate substrates prepared 
from a single specimen.
The serum blank specimens had an average response of 64 cts/s, with a standard 
deviation of 11 cts/s. We employed a confidence interval of >99% to define the LoD, which 
yielded a signal on the calibration curve that matched the blank response (64 cts/s) plus 
three times its standard deviation ( ±1 1  cts/s) for a cutoff of 97 cts/s. Patients were 
identified when using our SERS-based assay as “TB-positive” if the level of ManLAM was 
statistically measurable above the LoD. The fit to the data for the pretreated calibration 
samples used a linear least squares approach for the data spanning the blank serum samples 
up to serum samples spiked at 100 ng/mL (y = 12.9x + 64.1). For samples with signals 
beyond the linear portion of the dose-response plot (that is, ManLAM concentrations above 
~100 ng/mL), a second order polynomial fit (y = -0.00727x2 + 13.5x + 64.1) was used for 
quantification.
5.4 Results and Discussion
5.4.1 Preliminary Findings
As a starting point for this work, we conducted a set of studies to assess the 
effectiveness of our assay strategy by spiking PILAM derived from M. smegmatis, which 
is often used as a model in mycobacterium research for PILAM because of its
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nonpathogenic nature and its fast growth in culture,68-70 into negative human serum. M. 
smegmatis shares more than 2000 homologs with M. tuberculosis; and the cell wall 
structure is similar for both.69 That work, detailed in the companion paper,60 demonstrated 
the impact of complex formation on the detection of PILAM spiked at low levels into 
human serum, and pointed to component(s) in serum with a molecular weight (>100kDa) 
as likely culprits.
5.4.2 ManLAM Measurements in Untreated and 
Pretreated Human Serum
The first assessment of the potential merits of our integrated approach focused on 
a comparison of assays that analyzed ManLAM after spiking it into untreated, negative 
human serum and then subjecting the spiked serum samples to the acid pretreatment 
protocol per Figure 5.2. The SERS spectra and dose-response plot for the untreated samples 
are shown in Figure 5.3. Theses samples included serum banks and serum spiked with 
ManLAM in concentrations from 0 to 10 ^g/mL. There are three important points to draw 
from these spectra (Figure 5.3a). First, all of the observable spectral features can be 
assigned to functional groups of the monomolecular coating of the RRM on the ERLs (for 
example, Vs(NO2) at 1336 cm-1 and aromatic ring mode at 1558 cm-1 of the DSNB-derived 
coating).48 None of the vibrational modes of the ManLAM mAb layer on the ERLs are 
detectably enhanced. Second, the strengths of the spectral features increase with increasing 
amounts of ManLAM spiked into serum. This dependence follows expectations for a 
sandwich immunoassay. Third, there is evidence for a small, but measureable, level of ERL 
adsorption in the spectrum for the negative control. We attribute this observation to the
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Figure 5.3. SERS-based immunoassay for ManLAM spiked into untreated serum. (a) 
SERS spectra from a calibration run using ManLAM-spiked negative human serum: (i) 
10.0 (ii) 5.0; (iii) 2.5; (iv) 1.0; (v) 0.10; and (vi) 0.0 p,g/mL. The spectra are offset 
vertically for visualization. (b) Dose-response plot from averaging triplicate calibration 
runs (20.0 |iL) for ManLAM spiked from 0.10 to 10.0 p,g/mL into human serum and a 
negative control sample. The LoD was estimated to be ~0.5 p,g/mL (30 nM). It was 
determined as the signal for the blank sample plus three times its standard deviation via 
the data shown in the inset (y = 83.2x + 48.1; R2 = 0.99.) The signal at the cutoff for the 
LoD is indicated by the dashed black line in the inset.
effectiveness of the blocking agent and other preparative procedures (Experimental 
Section) to reduce nonspecific adsorption.
The dose-response plot for ManLAM in untreated serum is shown in Figure 5.3b.It 
was constructed from the average signal for the strongest feature in the SERS spectrum, 
Vs(NO2), from 10 different locations per sample and triplicate samples for each calibration 
point. The response at low levels of ManLAM follows a linear dependence. Though not 
shown, the response at higher ManLAM concentrations begins to level off (~5 |ig/mL) as 
binding sites on the capture substrate approach saturation, plateauing at ~10 |ig/mL. The 
LoD, calculated as the response on the calibration line that matches the blank signal plus 
three times its standard deviation, is ~500 ng/mL. This value is ~100x greater than the LoD 
found for PILAM from M. smegmatis, which is phosphoinositol-capped, using the same 
set assay conditions.60 As noted earlier, this difference is attributed to the lower affinity of 
the CS906.7 mAb for ManLAM versus that for PILAM.
Following the hypothesis that the complexes formed between ManLAM and serum 
constituents sterically inhibit binding to the capture mAb, the next set of assays analyzed 
the ManLAM-spiked sera after completing the acid-treatment procedure illustrated in 
Figure 5.2. Indeed, this assertion is in accord with a growing body of evidence for the 
presence of complexes for ManLAM in human serum,19, 22, 23, 37-39, 71 the most recent being 
the strong association of ManLAM with high density lipoproteins (HDLs).37 The impact 
of pretreatment is immediately evident in the results presented in Figure 5.4, which shows 
that the spectral responses for the pretreated samples are much stronger than those of the 
untreated samples. This difference is particularly evident when comparing the responses 
for a ManLAM concentration of 100 ng/mL. With the untreated sample, the response at
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Figure 5.4. SERS-based immunoassay for ManLAM in pretreated human serum. (a) 
SERS spectra using ManLAM-spiked into negative human serum followed by 
pretreatment: (i) 100.0 (ii) 50.0; (iii) 10.0; (iv) 5.0; (v) 1.0; and (vi) 0.0 ng/mL. The 
spectra are offset vertically for visualization. (b) Dose-response plot for triplicate 
calibration runs (20.0 pL pretreated serum samples) for ManLAM spikes from 1.0 to 
1000 ng/mL and a negative (pretreated serum) control sample. The LoD was estimated 
to be ~2 ng/mL (~0.1 nM). It was determined as the signal on the calibration plot that 
matches the blank signal plus three times its standard deviation via the data shown in the 
inset (y = 12.9x + 64.1; R2 > 0.99). The signal at the cutoff for the LoD is indicated by 
the dashed black line in the inset.
100 ng/mL is indistinguishable from that of the serum blank, whereas the signal for the 
acid pretreated specimen is slightly above 1400 cts/s. Another comparison shows that the 
signal for the untreated ManLAM sample at 1 ^g/mL (~130 cts/s) is close to the response 
(~170 cts/s) for the pretreated sample at a 100x lower ManLAM level, 0.010 ^g/mL.
The dose-response plot, obtained from triplicate samples for each calibration point 
runs for ManLAM spiked into negative human serum and then acid pretreated, is shown in 
Figure 5.4b. Like the data for ManLAM spiked into human serum without pretreatment 
(Figure 5.3), the response at low ManLAM levels follows a linear dependence and plateaus 
(data not shown) at higher amounts of ManLAM as mAb binding sites on the capture 
substrate begin to saturate. The LoD from an analysis of these data is ~2 ng/mL or ~250x 
below that in serum prior to pretreatment.
These results have another potentially important implication with respect to 
understanding the huge discrepancies observed in other studies that have examined the 
clinical accuracy of ManLAM from the urine of TB-infected patients. If we assume that 
the complexed form of ManLAM has a molecular weight above 100 kDa per the 
companion paper,60 then the ~30 kDa cutoff for passage by the filtration mechanisms of 
the kidneys would preclude passage of the complex into urine. ManLAM would then only 
be a viable diagnostic maker in urine specimens from patients suffering from renal failure. 
Such a train of thought is consistent with the increased performance levels reported in tests 
for ManLAM in the urine of HIV co-infected individuals.13, 19-21, 30, 31, 72, 73
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5.4.3 TB-Patient Assay
To test further the hypothesis that an effective pretreatment method significantly 
improves the utility of ManLAM as a diagnostic TB marker, we analyzed 24 TB-positive 
(identifiers #1 to #24) and 10 healthy control (identifiers #25 to #34) serum specimens. The 
post pretreatment results for the assays of the 34 specimens are presented in Figures 5.5 
and 5.6 and in Table 5.1. The small specimen volumes precluded the opportunity to 
compare the responses of these samples before and after pretreatment. Figure 5.5 
summarizes these measurements by using histograms to represent the average signal 
strength of the Vs(NO2) spectral feature measured for each sample, and includes a delimiter 
(dashed black line) for the LoD (2 ng/mL) of the SERS assay. Figure 5.6 consists of a small 
set of specimen spectra for illustrative purposes; it includes spectra for two of the healthy 
control samples (#25 and #30) and four of the TB-positive samples (#5, #6, #10, and #12).
As evident in Figure 5.5, ManLAM was detectable using our overall approach in 
21 of the 24 TB-positive samples. ManLAM was not found in three of the TB-positive 
samples (i.e., # 5, #7, and #15) or in any of the 10 healthy control specimens (i.e., ManLAM 
< 2 ng/mL). Importantly, these results yield a clinical sensitivity of 87.5% and a clinical 
specificity of 100%, both of which are rivaled only by NAAT tests.
Further inspection of these data per Table 5.1 points to three generalizable ranges 
for the ManLAM levels found in these patient serum specimens. First, a few of the TB- 
positive samples have ManLAM (#11, #12, #17, #18, and #22) greater than 100 ng/mL. 
Second, a few other samples (#2, #3, #6, #13, and #19) have ManLAM detectable levels 
above the LoD but below 20 ng/mL. Third, ManLAM levels in the majority of samples 
(#1, #4, #8, #9, #10, #14, #16, #20, #21, #23, and #24) is between 20 and 100 ng/mL. While
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Figure 5.5. SERS analysis of patient serum (pretreated) for the quantification of 
ManLAM represented in a bar chart. The black dashed-line delimiter represents the 
SERS LoD. The red bars indicate patient specimens that have been determined as TB+, 
based on culturing, and the blue bars represent patient specimen that are TB-, based on 
culturing. The average SERS signal is calculated from the peak height of the Vs(NO2) 
from baseline-corrected SERS spectra, and| all error bars represent the standard deviation 
of the response at ten different locations on duplicate samples.
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Figure 5.6. Representative SERS spectra from patient serum (pretreated) samples. 
Samples #25 and # 30 are healthy control serum specimens. Samples #5, #6, #10, and 
#12 are TB positive patient serum specimens. Sample #5 represents a patient sample 
below the LoD.
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Table 5.1. Patient Sample Identification with Corresponding SERS Responses and
Levels of Mannose-capped Lipoarabinomannan._____________________
Sample ID SERS / cts s-1 ManLAM / ng mL-1
1 728 ± 41 52 ± 3
2 282 ± 61 17 ± 5
3 219 ± 16 12 ± 1
4 553 ± 208 38 ± 16
5 43 ± 3 ND
6 301 ± 86 18 ± 7
7 131 ± 67 ND
8 1059 ± 194 77 ± 15
9 1034 ± 116 75 ± 9
10 533 ± 96 36 ± 7
11 3710 ± 208 328 ± 16
12 1728 ± 61 129 ± 5
13 295 ± 31 18 ± 2
14 1065 ± 61 78 ± 5
15 37 ± 9 ND
16 1096 ± 214 80 ± 17
17 3349 ± 173 288 ± 13
18 1460 ± 36 108 ± 3
19 187 ± 60 10 ± 5
20 803 ± 139 57 ± 11
21 814 ± 129 58 ± 10
22 2001 ± 170 157 ± 13
23 356 ± 115 23 ± 9
24 509 ± 146 35 ± 11
25 36 ± 4 ND
26 60 ± 15 ND
27 47 ± 11 ND
28 42 ± 14 ND
29 44 ± 7 ND
30 59 ± 27 ND
31 60 ± 21 ND
32 35 ± 8 ND
33 41 ± 27 ND
34 56 ± 11 ND
Notes: The calculated ManLAM levels are derived from the linear fit equation from the 
calibration curve (y = 12.9x + 64.1) for ManLAM ranging from 0-100 ng/mL in 
pretreated human serum. SERS responses corresponding ManLAM >100 ng/mL are 
calculated from a second order polynomial fit. (y = -0.00727x2 + 13.5x + 64.1) ND (not 
detected), that is, ManLAM below the LoD in human serum of 2 ng/mL.
not able to offer any correlations between ManLAM levels and the stage of disease 
progression, the ability to quantify small differences in ManLAM levels in TB-patient sera 
suggests that our approach may be useful in monitoring treatment responses, in determining 
the optimal duration of therapy, and in assessments of new drug treatment regimens and 
vaccines.74-76
These data also show that the responses for 3 of the TB-positive patient samples 
(#5, #7, and #15) were not distinguishable from those of the calibration blank or any of the 
controls. The inability to detect ManLAM in these specimens is attributed to one or a 
combination of three possibilities: (1) ManLAM was present in these three specimens at 
levels below the LoD of the assay; (2) these patients may have had a positive response to 
one of the drug treatments used in the TBTC-22 clinical trial; and (3) these specimens may 
have degraded during storage and/or shipment prior to receipt or from freeze/thaw cycling 
when realiquoted for distribution.
Finally, these data show that the responses for all 10 healthy control samples were 
commensurate with that of the serum blank used in the construction of the calibration plot. 
The spectra for sample #25 and #30 in Figure 5.6 are representative of those for the 
remaining healthy control samples. Moreover, we were unable to detect the presence of 
nonspecific ERL adsorption in these samples even after increasing the signal acquisition 
time from 1 to 60 s (data not shown).
Taken together, these results support the potential value of our integrated approach 
for the detection of TB. Experiments to validate more fully the performance of this 
methodology by analyzing a much larger specimen sample set and to evaluate other types 
of patient specimens (e.g., noncavitary lung disease, TB patients coinfected with HIV,
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children and those with extrapulmonary infections) are being planned. We also believe that 
one of the obstacles in the detection of ManLAM in other body fluids (e.g., urine and 
cerebral spinal fluid) is likely to be a consequence of very low concentrations of unbound 
antigen due to complexation. Efforts to more fully determine the mechanistic 
underpinnings of pretreatment and quantify recovery efficiencies are underway. We are 
also developing plans to evaluate the impact of pretreatment on ManLAM determinations 
by ELISA and other diagnostic platforms.
5.5 Conclusions and Prospectus 
These results begin to demonstrate the potential of ManLAM to serve as a 
long sought-after antigenic marker for TB and of our technological approach to become an 
exciting addition to the TB diagnostics toolbox. It is important, however, to ground these 
preliminary results with a reality check in terms of the many-faceted obstacles faced by TB 
diagnostics in meeting the global challenges in fighting this disease.
First and foremost is the challenge to prove the effectiveness of our ManLAM assay 
through an extensive series of validation studies. While the results herein point to a 
potential technical solution for a test for active infection, an extensive series of validation 
studies must be carried out. Both the number of specimens and types of specimens must be 
markedly increased. Examples of the types of specimens include those from patients who 
are TB-positive and HIV- positive; have cavitary, noncavitary, and extrapulmonary TB; 
and have been BCG (bacilli Calmette-Guerin) vaccinated. Longitudinal studies are also 
needed to validate the effectiveness of the test in for determining the stage of disease 
progression and in providing means to monitor the response to treatment. The goal of these
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validation studies is to quantify the clinical sensitivities and clinical specificities of 
ManLAM for each of these manifestations of TB, which requires specimens that are well 
characterized in terms of clinical symptoms, comparative data from other TB tests, (e.g., 
culture and molecular tests), and exacting patient health histories. Interestingly, the 2006 
Global Health Diagnostics Forum, which was convened by the Bill and Melinda Gates 
Foundation, estimated that a rapid and globally accessible diagnostic test for active TB 
infection which has a clinical sensitivity >85% and a clinical specificity of >97% could 
help save ~400,000 lives each year.77 Our small data set suggests that we may be able to 
reach these metrics, but it remains to be seen if this level of effectiveness can be realized 
with ManLAM alone or if a multiplexed test to include other antigenic markers for TB will 
be required. Interestingly, the latter possibility can be addressed by drawing on the 
extensibility of our78 or other11, 79, 80 platforms. There have also been recent efforts aimed 
at improving ManLAM detection by developing more specific and higher affinity 
antibodies,81 which may again lower the LoD, and therefore further improve clinical 
accuracy. We also note that there are a few other promising platforms for ManLAM 
detection,82 but any attempt to draw comparisons of performance is not possible as the 
capture and labeling reagents are not the same.
Another challenge revolves around accessibility in the regions of the world where 
the test is needed the most. The only platforms today that have a high clinical accuracy are 
microbial culturing and a NAAT test,10 but both have a cost, complexity, and/or specimen 
type limitation that impedes widespread use in resource-limited settings.7 Within this 
context, there are several development issues that need to be addressed with respect to 
instrumentation, sample processing, and reagent packaging and stability before potentially
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transitioning our approach from the research laboratory to field settings. More so, issues 
differ depending upon whether the test will be conducted in settings with reliable 
infrastructure (e.g., hospital clinic) in terms of power, sample refrigeration/freezing, and 
technical skills, or if the intent is to create a field-deployable (e.g., point-of-need) test in 
which case the infrastructure and technical capabilities may be limited. In either case, 
approaches to streamline sample preparation and readout, instrument and test 
standardization and calibration, reagent packaging and handling, and overall ease of use 
must be addressed.
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6.1 Future Perspectives 
The global population is desperately in need of diagnostic methods that are 
available, affordable, and reliable for low-resource regions. The regions display the highest 
burden due to close living quarters, lowered hygiene standards, limited health resources 
that allow for communicable diseases to thrive. Diseases such as human immunodeficiency 
virus/acquired immunodeficiency syndrome (HIV/AIDS), tuberculosis (TB), diarrheal 
diseases, vaccine-preventable diseases, malaria, respiratory infections, neonatal deaths, 
and maternal conditions experience increased mortality rates in low and middle income 
regions simply due to the lack available health care. The cost and resources required for 
state-of-the-art medical care, which reduces the availability to prevent, diagnose, and treat 
disease in areas with high exposure, limit the ability to implement these techniques. This 
indicates a high demand for the development of reliable and effective methods that can 
function with the limited resources for example, restricted electricity and clean water, in 
the region of need.
Large portions of research-based resources for diagnostics are directed towards the 
production of novel techniques. New methods that use state-of-the-art materials,
equipment, and novel concepts are commonly pursued. As such, the boundaries of 
knowledge are continually pushed. These technological advancements are however, 
inconsequential if an application of the research is never achieved. Diagnostic research 
directed towards potentially life-changing technologies that are cost effective, easy to use, 
and reliable is needed to validate new technology for the betterment of mankind. In order 
to develop this type of diagnostic method for regions with limited resources and mortality 
rates of curable and preventable infectious diseases a researcher should take into account 
the resources available at the point of care.
In order to move forward, reexamination of available methods is sometimes 
required. The fine tuning of fundamental principles involved can lead to advancements in 
the application of a method. This dissertation is predominantly directed towards the 
improvement of a nanoparticle (NP)-based surface-enhanced Raman scattering (SERS) 
immunoassay. The influence of extrinsic Raman label (ERL) sampling on the SERS 
substrate and AuNP sedimentation were investigated and revealed sources of error that 
cause decreased reproducibility of the results. Thoroughly understanding potential sources 
of error and implementation of methods that reduce their impact has led to advancement, 
not only in the reliability of the method, but also in the reliability of the results and the 
conclusions drawn from them.
In Chapter 2 and Chapter 3, fundamental investigation into sources of error in the 
results of an NP-based SERS immunoassay in terms of sampling and ERL sedimentation 
is investigated. The use of NP-based ERLs in a sandwich immunoassay format produces 
unique challenges that have not previously been well discussed, or were overlooked 
entirely. The variability in SERS signal intensity has led to speculation as to the reliability
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of SERS, based on the limited reproducibility of many systems. Understanding the specific 
sources of errors associated with the NP-based SERS immunoassay provides an avenue for 
increased accuracy and precision, resulting in more reliable and impactful results.
The NP-based SERS immunoassay quantification is based on the excitation of the 
localized surface plasmon resonance by the external laser source on the SERS substrate. 
The resulting signal strength is dependent on the number of ERLs within the excitation. 
This indicates that the focused laser spot on the surface defines the sample size. To 
determine the impact of the sample size on this specific type of analysis, a simulation of 
the distribution of ERLs on a SERS substrate and the subsequent analysis of the SERS 
substrate were conducted. Results from the simulation display how the number of replicate 
measurements on a substrate (^ replicate) and laser spot size influence the accuracy and
precision of results. While the accuracy is improved with increased r^eplicate, the precision
reaches a point where it cannot be improved past the fundamental error associated with the 
sample size. This fundamental error can be larger than instrumental error introducing a 
avoidable and large source of error. However, the accuracy and precision are improved by 
increasing the sample size, which statistically more reliably indicates the true density of 
ERLs on the substrate. The practical application of this information indicates that while an 
objective with a higher numerical aperture increases collection efficiency, the small 
focused laser spot inherently dictates the accuracy and precision of a measurement. This is 
backed by empirical data indicating the reproducibility of the results can be increased by 
increasing the laser spot size; however, there is inherent trade off in signal strength.
The results for the simulation in Chapter 2 follow the assumption that the ERLs on 
the SERS immunoassay substrate are randomly distributed on the substrate. This would
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follow a random sequential adsorption model for the adsorption of the ERLs. Assuming 
that the SERS signal intensity is related to the ERL density on the surface, high density 
Raman mapping of the SERS substrate should display a relatively even distribution of 
signal across the substrate with a given fundamental error. In Chapter 3, the preparation of 
ERLs and the SERS immunoassay substrate were investigated to determine methodologies 
to reduce signal variations across a single SERS immunoassay substrate. Investigation 
indicated that the sedimentation of ERLs on the surface disrupts the adsorption of the ERL. 
This is believed to be a consequence of settled ERLs potentially blocking specific biding 
sites and an increased level of nonspecific adsorption, and limiting specific interactions, 
which also leads to larger signal distributions. Investigation allowed for prediction and 
characterization of the ERL sedimentation through a finite volume method used to solve 
the partial differential described by the Mason-Weaver equation for NP sedimentation. 
Results show that through proper modification, ERL sedimentation can be minimized but 
that the AuNP core with a finite size and high density will always display some inherent 
sedimentation. The impact of transport due to sedimentation can be removed through 
simple inversion of the substrate during the ERL incubation step. This keeps stable 
particles free in solution to interact and bind to antigen immobilized on the capture 
substrate through strictly diffusional transport. This method produced a much more 
consistent and even signal distribution on the SERS immunoassay substrate.
Understanding the potential sources of error in the SERS immunoassay allows for 
the implementation of techniques that reduce the signal variability and increase 
reproducibility. These techniques were applied to the global health problem associated with 
tuberculosis (TB) detection. With one third of the world’s population believed to be
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infected with the causative agent Mycobacterium tuberculosis (M. tuberculosis) and as the 
world’s second deadliest infectious disease for a single infectious agent, TB is a 
considerable global threat. This is primarily due to the lowered health and sanitation 
standards for low-resource regions as well as a high occurrence of coinfection with immune 
suppressing diseases. Areas of Asia and Africa display the highest burden from TB as these 
regions that lack simple resources such as medical professionals, clean needles, electrical 
power, and a clean water source. These limited resources put a large number restrictions 
on a diagnostic method due to the additional constraints of resources for development of a 
reliable test.
Initially, the primary goal was to develop a serological test for an antigenic marker 
or markers that is reliable for potentially immunocompromised patients in regions with 
high exposure. This excludes testing for antibodies because of low production of antibodies 
in some immunocompromised patients and production of antibodies in noninfected patients 
that have been exposed to antigens, respectively. The goals of the project were expanded 
after the World Health Organization (WHO) called for the ban of all currently available 
serologically-based TB tests due to the level of inaccuracy having negative impact on the 
patients’ health. There were many steps to try and identify a reliable TB marker, including 
assay development, investigation of multiple antigenic markers, identification of the 
unique potential of lipoarabinomannan (LAM) as a lipopolysaccharide, investigation of 
serum pretreatment, and application of findings towards the identification of mannose- 
capped LAM (ManLAM) in a panel of serum samples from an endemic area. However, the 
potential impact of this work is based on cumulative understanding of the detection 
platform, the study of antigenic TB markers, and identification of methods that reduce
184
serum matrix effects. With the combination of advancements, results from a panel of 
endemic serum samples indicate potential validation of a new diagnostic method as well 
as indicate the potential of ManLAM as reliable antigenic marker for TB.
I believe that if the progresses and/or conceptual advancements in this dissertation 
can be implemented towards the eventual application of technology that improves the 
quality of a single life, then all the effort is validated. Applicable advancements do not 
happen overnight and are possible due to the combination of work achieved by previous 
generations of scientists, parallel developments, and collaboration. Only time will tell what 
the future will bring, but I have done my best to try and ensure that my research has what
I consider a positive impact.
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